-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ITW9SpP1lFAd3FHGvrGvjWzFXS3A8GqOTLDCPZp41FktDyWCiCoFqObggvXUQhkk NIEsQcG7luX2f+d2WeWZwA== 0001193125-10-094994.txt : 20100427 0001193125-10-094994.hdr.sgml : 20100427 20100427170259 ACCESSION NUMBER: 0001193125-10-094994 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20100331 FILED AS OF DATE: 20100427 DATE AS OF CHANGE: 20100427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 10774132 BUSINESS ADDRESS: STREET 1: 5959 S SHERWOOD FOREST BLVD CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 5959 S SHERWOOD FOREST BLVD CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 10-Q 1 d10q.htm QUARTERLY REPORT FOR THE PERIOD ENDED MARCH 31, 2010 Quarterly Report for the Period Ended March 31, 2010
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2010

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission File Number: 0-24260

 

 

LOGO

AMEDISYS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   11-3131700

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ¨    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer þ

  Accelerated filer ¨   Non-accelerated filer ¨   Smaller reporting company ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  þ

The number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, 28,559,614 shares outstanding as of April 22, 2010.

 

 

 


Table of Contents

TABLE OF CONTENTS

 

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION

   1

PART I. FINANCIAL INFORMATION

  

ITEM 1.

 

FINANCIAL STATEMENTS (UNAUDITED):

  
 

CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2010 AND DECEMBER 31, 2009

   2
 

CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2010 AND 2009

   3
 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2010 AND 2009

   4
 

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

   5

ITEM 2.

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

   11

ITEM 3.

 

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

   18

ITEM 4.

 

CONTROLS AND PROCEDURES

   18

PART II. OTHER INFORMATION

  

ITEM 1.

 

LEGAL PROCEEDINGS

   19

ITEM 1A.

 

RISK FACTORS

   19

ITEM 2.

 

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

   19

ITEM 3.

 

DEFAULTS UPON SENIOR SECURITIES

   19

ITEM 4.

 

RESERVED

   19

ITEM 5.

 

OTHER INFORMATION

   19

ITEM 6.

 

EXHIBITS

   20

SIGNATURES

   22

INDEX TO EXHIBITS

   23


Table of Contents

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION

Special Caution Concerning Forward-Looking Statements

When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (“SEC”) or in statements made by or on behalf of our company, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open agencies, acquire additional agencies and integrate and operate these agencies effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on February 23, 2010, particularly Part I, Item 1A. – “Risk Factors” therein, which are incorporated herein by reference. Additional risk factors may also be described in reports that we file from time to time with the SEC.

Available Information

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, Corporate Governance Guidelines and the charters for the Audit, Compensation and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Corporate Governance”).

Additionally, our filings can also be obtained at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at (800) SEC-0330. Our electronically filed reports can also be obtained on the SEC’s internet site at http://www.sec.gov.

 

1


Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share data)

(Unaudited)

 

     March 31, 2010     December 31, 2009  
ASSETS     

Current assets:

    

Cash and cash equivalents

   $ 81,980      $ 34,485   

Patient accounts receivable, net of allowance for doubtful accounts of $25,806 and $26,371

     150,572        150,269   

Prepaid expenses

     12,651        10,279   

Other current assets

     15,905        23,003   
                

Total current assets

     261,108        218,036   

Property and equipment, net of accumulated depreciation of $65,658 and $59,780

     95,440        91,919   

Goodwill

     789,054        786,923   

Intangible assets, net of accumulated amortization of $13,337 and $11,824

     59,093        57,608   

Other assets, net

     17,750        17,865   
                

Total assets

   $ 1,222,445      $ 1,172,351   
                
LIABILITIES AND EQUITY     

Current liabilities:

    

Accounts payable

   $ 21,554      $ 16,535   

Payroll and employee benefits

     124,832        119,619   

Accrued expenses

     35,592        33,035   

Obligations due Medicare

     4,618        4,618   

Current portion of long-term obligations

     40,581        44,254   

Current portion of deferred income taxes

     11,446        11,245   
                

Total current liabilities

     238,623        229,306   

Long-term obligations, less current portion

     162,799        170,899   

Deferred income taxes

     30,821        29,399   

Other long-term obligations

     5,787        6,412   
                

Total liabilities

     438,030        436,016   
                

Commitments and Contingencies - Note 6

    

Equity:

    

Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding

     -        -   

Common stock, $0.001 par value, 60,000,000 shares authorized; 28,548,967 and 28,303,216 shares issued; and 28,435,994 and 28,191,174 shares outstanding

     29        28   

Additional paid-in capital

     374,981        363,670   

Treasury stock at cost, 112,973 and 112,042 shares of common stock

     (791     (735

Accumulated other comprehensive income

     108        114   

Retained earnings

     408,735        372,089   
                

Total Amedisys, Inc. stockholders’ equity

     783,062        735,166   

Noncontrolling interests

     1,353        1,169   
                

Total equity

     784,415        736,335   
                

Total liabilities and equity

   $ 1,222,445      $ 1,172,351   
                

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

2


Table of Contents

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Amounts in thousands, except per share data)

(Unaudited)

 

     For the three-month periods ended March 31,  
     2010     2009  

Net service revenue

   $ 412,967      $ 341,838   

Cost of service, excluding depreciation and amortization

     204,062        165,039   

General and administrative expenses:

    

Salaries and benefits

     87,499        73,025   

Non-cash compensation

     2,513        2,141   

Other

     44,648        42,266   

Provision for doubtful accounts

     4,345        6,166   

Depreciation and amortization

     8,186        6,282   
                

Operating expenses

     351,253        294,919   
                

Operating income

     61,714        46,919   

Other (expense) income:

    

Interest income

     85        81   

Interest expense

     (2,411     (3,455

Equity in earnings from unconsolidated joint ventures

     788        424   

Miscellaneous, net

     201        354   
                

Total other expense

     (1,337     (2,596
                

Income before income taxes

     60,377        44,323   

Income tax expense

     (23,547     (17,286
                

Net income

     36,830        27,037   

Net income attributable to noncontrolling interests

     (184     (15
                

Net income attributable to Amedisys, Inc.

   $ 36,646      $ 27,022   
                

Net income per share attributable to Amedisys, Inc. common stockholders:

    

Basic

   $ 1.32      $ 1.01   
                

Diluted

   $ 1.29      $ 0.99   
                

Weighted average shares outstanding:

    

Basic

     27,821        26,854   
                

Diluted

     28,359        27,293   
                

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3


Table of Contents

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)

 

     For the three-month periods
ended March 31,
 
     2010     2009  

Cash Flows from Operating Activities:

    

Net income

   $ 36,830      $ 27,037   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     8,186        6,282   

Provision for doubtful accounts

     4,345        6,166   

Non-cash compensation

     2,513        2,141   

401(k) employer match

     5,705        4,530   

Loss on disposal of property and equipment

     171        98   

Deferred income taxes

     1,623        1,141   

Equity in earnings of unconsolidated joint ventures

     (788     (424

Amortization of deferred debt issuance costs

     394        394   

Return on equity investment

     90        -   

Changes in operating assets and liabilities, net of impact of acquisitions:

    

Patient accounts receivable

     (4,648     15,112   

Other current assets

     4,885        (2,981

Other assets

     295        507   

Accounts payable

     4,636        (99

Accrued expenses

     7,425        (5,252

Other long-term obligations

     (625     (167
                

Net cash provided by operating activities

     71,037        54,485   
                

Cash Flows from Investing Activities:

    

Proceeds from sale of deferred compensation plan assets

     -        356   

Purchases of deferred compensation plan assets

     (54     (454

Purchases of property and equipment

     (9,966     (7,478

Acquisitions of businesses, net of cash acquired

     (1,969     (7,490

Acquisitions of reacquired franchise rights

     (2,377     -   
                

Net cash (used in) investing activities

     (14,366     (15,066
                

Cash Flows from Financing Activities:

    

Outstanding checks in excess of bank balance

     -        313   

Proceeds from issuance of stock upon exercise of stock options and warrants

     939        425   

Proceeds from issuance of stock to employee stock purchase plan

     1,445        1,222   

Tax benefit from stock option exercises

     714        672   

Proceeds from Revolving Line of Credit

     -        24,200   

Repayments of Revolving Line of Credit

     -        (31,200

Principal payments of long-term obligations

     (12,274     (12,250
                

Net cash (used in) financing activities

     (9,176     (16,618
                

Net increase in cash and cash equivalents

     47,495        22,801   

Cash and cash equivalents at beginning of period

     34,485        2,847   
                

Cash and cash equivalents at end of period

   $ 81,980      $ 25,648   
                

Supplemental Disclosures of Cash Flow Information:

    

Cash paid for interest

   $ 3,735      $ 5,034   
                

Cash paid for income taxes, net of refunds received

   $ 14,620      $ 16,565   
                

Supplemental Disclosures of Non-Cash Financing and Investing Activities:

    

Notes payable issued for acquisitions

   $ 500      $ 1,534   
                

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


Table of Contents

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS

Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (“Amedisys,” “we,” “us,” or “our”) are a multi-state provider of home health and hospice services with approximately 87% of our net service revenue derived from Medicare for the three-month periods ended March 31, 2010 and 2009. As of March 31, 2010, we had 532 Medicare-certified home health and 68 Medicare-certified hospice agencies in 42 states within the United States, the District of Columbia and Puerto Rico.

Basis of Presentation

In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission (“SEC”) on February 23, 2010 (the “Form 10-K”), which includes information and disclosures not included herein.

Use of Estimates

Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications and Comparability

Certain reclassifications have been made to prior periods’ financial statements in order to conform them to the current period’s presentation.

As a result of our rapid growth through acquisition and start-up activities, our operating results may not be comparable for the periods that are presented.

Principles of Consolidation

These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.

Equity Investments

We consolidate subsidiaries and/or joint ventures when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.

For subsidiaries or joint ventures in which we do not have a controlling interest or for which we are not the primary beneficiary, we record such investments under the equity method of accounting.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

We earn net service revenue through our home health and hospice agencies by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis (on a 60-day episode of care basis for home health services and on a 90-day episode of care basis for the first two hospice episodes of care and on a 60-day episode of care basis for any subsequent hospice episodes), on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day episode of care as episodic-based revenue. For the services we provide, Medicare is our largest payor.

 

5


Table of Contents

When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results.

Home Health Revenue Recognition

Medicare Revenue

Net service revenue is recorded under the Medicare payment program (“PPS”) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if our patient’s care was unusually costly; (b) a low utilization adjustment (“LUPA”) if the number of visits was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required (thresholds set at 6, 14 and 20 visits); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare Program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

We make adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of such payment adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. During the three-month periods ended March 31, 2010 and 2009, we recorded $0.2 million and $2.1 million, respectively, in estimated revenue adjustments to Medicare revenue.

In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of March 31, 2010 and 2009, the difference between the cash received from Medicare for a request for anticipated payment (“RAP”) on episodes in progress and the associated estimated revenue was included as a reduction to our outstanding patient accounts receivable in our condensed consolidated balance sheets for such periods, since only a nominal amount represents cash collected in advance of providing services.

Non-Medicare Revenue

Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.

Hospice Revenue Recognition

Hospice Medicare Revenue

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four main levels of care we provide are routine care, general inpatient care, continuous home care and respite care. We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit

 

6


Table of Contents

risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable.

Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider numbers and estimate amounts due back to Medicare if a cap has been exceeded. We record these adjustments as a reduction to revenue and increase other accrued liabilities. As of March 31, 2010 and December 31, 2009, we had $0.3 million and $0.1 million, respectively, recorded for estimated amounts due back to Medicare in other accrued liabilities in our accompanying condensed consolidated balance sheets. As a result of our adjustments, we believe our revenue and patients accounts receivable are recorded at amounts that will be ultimately realized.

Hospice Non-Medicare Revenue

We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per visit rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receivable.

Patient Accounts Receivable

Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. We believe the credit risk associated with our Medicare accounts, which represent 74% and 77% of our net patient accounts receivable at March 31, 2010 and December 31, 2009, respectively, is limited due to (i) our historical collection rate of over 99% from Medicare and (ii) the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. There is no other single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables, and thus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable.

We fully reserve for accounts which are aged at 360 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible.

Medicare Home Health

Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (“final billed”). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted.

Medicare Hospice

For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient.

Non-Medicare Home Health and Hospice

For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient’s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor based on either the contracted rates or expected payment rates, which are based on our historical experience. We estimate an allowance for doubtful accounts to reduce the carrying amount of the receivables to the amounts we estimate will be ultimately collected. Our review and evaluation of non-Medicare accounts includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. Where such groups have been identified, we have given special consideration to both the billing methodology and evaluation of the ultimate collectibility of the accounts. In addition, the amount of the allowance for doubtful accounts is based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectibility based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk.

 

7


Table of Contents

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and fair value differ (amounts in millions):

 

          Fair Value at Re porting Date Using

Financial Instrument

   As of March 31, 2010    Quoted Prices in
Active Markets for
Identical Items
(Level 1)
   Significant Other
Observable Inputs
(Level 2)
   Significant
Unobservable Inputs
(Level 3)

Long-term obligations, excluding capital leases

   $ 203.3    $ -    $ 195.8    $ -

The estimates of the fair value of our long-term debt are based upon a discounted present value analysis of future cash flows. Due to the existing uncertainty in the capital and credit markets, the actual rates that would be obtained to borrow under similar conditions could materially differ from the estimates we have used.

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:

 

   

Level 1 — Quoted prices in active markets for identical assets and liabilities.

 

   

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

   

Level 3 — Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable and accrued expenses, we estimate the carrying amounts’ approximate fair value due to their short term maturity. Our deferred compensation plan assets are recorded at fair value.

Weighted-Average Shares Outstanding

Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income per share attributable to Amedisys, Inc. common stockholders (amounts in thousands):

 

     For the three-month periods
ended Marc h 31,
     2010    2009

Weighted average number of shares outstanding - basic

   27,821    26,854

Effect of dilutive securities:

     

Stock options

   175    250

Non-vested stock and stock units

   363    189
         

Weighted average number of shares outstanding - diluted

   28,359    27,293
         

For the three-month periods ended March 31, 2010 and 2009, there were 4,222 and 41,501 shares, respectively, of additional securities that were anti-dilutive.

3. ACQUISITIONS

We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health and hospice services. The purchase price paid for acquisitions is negotiated through arm’s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows for each transaction. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy.

 

8


Table of Contents

2010 Acquisitions

On February 1, 2010, we acquired certain assets and liabilities of a home health agency in DeQueen, Arkansas for a total purchase price of $2.5 million ($2.0 million in cash and a $0.5 million promissory note). In connection with the acquisition, we recorded substantially the entire purchase price as goodwill ($2.1 million) and other intangibles ($0.4 million).

4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET

The following table summarizes the activity related to our goodwill and our other intangible assets, net, as of and for the three-month period ended March 31, 2010 (amounts in millions):

 

     Goodwill
     Home Health    Hospice    Total

Balances at December 31, 2009

   $ 719.9    $ 67.0    $ 786.9

Additions

     2.1      -      2.1
                    

Balances at March 31, 2010

   $ 722.0    $ 67.0    $ 789.0
                    

 

     Other Intangible Assets, Net  
     Certificates
Of Need and
Licenses
   Acquired
Name of
Business
(1)
   Non-Compete
Agreements &
Reacquired
Franchise
Rights (2)
    Total  

Balances at December 31, 2009

     43.4      4.7      9.5        57.6   

Additions

     0.2      0.1      2.7        3.0   

Amortization

     -      -      (1.5     (1.5
                              

Balances at March 31, 2010

   $ 43.6    $ 4.8    $ 10.7      $ 59.1   
                              

 

(1)

Acquired Names of Business includes $4.4 million of unamortized acquired names and $0.4 million of amortized acquired names which have a weighted-average amortization period of 3.1 years.

(2)

The weighted-average amortization period of our non-compete agreements and reacquired franchise rights is 3.2 and 2.6 years, respectively.

5. LONG-TERM OBLIGATIONS

Long-term debt, including capital lease obligations, consisted of the following for the periods indicated (amounts in millions):

 

     March 31, 2010     December 31, 2009  

Senior Notes:

    

$35.0 million Series A Notes; semi-annual interest only payments; interest rate at 6.07% per annum; due March 25, 2013

   $ 35.0      $ 35.0   

$30.0 million Series B Notes; semi-annual interest only payments; interest rate at 6.28% per annum; due March 25, 2014

     30.0        30.0   

$35.0 million Series C Notes; semi-annual interest only payments; interest rate at 6.49% per annum; due March 25, 2015

     35.0        35.0   

$150.0 million Term Loan; $7.5 million principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (1.01% at March 31, 2010); due March 26, 2013

     90.0        97.5   

Promissory notes

     13.3        17.6   

Capital leases

     -        0.1   
                
     203.3        215.2   

Current portion of long-term obligations

     (40.5     (44.3
                

Total

   $ 162.8      $ 170.9   
                

Our weighted-average interest rate for our five year Term Loan for the quarters ended March 31, 2010 and 2009 was 1.0% and 2.6%, respectively.

As of March 31, 2010, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.7 and our fixed charge coverage ratio was 2.6.

 

9


Table of Contents

As of March 31, 2010, our availability under our $250.0 million Revolving Credit Facility was $234.6 million as we had $15.4 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

6. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.

Insurance

We are obligated for certain costs associated with our insurance programs, including employee health, workers’ compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported, up to specified deductible limits. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.

Our health insurance has a retention limit of $0.5 million, our workers’ compensation insurance has a retention limit of $0.4 million and our professional liability insurance has a retention limit of $0.3 million.

7. SEGMENT INFORMATION

Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the home of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. The “other” column in the following tables consists of costs relating to corporate support functions that are not directly attributable to a specific segment.

Management evaluates performance and allocates resources based on the operating income of the reportable segments, which exclude corporate expenses, but includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company’s chief operating decision maker and therefore are not disclosed below. The following table summarizes our segment information for the periods indicated (amounts in millions):

 

     For the Three-Month Period Ended March 31, 2010
     Home Health    Hospice    Other     Total

Net service revenue

   $ 380.5    $ 32.5    $ -      $ 413.0

Cost of service, excluding depreciation and amortization

     187.0      17.1      -        204.1

General and administrative expenses

     86.3      7.8      40.6        134.7

Provision for doubtful accounts

     3.8      0.5      -        4.3

Depreciation and amortization

     3.6      0.1      4.5        8.2
                            

Operating expenses

     280.7      25.5      45.1        351.3
                            

Operating income

   $ 99.8    $ 7.0    $ (45.1   $ 61.7
                            
     For the Three-Month Period Ended March 31,  2009
     Home Health    Hospice    Other     Total

Net service revenue

   $ 321.5    $ 20.3    $ -      $ 341.8

Cost of service, excluding depreciation and amortization

     153.5      11.5      -        165.0

General and administrative expenses

     71.5      5.2      40.7        117.4

Provision for doubtful accounts

     5.9      0.3      -        6.2

Depreciation and amortization

     3.2      0.2      2.9        6.3
                            

Operating expenses

     234.1      17.2      43.6        294.9
                            

Operating income

   $ 87.4    $ 3.1    $ (43.6   $ 46.9
                            

 

10


Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three-month period ended March 31, 2010. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, the consolidated financial statements and notes and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission (“SEC”) on February 23, 2010 (the “Form 10-K”), which are incorporated herein by this reference.

Unless otherwise provided, “Amedisys,” “we,” “us,” “our” and the “Company” refer to Amedisys, Inc. and our consolidated subsidiaries.

Overview

We are a leading provider of high-quality, low-cost home health services to the chronic, co-morbid, aging American population. Our services include home health and hospice services, and approximately 87% of our revenue was derived from Medicare for the three-month periods ended March 31, 2010 and 2009. During the three-month period ended March 31, 2010, we had $413.0 million in net service revenue, recorded earnings per diluted share of $1.29 and had cash flow from operations of $71.1 million. The following details our owned Medicare-certified agencies, which are located in 42 states within the United States, the District of Columbia and Puerto Rico. The agencies closed were consolidated with agencies servicing the same areas.

 

     Owned and Operated Agencies
     Home health     Hospice

At December 31, 2009

   521      65

Acquisitions

   1      -

Start-ups

   14      3

Closed

   (4   -
          

At March 31, 2010

   532      68
          

Recent Developments

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act (“PPACA”) and the Health Care and Education Reconciliation Act of 2010 (“HCERA”), which amends the PPACA (collectively, the “Health Care Reform Bills”). The Health Care Reform Bills make a number of changes to Medicare payment rates including the reinstatement of the 3% home health rural add-on which began on April 1, 2010 (expiring January 1, 2016). Beginning in 2011, we are expecting the changes made by the Health Care Reform Bills, excluding the rural add-on and including the adjustment to the base rate made by CMS each year, to reduce our Medicare payment rates by approximately 3-4% based on the following:

 

   

market basket adjustment for 2011 to be determined by CMS, offset by a 1% reduction (a similar 1% reduction to market basket updates is set for 2012 and 2013);

 

   

revised outlier payment policy beginning in 2011 that we anticipate will result in a 2.5% reduction to the base rate; and

 

   

a negative 2.71% case–mix adjustment.

The Health Care Reform Bills also include a systemic rebasing phased in over four years, beginning in 2014. We anticipate that many of the provisions of the Health Care Reform Bills may be subject to further clarification and modification through the rule-making process. It is uncertain at this time the effect the rebasing will have on our future results of operations or cash flows.

Additionally, the Health Care Reform Bills expand health care coverage to many uninsured individuals and expands coverage to those already insured. The changes required by this legislation will largely be funded through tax increases to both insurers and the insured. We do not expect any short term impact on our financial results as a result of the legislation. One provision that will impact certain companies significantly is the elimination of the tax deductibility of the Medicare Part D subsidy. This provision does not affect us as we do not provide retiree health benefits.

Results of Operations

Our operating results may not be comparable for the periods presented, primarily as a result of our acquisition and start-up agencies.

When we refer to “base business,” we mean home health and hospice agencies that we have operated for at least the last twelve months; when we refer to “acquisitions,” we mean home health and hospice agencies that we acquired within the last twelve months; and when we refer to “start-ups,” we mean any home health or hospice agency opened by us in the last twelve months. Once an agency has been in operation for a twelve month period, the results for that particular agency are included as part of our base business

 

11


Table of Contents

from that date forward. When we refer to episodic-based revenue, admissions, recertifications or completed episodes, we mean home health revenue, admissions, recertifications or completed episodes of care for those payors that pay on an episodic-basis, which includes Medicare and other insurance carriers, including Medicare Advantage programs.

Three-Month Period Ended March 31, 2010 Compared to the Three-Month Period Ended March 31, 2009

Net Service Revenue

The following table summarizes our net service revenue growth (amounts in millions):

 

     For the three-month periods ended March 31,     
     2010    2009     
     Base/Start- ups (2)    Acquisitions    Total    Total    Variance

Home health revenue:

              

Medicare revenue

   $ 322.1    $ 6.6    $ 328.7    $ 279.8    $ 48.9

Non-Medicare, episodic-based revenue

     32.9      0.1      33.0      24.8      8.2
                                  

Total episodic-based revenue

     355.0      6.7      361.7      304.6      57.1

Non-Medicare revenue

     17.7      1.1      18.8      16.9      1.9
                                  
     372.7      7.8      380.5      321.5      59.0
                                  

Hospice revenue:

              

Medicare revenue

     26.4      4.4      30.8      19.1      11.7

Non-Medicare revenue

     1.4      0.3      1.7      1.2      0.5
                                  
     27.8      4.7      32.5      20.3      12.2
                                  

Total revenue:

              

Medicare revenue

     348.5      11.0      359.5      298.9      60.6

Non-Medicare revenue

     52.0      1.5      53.5      42.9      10.6
                                  
   $ 400.5    $ 12.5    $ 413.0    $ 341.8    $ 71.2
                                  

Internal episodic-based revenue growth (1)

     17%            23%   
                      

 

(1)

Internal episodic-based revenue growth is the percent increase in our base/start-up episodic-based revenue for the period as a percent of the total episodic-based revenue of the prior period.

(2)

Our net service revenue for our base/start-up agencies of $400.5 million included $11.3 million from our start-up agencies.

Our net service revenue increased $71.2 million from 2009 to 2010 and consisted of an increase of $59.0 million in home health revenue and $12.2 million in hospice revenue.

Our home health revenue growth consisted of $40.9 million from our base agencies, $10.3 million from our start-up agencies and $7.8 million from our acquisitions. The increase in our base/start-up agencies was primarily related to our internal episodic-based revenue, which increased by $50.4 million or 17% from 2009 to 2010, with 8% of the increase related to admission and recertification growth and 9% of the increase attributable to an increase in revenue per episode.

Our average episodic-based revenue per completed episode increased from $3,033 to $3,282 from 2009 to 2010 and was due primarily to the continued deployment of our therapy intensive specialty programs to more of our home health agencies, a 1.8% increase in our base rate effective January 1, 2010, and a 3% increase in the base rate on rural episodes in progress effective April 1, 2010. The rural add-on impacts approximately 25% of our episodes.

Our hospice revenue growth consisted of $6.5 million from our base agencies, $1.0 million from our start-up agencies and $4.7 million from our acquisitions. Hospice revenue is primarily impacted by average daily census, levels of care and payment rates. Overall, our average daily census increased from 1,710 in 2009 to 2,628 in 2010 with 2,261 of our census attributable to our base/start-up agencies during the first quarter of 2010. Our patients’ average length of stay was 74 days for 2009 and 87 days for 2010. Our 2010 revenue was impacted by approximately 1.4% due to the annual hospice rate increase effective October 1, 2009.

 

12


Table of Contents

Home Health Statistics

The following table summarizes our total home health patient admissions, recertifications and completed episodes:

 

     For the three-month periods ended Marh 31,       
     2010    2009       
     Base/Start-ups    Acquisitions    Total    Total    Variance  

Admissions:

              

Medicare

   54,902    1,845    56,747    50,443    6,304   

Non-Medicare, episodic-based

   8,503    28    8,531    5,669    2,862   
                          

Total episodic-based

   63,405    1,873    65,278    56,112    9,166   

Non-Medicare

   9,225    767    9,992    9,491    501   
                          
   72,630    2,640    75,270    65,603    9,667   
                          

Internal episodic-based admission growth (1)

   13%          8%   
                  

Recertifications:

              

Medicare

   44,843    612    45,455    45,025    430   

Non-Medicare, episodic-based

   4,246    14    4,260    3,739    521   
                          

Total episodic-based

   49,089    626    49,715    48,764    951   

Non-Medicare

   4,769    127    4,896    5,769    (873
                          
   53,858    753    54,611    54,533    78   
                          

Internal episodic-based recertification growth (2)

   1%          15%   
                  

Completed Episodes:

              

Medicare

   93,422    2,159    95,581    88,090    7,491   

Non-Medicare, episodic-based

   9,478    37    9,515    8,209    1,306   
                          
   102,900    2,196    105,096    96,299    8,797   
                          

 

(1)

Internal episodic-based admission growth is the percent increase in our base/start-up episodic-based admissions for the period as a percent of the total episodic-based admissions of the prior period.

(2)

Internal episodic-based recertification growth is the percent increase in our base/start-up episodic-based recertifications for the period as a percent of the total episodic-based recertifications of the prior period.

Internal episodic-based admission growth rate of 13% exceeded 10% for the first time since the fourth quarter of 2008. During the three-month period ended March 31, 2010, we saw improvement in our TLC acquired agencies, experienced growth in admissions under our new contract with Humana, which was effective January 1, 2010 and benefited from the strategic realignment of our sales territory during the second half of 2009.

Internal episodic-based recertification growth has decreased from 15% for the first quarter of 2009 to 1% for the first quarter of 2010. The primary factor impacting the rate of recertifications is the clinical needs of our patient, in addition, recertifications are derived from, and lag behind, admissions. As such, our declining admission growth during 2009, including the impact of TLC agencies, negatively impacted recertification growth during the quarter.

Cost of Service, Excluding Depreciation and Amortization

Our cost of service consists of the following expenses incurred by our clinical and clerical personnel in our agencies:

 

   

salaries and related benefits (including health care insurance and workers’ compensation insurance);

 

   

transportation expenses (primarily reimbursed mileage at a standard rate); and

 

   

supplies and services expenses (including payments to contract therapists).

 

13


Table of Contents

The following summarizes our cost of service, visit and cost per visit information:

 

     For the three-month periods ended March 31,     
     2010    2009     
     Base/Start-ups    Acquisitions    Total    Total    Variance

Cost of service (amounts in millions):

              

Home health

   $ 182.0    $ 5.0    $ 187.0    $ 153.5    $ 33.5

Hospice

     14.3      2.8      17.1      11.5      5.6
                                  
   $ 196.3    $ 7.8    $ 204.1    $ 165.0    $ 39.1
                                  

Home health:

              

Visits during the period:

              

Medicare

     1,849,327      35,181      1,884,508      1,672,677      211,831

Non-Medicare, episodic-based

     206,053      692      206,745      149,888      56,857
                                  

Total episodic-based

     2,055,380      35,873      2,091,253      1,822,565      268,688

Non-Medicare

     198,729      9,343      208,072      196,355      11,717
                                  
     2,254,109      45,216      2,299,325      2,018,920      280,405
                                  

Home health cost per visit (1)

   $ 80.73    $ 110.45    $ 81.32    $ 76.05    $ 5.27
                                  

 

(1)

We calculate home health cost per visit as home health cost of service divided by total home health visits during the period.

Of the $39.1 million increase in cost of service, $31.3 million is related to increased costs from our base/start-up agencies and $7.8 million is related to acquisitions. The $31.3 million increase in base/start-up expenses consisted primarily of $29.9 million related to salaries, taxes and benefits, with $17.9 million of the increase related to the increase in the number of visits performed with the remainder related to the $5.27 increase in cost per visit.

We carefully monitor our cost per visit in order to deliver high-quality low cost care to our patients. Factors contributing to the increase in our cost per visit include the mix of clinicians performing visits (i.e. registered nurses, therapists, home health aides, etc.), wage inflation and use of contract therapists. While the majority of our clinicians are paid on a per visit basis, we do hire some clinicians (primarily therapists) on a salaried basis for an initial period before converting to our pay per visit model. Also, newly acquired agencies generally have a higher cost per visit and take up to 18 to 24 months to reach the labor efficiencies of our existing agencies. The $5.27 increase in cost per visit is primarily due to an increase in salaries and wages related to an increase in therapists retained in connection with our Balance for Life program and increases in our employee benefit costs related to health insurance and payroll taxes.

General and Administrative Expenses, Provision for Doubtful Accounts, Depreciation and Amortization and Other Expense, net

The following table summarizes our general and administrative expenses, provision for doubtful accounts, depreciation and amortization expense and other expense, net (amounts in millions):

 

     For the three-month  periods
ended March 31,
       
     2010     2009     Variance  

General and administrative expenses:

      

Salaries and benefits

   $ 87.5      $ 73.0      $ 14.5   

Non-cash compensation

     2.5        2.1        0.4   

Rent and utilities

     15.1        13.6        1.5   

Other

     29.5        28.7        0.8   

Provision for doubtful accounts

     4.3        6.2        (1.9

Depreciation and amortization

     8.2        6.3        1.9   

Other expense, net

     (1.3     (2.6     1.3   

Salaries and benefits increased $14.5 million, which consisted of an increase of $12.1 million in base/start-up agency and corporate office expenses and $2.4 million in acquisition agency expenses. The base/start-up agency and corporate office expenses increased by $12.1 million primarily due to increased personnel costs for our field administrative staff and corporate staff necessitated by our internal growth and acquisitions.

 

14


Table of Contents

Rent and utilities increased $1.5 million, which consisted of an increase of $1.2 million in base/start-up agency and corporate office expenses and the inclusion of $0.3 million in acquisition agency expenses.

Our provision for doubtful accounts decreased $1.9 million due to improved cash collections and billing processes resulting in an increase of $55.3 million in cash collections compared to the first quarter of 2009. For additional information on our provision for doubtful accounts see “Liquidity and Capital Resources – Outstanding Patient Accounts Receivable.”

Depreciation and amortization expense increased $1.9 million primarily due to the purchase of equipment and furniture and the development of computer software, which are depreciated over three to seven years.

Other expense, net decreased $1.3 million primarily as a result of a decrease in interest expense of $1.0 million as we have reduced our outstanding debt by $107.6 million from March 31, 2009 to March 31, 2010.

Income Tax Expense

The following table summarizes our income tax expense and estimated income tax rate (amounts in millions, except for estimated income tax rate):

 

     For the three-month  periods
ended March 31,
       
     2010     2009     Variance  

Income before income taxes

   $ 60.4      $ 44.3      $ 16.1   

Income tax (expense)

     (23.5     (17.3     (6.2

Estimated income tax rate

     39.0%        39.0%        -   

The increase in income tax expense of $6.2 million is attributable to an increase in income before income taxes as our estimated income tax rate remained unchanged from 2009 to 2010.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flows for the Three-Month Period Ended March 31, 2010 Compared to the Three-Month Period Ended March 31, 2009

The following table summarizes our cash flows for the periods indicated (amounts in millions):

 

     For the three-month  periods
ended March 31,
     
     2010     2009     Variance

Cash provided by operating activities

   $ 71.1      $ 54.5      $ 16.6

Cash (used in) investing activities

     (14.4     (15.1     0.7

Cash (used in) financing activities

     (9.2     (16.6     7.4
                      

Net increase in cash and cash equivalents

     47.5        22.8        24.7

Cash and cash equivalents at beginning of period

     34.5        2.8        31.7
                      

Cash and cash equivalents at end of period

   $ 82.0      $ 25.6      $ 56.4
                      

Cash provided by operating activities increased $16.6 million during 2010 compared to 2009, primarily as a result of $11.7 million improvement in net income after adjusting for non-cash items, a decrease in other receivables and an increase in our accounts payable and payroll and employee benefits.

Cash used in investing activities decreased $0.7 million during 2010 compared to 2009 primarily due to a decrease in acquisition activity offset by an increase in our capital expenditures.

Cash used in financing activities decreased $7.4 million during 2010 compared to 2009 primarily due to a decrease in draws and/or repayments on our revolving credit facility. We have decreased our outstanding long-term obligations net of borrowings by $107.6 million from March 31, 2009.

Liquidity

Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program; however, from time to time, we can and do obtain additional sources of liquidity through sales of our equity or by incurrence of additional indebtedness. As of March 31, 2010, we had $82.0 million in cash and cash equivalents and $234.6 million in availability under our $250.0 million Revolving Credit Facility.

During the three-month period ended March 31, 2010, we made $10.0 million in routine capital expenditures, which primarily included equipment and furniture and computer software. We are currently in the process of implementing an enterprise resource planning (ERP) system, which is expected to be fully implemented for 2011. Routine capital expenditures as a percent of net service revenue was 2.4% for 2009 and we are forecasting routine capital expenditures to be approximately 3% of net service revenue for 2010 Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements over the next twelve months and into the foreseeable future.

 

15


Table of Contents

As we manage our liquidity needs to meet our operating forecasts, debt service requirements and our acquisition and start-up activities, we are monitoring the creditworthiness and solvency of our syndicate of banks that provide the availability of credit under our Revolving Credit Facility as well as the status of the overall equity and credit markets. As of the date of this filing, we do not believe the availability of funds under our Revolving Credit Facility is at risk. If the availability under our current Revolving Credit Facility decreases, we may need to consider adjusting our strategy to meet our operating forecasts, debt service requirements and acquisition and start-up activity needs.

Outstanding Patient Accounts Receivable

Our patient accounts receivable, net increased $0.3 million from December 31, 2009 to March 31, 2010 primarily due to improved billing processes and increases in our cash collection efforts during 2010. Our cash collection as a percentage of revenue was 100.9% and 96.0% for the three-months ended March 31, 2010 and for the three-months ended December 31, 2009, respectively.

Our patient accounts receivable includes unbilled receivables, which are aged based upon our initial service date. At March 31, 2010, the unbilled patient accounts receivable, as a percentage of gross patient accounts receivable, was 25.8%, or $47.3 million compared to 19.8% or $36.7 million at December 31, 2009. We monitor unbilled receivables on an agency by agency basis to ensure that all efforts are made to bill claims within timely filing deadlines. The timely filing deadlines vary by state for Medicaid and among insurance companies. As of March 31, 2010, agencies acquired during the past twelve months represented $3.4 million or 7.2% of our unbilled accounts receivable compared to $2.0 million or 5.5% as of December 31, 2009.

Our provision for estimated revenue adjustments (which is deducted from our service revenue to determine net service revenue) and provision for doubtful accounts were as follows for the periods indicated (in millions). We fully reserve for both our Medicare and other patient accounts receivable that are aged over 360 days.

 

     For the three-month  periods
ended March 31,
     2010    2009

Provision for estimated revenue adjustments

   $ 0.2    $ 2.1

Provision for doubtful accounts

     4.3      6.1
             

Total

   $ 4.5    $ 8.2
             

As a percent of revenue

     1.1%      2.4%
             

Our provision for estimated revenue adjustments and doubtful accounts as a percent of revenue decreased for 2010 as compared to the same period in 2009 due to significant improvement in cash collections since the first quarter of 2009 as evidenced by our reduction in our days revenue outstanding, net since the first quarter of 2009. Accounts receivable aged greater than 90 days decreased $21.1 million and $8.6 million since the first and fourth quarters of 2009, respectively. The first quarter of 2010 benefited from strong collections on Medicare aged balances which were significantly reserved for at December 31, 2009.

 

16


Table of Contents

The following schedule details our patient accounts receivable, net of estimated revenue adjustments, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding, net):

 

     0-90    91-180    181-365    Over 365    Total  

At March 31, 2010:

              

Medicare patient accounts receivable, net (1)

   $ 91.1    $ 18.8    $ 1.8    $ -    $ 111.7   
                                    

Other patient accounts receivable:

              

Medicaid

     6.2      3.1      3.4      2.0      14.7   

Private

     27.9      9.0      8.2      4.9      50.0   
                                    

Total

   $ 34.1    $ 12.1    $ 11.6    $ 6.9    $ 64.7   
                              

Allowance for doubtful accounts (2)

                 (25.8
                    

Non-Medicare patient accounts receivable, net

               $ 38.9   
                    

Total patient accounts receivable, net

               $ 150.6   
                    

Days revenue outstanding, net (3)

                 32.6   
                    
     0-90    91-180    181-365    Over 365    Total  

At December 31, 2009:

              

Medicare patient accounts receivable, net (1)

   $ 90.1    $ 20.4    $ 4.8    $ 0.2    $ 115.5   
                                    

Other patient accounts receivable:

              

Medicaid

     6.3      2.7      3.5      2.8      15.3   

Private

     20.5      10.6      9.7      5.1      45.9   
                                    

Total

   $ 26.8    $ 13.3    $ 13.2    $ 7.9    $ 61.2   
                              

Allowance for doubtful accounts (2)

                 (26.4
                    

Non-Medicare patient accounts receivable, net

               $ 34.8   
                    

Total patient accounts receivable, net

               $ 150.3   
                    

Days revenue outstanding, net (3)

                 33.9   
                    

 

(1)

The following table summarizes the activity and ending balances in our estimated revenue adjustments (amounts in millions), which is recorded to reduce our Medicare outstanding patient accounts receivable to their estimated net realizable value, as we do not estimate an allowance for doubtful accounts for our Medicare claims.

 

     For the three-month period ended  
     March 31, 2010     December 31, 2009  

Balance at beginning of period

   $ 8.7      $ 7.8   

Provision for estimated revenue adjustments

     0.2        2.9   

Write offs

     (2.0     (2.0
                

Balance at end of period

   $ 6.9      $ 8.7   
                

Our estimated revenue adjustments were 5.8% and 7.0% of our outstanding Medicare patient accounts receivable at March 31, 2010 and December 31, 2009, respectively.

(2)

The following table summarizes the activity and ending balances in our allowance for doubtful accounts (amounts in millions), which is recorded to reduce only our Medicaid and private outstanding patient accounts receivable to their estimated net realizable value.

 

     For the three-month period ended  
     March 31, 2010     December 31, 2009  

Balance at beginning of period

   $ 26.4      $ 28.3   

Provision for doubtful accounts

     4.3        3.8   

Write offs

     (4.9     (5.7
                

Balance at end of period

   $ 25.8      $ 26.4   
                

 

17


Table of Contents

Our allowance for doubtful accounts was 39.9% and 43.1% of our outstanding Medicaid and private patient accounts receivable at March 31, 2010 and December 31, 2009, respectively.

(3)

Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts receivable (i.e. net of estimated revenue adjustments and allowance for doubtful accounts) at March 31, 2010 and December 31, 2009 by our average daily net patient revenue for the three-month periods ended March 31, 2010 and December 31, 2009, respectively.

Indebtedness

Our weighted-average interest rate for our five year Term Loan for the quarters ended March 31, 2010 and 2009 was 1.0% and 2.6%, respectively.

As of March 31, 2010, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.7 and our fixed charge coverage ratio was 2.6.

As of March 31, 2010, our availability under our $250.0 million Revolving Credit Facility was $234.6 million as we had $15.4 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

Inflation

We do not believe that inflation has significantly impacted our results of operations.

Critical Accounting Policies

See Part II, Item 7 — Critical Accounting Policies and our consolidated financial statements and related notes in Part IV, Item 15 of our Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting policies include revenue recognition; patient accounts receivable; insurance; goodwill and intangible assets; and income taxes. There have not been any changes to our significant accounting policies or their application, since we filed our Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our Revolving Credit Facility and Term Loan carry a floating interest rate which is tied to the Eurodollar rate (i.e. LIBOR) and the Prime Rate and, therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows will be exposed to changes in interest rates. As of March 31, 2010, the total amount of outstanding debt subject to interest rate fluctuations was $90.0 million. A 1.0% interest rate increase would increase interest expense by approximately $0.9 million annually.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC’s rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.

In connection with the preparation of this Quarterly Report on Form 10-Q, as of March 31, 2010, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.

Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2010, the end of the period covered by this Quarterly Report.

Changes in Internal Controls

There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended March 31, 2010, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

18


Table of Contents

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 6 to the condensed consolidated financial statements for information concerning our legal proceedings.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the Risk Factors included in Part I, “Item 1A. — “Risk Factors” of our Annual Report on Form 10-K. These Risk Factors could materially impact our business, financial condition and/or operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely impact our business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended March 31, 2010:

 

Period

   (a) Total Number
of Shares
(or Units)
Purchased
    (b) Average
Price Paid
per Share
(or Unit)
   (c) Total Number of
Share (or Units)
Purchased as Part of
Publicly Announced
Plans or Programs
   (d) Maximum Number
(or  Approximate Dollar
Value) of Shares
(or Units) that May Yet Be
Purchased Under the
Plans or Programs

January 1, 2010 to January 31, 2010

   -      $ -    -    -

February 1, 2010 to February 28, 2010

   931 (1)    $ 60.40    -    -

March 1, 2010 to March 31, 2010

   -      $ -    -    -
                      

Total

   931      $ 60.40    -    -
                      

 

(1)

Represents shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 Omnibus Incentive Compensation Plan.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. RESERVED

None.

ITEM 5. OTHER INFORMATION

None.

 

19


Table of Contents

ITEM 6. EXHIBITS

The exhibits marked with the cross symbol (†) are filed and the exhibits marked with the double cross symbol (††) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

 

Exhibit

Number

  

Document Description

  

Report or Registration Statement

  

SEC File or

Registration

Number

  

Exhibit or

Other

Reference

3.1

  

Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007

  

The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007

   0-24260    3.1

3.2

  

Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009

  

The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009

   0-24260    3.2

4.1

  

Common Stock Specimen

  

The Company’s Registration Statement on Form S-3 filed August 20, 2007

   333-145582    4.8

4.2.1

  

Shareholder Rights Agreement

  

The Company’s Current Report on Form 8-K filed June 16, 2000, and the Company’s Registration Statement on Form 8-A12G filed June 16, 2000

   0-24260    4

4.2.2

  

Amendment No. 1 to Shareholder Rights Agreement, dated as of July 26, 2006

  

The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2006

   0-24260    4.1

4.3

  

Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) $35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) $30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) $35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.1

4.4

  

Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.2

4.5

  

Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.3

4.6

  

Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.4

10.1.1*

  

Employment Agreement dated January 4, 2010 by and among Michael D. Snow, the Company and Amedisys Holding, L.L.C.

  

The Company’s Current Report on Form 8-K filed on January 7, 2010

   0-24260    10.1

10.1.2*

  

First Amendment dated January 22, 2010 to Employment Agreement dated January 4, 2010 by and among Michael D. Snow, the Company and Amedisys Holding, L.L.C.

  

The Company’s Current Report on Form 8-K filed on January 26, 2010

   0-24260    10.1

10.2*

  

Employment Agreement dated January 4, 2010 by and among T.A. Barfield, Jr., the Company and Amedisys Holding, L.L.C.

  

The Company’s Current Report on Form 8-K filed on January 7, 2010

   0-24260    10.2

 

20


Table of Contents

Exhibit

Number

  

Document Description

  

Report or Registration Statement

  

SEC File or

Registration

Number

  

Exhibit or

Other

Reference

†31.1

  

Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

        

†31.2

  

Certification of Dale E. Redman, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

        

††32.1

  

Certification of William F. Borne, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        

††32.2

  

Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        

††101.INS

   XBRL Instance         

††101.SCH

   XBRL Taxonomy Extension Schema Document         

††101.CAL

   XBRL Taxonomy Extension Calculation Linkbase Document         

††101.LAB

   XBRL Taxonomy Extension Labels Linkbase Document         

††101.PRE

   XBRL Taxonomy Extension Presentation Linkbase Document         

††101.DEF

   XBRL Taxonomy Extension Definition Linkbase Document         

 

21


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

AMEDISYS, INC.

(Registrant)

By:

 

/s/ Dale E. Redman

 

    Dale E. Redman

 

    Chief Financial Officer and

    Duly Authorized Officer

DATE: April 27, 2010

 

22


Table of Contents

EXHIBIT INDEX

The exhibits marked with the cross symbol (†) are filed and the exhibits marked with the double cross symbol (††) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

 

Exhibit

Number

  

Document Description

  

Report or Registration Statement

  

SEC File or

Registration

Number

  

Exhibit or

Other

Reference

3.1   

Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007

  

The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007

   0-24260    3.1
3.2   

Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009

  

The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009

   0-24260    3.2
4.1   

Common Stock Specimen

  

The Company’s Registration Statement on Form S-3 filed August 20, 2007

   333-145582    4.8
4.2.1   

Shareholder Rights Agreement

  

The Company’s Current Report on Form 8-K filed June 16, 2000, and the Company’s Registration Statement on Form 8-A12G filed June 16, 2000

   0-24260    4
4.2.2   

Amendment No. 1 to Shareholder Rights Agreement, dated as of July 26, 2006

  

The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2006

   0-24260    4.1
4.3   

Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) $35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) $30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) $35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.1
4.4   

Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.2
4.5   

Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.3
4.6   

Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)

  

The Company’s Current Report on Form 8-K filed on April 1, 2008

   0-24260    4.4
10.1.1*   

Employment Agreement dated January 4, 2010 by and among Michael D. Snow, the Company and Amedisys Holding, L.L.C.

  

The Company’s Current Report on Form 8-K filed on January 7, 2010

   0-24260    10.1
10.1.2*   

First Amendment dated January 22, 2010 to Employment Agreement dated January 4, 2010 by and among Michael D. Snow, the Company and Amedisys Holding, L.L.C.

  

The Company’s Current Report on Form 8-K filed on January 26, 2010

   0-24260    10.1

 

23


Table of Contents

Exhibit

Number

  

Document Description

  

Report or Registration Statement

  

SEC File or

Registration

Number

  

Exhibit or

Other

Reference

10.2*   

Employment Agreement dated January 4, 2010 by and among T.A. Barfield, Jr., the Company and Amedisys Holding, L.L.C.

  

The Company’s Current Report on Form 8-K filed on January 7, 2010

   0-24260    10.2
†31.1   

Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

        
†31.2   

Certification of Dale E. Redman, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

        
††32.1   

Certification of William F. Borne, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        
††32.2   

Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        
††101.INS   

XBRL Instance

        
††101.SCH    XBRL Taxonomy Extension Schema Document         
††101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document         
††101.LAB    XBRL Taxonomy Extension Labels Linkbase Document         
††101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document         
††101.DEF    XBRL Taxonomy Extension Definition Linkbase Document         

 

24

EX-31.1 2 dex311.htm CERTIFICATION OF CEO SECTION 302 Certification of CEO Section 302

Exhibit 31.1

CERTIFICATION

I, William F. Borne, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, of Amedisys, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 27, 2010

 

/s/ William F. Borne

William F. Borne

Chairman and Chief Executive Officer

EX-31.2 3 dex312.htm CERTIFICATION OF CFO SECTION 302 Certification of CFO Section 302

Exhibit 31.2

CERTIFICATION

I, Dale E. Redman, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, of Amedisys, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 27, 2010

 

/s/ Dale E. Redman

Dale E. Redman

Chief Financial Officer

EX-32.1 4 dex321.htm CERTIFICATION OF CEO SECTION 906 Certification of CEO Section 906

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Amedisys, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2010 (the “Report”), I, William F. Borne, Chairman and Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 27, 2010

 

/s/ William F. Borne

William F. Borne

Chairman and Chief Executive Officer

EX-32.2 5 dex322.htm CERTIFICATION OF CFO SECTION 906 Certification of CFO Section 906

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Amedisys, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2010 (the “Report”), I, Dale E. Redman, Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 27, 2010

 

/s/ Dale E. Redman

Dale E. Redman

Chief Financial Officer

EX-101.INS 6 amed-20100331.xml XBRL INSTANCE DOCUMENT 28559614 25648000 1534000 81980000 21554000 35592000 150572000 65658000 108000 374981000 1222445000 261108000 25806000 0.001 60000000 28548967 28435994 29000 11446000 30821000 124832000 13337000 789054000 59093000 438030000 1222445000 238623000 162799000 40581000 1353000 500000 15905000 17750000 5787000 0.001 5000000 0 0 12651000 95440000 408735000 783062000 784415000 112973 791000 4618000 2847000 34485000 16535000 33035000 150269000 59780000 114000 363670000 1172351000 218036000 26371000 0.001 60000000 28303216 28191174 28000 11245000 29399000 119619000 11824000 786923000 57608000 436016000 1172351000 229306000 170899000 44254000 1169000 23003000 17865000 6412000 0.001 5000000 0 0 10279000 91919000 372089000 735166000 736335000 112042 735000 4618000 22801000 394000 165039000 294919000 1141000 6282000 1.01 0.99 672000 -98000 341838000 44323000 424000 16565000 17286000 -99000 -15112000 -5252000 -507000 -167000 2981000 3455000 5034000 81000 73025000 -16618000 -15066000 54485000 27022000 15000 -2596000 46919000 42266000 354000 7490000 7478000 454000 24200000 313000 356000 425000 1222000 27037000 6166000 12250000 31200000 2141000 27293000 26854000 4530000 --12-31 AMED AMEDISYS INC Q1 2010 2010-03-31 10-Q 0000896262 Large Accelerated Filer false 47495000 394000 <div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> </p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>6. COMMITMENTS AND CONTINGENCIES</b></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Legal Proceedings</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Insurance</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported, up to specified deductible limits. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our health insurance has a retention limit of $0.5 million, our workers&#x2019; compensation insurance has a retention limit of $0.4 million and our professional liability insurance has a retention limit of $0.3 million.</font></p> </div> 204062000 351253000 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>5. LONG-TERM OBLIGATIONS</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt, including capital lease obligations, consisted of the following for the periods indicated (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>March&#xA0;31,&#xA0;2010</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2009</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Senior Notes:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">$35.0 million Series A Notes; semi-annual interest only payments; interest rate at 6.07%&#xA0;per annum; due March&#xA0;25, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">$30.0 million Series B Notes; semi-annual interest only payments; interest rate at 6.28%&#xA0;per annum; due March&#xA0;25, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">30.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">30.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">$35.0 million Series C Notes; semi-annual interest only payments; interest rate at 6.49%&#xA0;per annum; due March&#xA0;25, 2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">$150.0 million Term Loan; $7.5 million principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (1.01% at March&#xA0;31, 2010); due March&#xA0;26, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">90.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">97.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Capital leases</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">215.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Current portion of long-term obligations</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(44.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 5em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">162.8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">170.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our weighted-average interest rate for our five year Term Loan for the quarters ended March&#xA0;31, 2010 and 2009 was 1.0% and 2.6%, respectively.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">As of March&#xA0;31, 2010, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.7 and our fixed charge coverage ratio was 2.6.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">As of March&#xA0;31, 2010, our availability under our $250.0 million Revolving Credit Facility was $234.6 million as we had $15.4 million outstanding in letters of credit.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.</font></p> </div> 1623000 8186000 1.32 1.29 90000 714000 -171000 <div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes the activity related to our goodwill and our other intangible assets, net, as of and for the three-month period ended March&#xA0;31, 2010 (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="8" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Goodwill</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Home&#xA0;Health</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Hospice</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at December 31, 2009</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">719.9</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">67.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">786.9</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.1</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at March 31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">722.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">67.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">789.0</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="69%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="12" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other Intangible Assets, Net</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Certificates<br /> Of&#xA0;Need&#xA0;and<br /> Licenses</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Acquired<br /> Name&#xA0;of<br /> Business<br /> (1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Non-Compete<br /> Agreements&#xA0;&amp;<br /> Reacquired<br /> Franchise<br /> Rights (2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at December 31, 2009</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43.4</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.7</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at March 31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43.6</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">59.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td> <td valign="top" align="left"> <p align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Acquired Names of Business includes $4.4 million of unamortized acquired names and $0.4 million of amortized acquired names which have a weighted-average amortization period of 3.1 years.</font></p> </td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(2)</font></td> <td valign="top" align="left"> <p align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The weighted-average amortization period of our non-compete agreements and reacquired franchise rights is 3.2 and 2.6 years, respectively.</font></p> </td> </tr> </table> </div> 412967000 60377000 788000 14620000 23547000 4636000 4648000 7425000 -295000 -625000 -4885000 2411000 3735000 85000 87499000 -9176000 -14366000 71037000 36646000 184000 -1337000 61714000 <div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="center"></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (&#x201C;Amedisys,&#x201D; &#x201C;we,&#x201D; &#x201C;us,&#x201D; or &#x201C;our&#x201D;) are a multi-state provider of home health and hospice services with approximately 87% of our net service revenue derived from Medicare for the three-month periods ended March&#xA0;31, 2010 and 2009. As of March&#xA0;31, 2010, we had 532 Medicare-certified home health and 68 Medicare-certified hospice agencies in 42 states within the United States, the District of Columbia and Puerto Rico.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of Presentation</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201C;U.S. GAAP&#x201D;). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#xA0;31, 2009 as filed with the Securities and Exchange Commission (&#x201C;SEC&#x201D;) on February&#xA0;23, 2010 (the &#x201C;Form 10-K&#x201D;), which includes information and disclosures not included herein.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reclassifications and Comparability</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior periods&#x2019; financial statements in order to conform them to the current period&#x2019;s presentation.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">As a result of our rapid growth through acquisition and start-up activities, our operating results may not be comparable for the periods that are presented.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Principles of Consolidation</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Equity Investments</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We consolidate subsidiaries and/or joint ventures when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For subsidiaries or joint ventures in which we do not have a controlling interest or for which we are not the primary beneficiary, we record such investments under the equity method of accounting.</font></p> </div> 44648000 201000 1969000 2377000 9966000 54000 939000 1445000 36830000 4345000 12274000 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>3. ACQUISITIONS</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health and hospice services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows for each transaction. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>2010 Acquisitions</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">On February&#xA0;1, 2010, we acquired certain assets and liabilities of a home health agency in DeQueen, Arkansas for a total purchase price of $2.5 million ($2.0 million in cash and a $0.5 million promissory note). In connection with the acquisition, we recorded substantially the entire purchase price as goodwill ($2.1 million) and other intangibles ($0.4 million).</font></p> </div> <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>7. SEGMENT INFORMATION</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the home of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. The &#x201C;other&#x201D; column in the following tables consists of costs relating to corporate support functions that are not directly attributable to a specific segment.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which exclude corporate expenses, but includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below. The following table summarizes our segment information for the periods indicated (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="12" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For&#xA0;the&#xA0;Three-Month&#xA0;Period&#xA0;Ended&#xA0;March&#xA0;31,&#xA0;2010</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Home&#xA0;Health</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Hospice</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net service revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">380.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">32.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">413.0</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of service, excluding depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">187.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">204.1</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and administrative expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">86.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">134.7</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Provision for doubtful accounts</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.3</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.6</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.2</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">280.7</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">45.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">351.3</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">99.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(45.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">61.7</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> <tr> <td height="16"></td> <td height="16" colspan="13"></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="12" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For&#xA0;the&#xA0;Three-Month&#xA0;Period&#xA0;Ended&#xA0;March&#xA0;31,&#xA0; 2009</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Home Health</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Hospice</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net service revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">321.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">341.8</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of service, excluding depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">153.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">165.0</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and administrative expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40.7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">117.4</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Provision for doubtful accounts</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.9</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.2</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.3</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">234.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">294.9</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">87.4</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(43.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">46.9</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> </table> </div> 2513000 <div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> </p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue Recognition</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We earn net service revenue through our home health and hospice agencies by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis (on a 60-day episode of care basis for home health services and on a 90-day episode of care basis for the first two hospice episodes of care and on a 60-day episode of care basis for any subsequent hospice episodes), on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day episode of care as episodic-based revenue. For the services we provide, Medicare is our largest payor.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Home Health Revenue Recognition</i></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Net service revenue is recorded under the Medicare payment program (&#x201C;PPS&#x201D;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&#xA0;an outlier payment if our patient&#x2019;s care was unusually costly; (b)&#xA0;a low utilization adjustment (&#x201C;LUPA&#x201D;) if the number of visits was fewer than five; (c)&#xA0;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&#xA0;a payment adjustment based upon the level of therapy services required (thresholds set at 6, 14 and 20 visits); (e)&#xA0;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f)&#xA0;changes in the base episode payments established by the Medicare Program; (g)&#xA0;adjustments to the base episode payments for case mix and geographic wages; and (h)&#xA0;recoveries of overpayments.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We make adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of such payment adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. During the three-month periods ended March&#xA0;31, 2010 and 2009, we recorded $0.2 million and $2.1 million, respectively, in estimated revenue adjustments to Medicare revenue.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of March&#xA0;31, 2010 and 2009, the difference between the cash received from Medicare for a request for anticipated payment (&#x201C;RAP&#x201D;) on episodes in progress and the associated estimated revenue was included as a reduction to our outstanding patient accounts receivable in our condensed consolidated balance sheets for such periods, since only a nominal amount represents cash collected in advance of providing services.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Non-Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Episodic-based Revenue.</i> We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Non-episodic Based Revenue.</i> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Hospice Revenue Recognition</i></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Hospice Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four main levels of care we provide are routine care, general inpatient care, continuous home care and respite care. We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider numbers and estimate amounts due back to Medicare if a cap has been exceeded.&#xA0;We record these adjustments as a reduction to revenue and increase other accrued liabilities.&#xA0;As of March&#xA0;31, 2010 and December&#xA0;31, 2009, we had $0.3 million and $0.1 million, respectively, recorded for estimated amounts due back to Medicare in other accrued liabilities in our accompanying condensed consolidated balance sheets. As a result of our adjustments, we believe our revenue and patients accounts receivable are recorded at amounts that will be ultimately realized.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Hospice Non-Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per visit rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receivable.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Patient Accounts Receivable</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. We believe the credit risk associated with our Medicare accounts, which represent 74% and 77% of our net patient accounts receivable at March&#xA0;31, 2010 and December&#xA0;31, 2009, respectively, is limited due to (i)&#xA0;our historical collection rate of over 99% from Medicare and (ii)&#xA0;the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. There is no other single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables, and thus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We fully reserve for accounts which are aged at 360 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Medicare Home Health</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#x201C;final billed&#x201D;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Medicare Hospice</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Non-Medicare Home Health and Hospice</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor based on either the contracted rates or expected payment rates, which are based on our historical experience. We estimate an allowance for doubtful accounts to reduce the carrying amount of the receivables to the amounts we estimate will be ultimately collected. Our review and evaluation of non-Medicare accounts includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. Where such groups have been identified, we have given special consideration to both the billing methodology and evaluation of the ultimate collectibility of the accounts. In addition, the amount of the allowance for doubtful accounts is based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectibility based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Fair Value of Financial Instruments</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The following details our financial instruments where the carrying value and fair value differ (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="46%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="8" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair Value at Re porting Date Using</b></font></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 72pt"> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Financial Instrument</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>As&#xA0;of&#xA0;March&#xA0;31,&#xA0;2010</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quoted&#xA0;Prices&#xA0;in<br /> Active&#xA0;Markets&#xA0;for<br /> Identical Items<br /> (Level 1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Significant&#xA0;Other<br /> Observable&#xA0;Inputs<br /> (Level 2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Significant<br /> Unobservable&#xA0;Inputs<br /> (Level 3)</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term obligations, excluding capital leases</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">195.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The estimates of the fair value of our long-term debt are based upon a discounted present value analysis of future cash flows. Due to the existing uncertainty in the capital and credit markets, the actual rates that would be obtained to borrow under similar conditions could materially differ from the estimates we have used.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 2 &#x2014; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable and accrued expenses, we estimate the carrying amounts&#x2019; approximate fair value due to their short term maturity. Our deferred compensation plan assets are recorded at fair value.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Weighted-Average Shares Outstanding</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income per share attributable to Amedisys, Inc. common stockholders (amounts in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="86%"></td> <td valign="bottom" width="2%"></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="3" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For&#xA0;the&#xA0;three-month&#xA0;periods<br /> ended Marc h 31,</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2010</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average number of shares outstanding - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,821</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,854</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Effect of dilutive securities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">175</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">250</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-vested stock and stock units</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">363</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">189</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average number of shares outstanding - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28,359</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,293</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For the three-month periods ended March&#xA0;31, 2010 and 2009, there were 4,222 and 41,501 shares, respectively, of additional securities that were anti-dilutive.</font></p> </div> 28359000 27821000 5705000 0000896262 2010-01-01 2010-03-31 0000896262 2009-01-01 2009-03-31 0000896262 2009-01-01 2009-12-31 0000896262 2009-12-31 0000896262 2008-12-31 0000896262 2010-03-31 0000896262 2009-03-31 0000896262 2010-04-22 shares iso4217:USD iso4217:USD shares EX-101.SCH 7 amed-20100331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONDENSED CONSOLIDATED INCOME STATEMENTS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - ACQUISITIONS link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - LONG-TERM OBLIGATIONS link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - COMMITMENTS AND CONTINGENCIES link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - SEGMENT INFORMATION link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Common Domain Members link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 amed-20100331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 amed-20100331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 amed-20100331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 amed-20100331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 g37026cov.jpg GRAPHIC begin 644 g37026cov.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`/`#"`P$1``(1`0,1`?_$`,8````&`P$!`0`````` M```````&!P@)"@$"!`,%"P$```%"(S-3%O%B/L#7Q'3VZ![].&QK.#B$XQSR09J8P)@#3 M4=.8="ZF^D/CX!\H^'!?/=R@>0WF82#->>,3[=L>6#*^:;W7\'^.M4;&-AMVZG*+-P9DYQOM/I\QFR: M:N!'1%O+3E9!2BU]%0P:'5>RR!4P`3&T`!XJUOTM7MU-XK`2$\PEA3C(E2G$ M2B9J9VG3#39_Q`9RG,::`Z\XU89=[BF5104QQM:Q+MTK[EJDL26W095=6F[M MTU5#$.8N+L*L9>.*X1*'.5-W840UT*(E'71Z+7'6X5U1SBG[@EKHI/X0@_)9 M&X!2F@[=?4&P<$-N.ZFVK&-E/?3?6358`,K7\`XCQIB6*2*8H&.V^T%M;98O M8"4XB4J[>3:#RAXD`=!`5+ZTMVE]"DQQT0^+TI,>F$J5O=W+TN7.8P34>&?) M9[[A,HLU2B1RVR3G?)-A:.!,40.8\4WG8V';D.8-0%)(H M:_T0#@E/J&ZH@BC2IL:?RTV^U085=AK9\W5'EW:X_C!%#M@;$DG9'R6W*I>? M*N"Y9$DM=0DDG7,)@=*/QM)CJGYO'4??P?\`N2^>0'2:LU8Q/_0#[8(["6Q8 M13<3427B=_\`+[H4UUM*K\>S;M\8<9QCA>K3M-;N'9 M?4I^N`S\@WYG*T61!,YRH_+MK!62/L/'76'+;HT/"Z?W0^W[T< M%^\T1^X?^,_ZY^['^_?U?_3XCO)N.7[R:<>6FL.]]M^8>O\`;!VX*'`Z0\(( MUC4QR$$`.8"\PZ%$?HF-J(6J-B*M3$XRK$5.WN=:0$9(6&1(JHQA6KIV)2*R#E)!0Y4P\>0AC#H`"/$A M98R^R)2QINJ.14&J=Q[H9WM]:8YGF7M04V<]>S@O."[@?=]MBW0GMA-O. M9B-17#%K<#42<1FDJ^O)-_-1Y)!9$H)$!XW^),0$0-[-=>#7V*R.,`-_2=24 M27U\%GV:PE897'Y3_P"A5%1.0(XIQ`XPXL#%$3``ZB4=#![P'0!T']0Z_HXC M-[2PO_=!2'[CM>*;OB(4=VFL;>[7W!P*51E;^65]GO@5'"B%J2]ON@"&FFOO M]G`-1C7AA/B,=;XF[Q\,8Y@UT_R^`?R^SA4L<`O"$F5J=1^QA5P[#&?`?8(# M^@0X*9#=PA5_@FZ49T'733QX;,NZ%1_EM)W]Q_".EI#=QTC'R_,.@_IX=%I` M4Z05C@\$MFD8$0`-1]G")K4P4)/J/X09@-2;)P5;A=ZQ0:O8+G;)$T76ZM%. MYJ=D"L9"0.RCV)#'XH\.J5&I7(;2"DGF![XZ]I MIS?(1"U0Y*6ATQ!6.:X/RFR,H\,@+IBS31LE6B7#=:20 M$@IJ*%(B8#E'700XNMO].>IKJW%U1M-U)S0Y=S-"-RZ\M.<4"]^H/3MA#3Q_'2%XPUW<-L.2-I"6\K*L@\VMXFG+)9("DGS4\AFMA MN;.#7:MH^PU6#KCY])3K.9=..F@T;$5<\X"4P`/$)5Z;OZ5W\BZB?FAJ/VZ: M3UAY3ZPQ=:V^<95)M^>UWNVK[(@/[B.>LV]]^E(86V`;7XOTGGN M^2<5CK'U]7C8H&T?!P$-8U&!Y$[IR511D!G"I]?B,1,PB4-/Z*9CNBL@VIU, MYE)SBT;4WH%+E\.XE01-`$BC=2UZW5UFY^`+ZDCP+:DQQXQ!EC'LD] MS7+%Z98T5VJY-QFC).48V>OF16#6L4JLLG"BC8T\YF7CHQ9Y*%:BHU2&.'%@T*#E&:X7H+JRWRH??T'L MM]X*^8'$#,-X^Q+3(*LPS&DU"O0#M[6H2.@&\Y M,Q<4T9R\RX:0[1B4QY5\W,L8YA$ZG,'/[./&N1R]?-Y"O63ER7B87=/G$-3`!0$OB`_"?G`1`>4I3F3*D(>(`'CK[> M(XT34)`J?;UQ).J?+!7L`'H^Z-ST1_F`1'CE&V-&IN:=[DT5/3,Q MPUFW3-CQMIJJCW2G`*8#>!=?E#Q$/\NG#@O>-6#_`)A!/E;?\[O;&XE'VF#P M#Y]?\_"9JEX\L-F>T0=EM2IN#VN*CO@:A^D/DY3'U_ZOM-^CW\%#:E$+PARX M;Q!1N<-7[14;57+-&LY&`L%'%"M4+VEJHHAA790:UV[XD/#[:1^:A]YF;/\`&EP_//37MCS1^L]5?D?\:?&-/7I'Z;W'DI=C MD,>IDW!1"79:RU0\)8\N^5,CV*/J5#H$$_L=PL+]T1NA$,&")E=>4XB`NGAN M5-)(H]9=58@$#4P<2]G:.NWMITPKW%`.>B^K[3B$R.0%DTDF0$SZXH`]SN>W M/]S'"^2NZ'88^7I.S_#]X@,9[9L9RC=QUIZMV.:1@+'E)`(*\BA!:!)`8PGZ@G-WU$Y! MM0ML'CPIHBM1)\]>^%S_`"KN7V]5W:YRPT[=F!OEO%3:Q0;==;P/,462=.I4 MR:13`@?IPI@^($N8"Z>.G'/KA:6%O;TZ]!B%KQHDU9H8/])3D*MP657"8YG@ M]5[Y1=KRMN-P#@)!JKFW-&+,3)O2+'8#D6^5BGKR"+0"IF5:)3\JR1M'$R]'&/0F0K4<;;"YKN";1,]Q/O!6&U MTKNE[$LFYTHVV[%FX>GY0RWD1I,OJ[!8Y"0N4:5K`13R9D5)BR0;-Y`0IB,6 M*@ID7<%.J<`(`:B'$[>=+97%4O,N:)I#_,1P2/XC@V4 M]0O,?;6',/\`>#MJC,"UWY9)R:3S[(?CE+-V*<'55[>Z)>I MGK'YCY4D`J!ZXC%L7?Q[8E?3B9%3.L_(TV8F',&QR=%8GR>XQHXD6`%]111M MBU6;-G@QQU"$6!N1@F%EB,L3-FB82COHB4 M'IQRZ,W+.63;K/G&B221A*JHL/3`O4^'B-I65Q>GRZ=-Q<4ER_#A"U3J&SHM M4$`'G]NR(YE>]MM%M,E88[;W5=RV[E*J.?+VFP[<,&7&[4RNF:H&HW)`9XD( MTY?;2443=XN35^Y=W*KSH^D>F+6S%`.MFVS4+E)(0,'6C*F',L4.M;,$]! M*060\AU=2`!CZAQC]UANK(R[;K;C^LOTH>R92J&$LRV/&,!(GZFC*0N M["D+P+98O)X@*@E^(H@(@8#<.KOI7+6+Q0N06.?H"X*54<%XPXL,]BLC1-Q2 MF&@^P+]\+C4^Y]V]KG16>28+>5MW&GR`K$:/IK*M3K4@=9NF"BS5:`L,E%V! MN\1`0YT3,P4+[RZ<1M;HW,,NJ=M194#ZP+I3#DX@Z2Y$K!K?J/'7%.O6):UM M!P;_`,T<-#[HNQ/+6:JGM[Q+N%IN3\J75I(O:_"T3U*S12J$6V1=/`?VB*8N M*[%KID7`.DNX*KS@)1*`\.C(!%X M:$.DV4(X.BY,FY\LJFL"8D.`\(V?1F:RHW6>XU.PC22^\0I<9FRQE7;A,\:SZ3Z=56.0EWA"IP)U]"ZQQO4F/JHYCFH1 MW^[[TA/S=Y;M\1EUKV/KWFB7Q!9[:1DI5F>:\79-Q,VL",BX\HS<1TC=:I$L M!:JN_JNJJHDF!_`1UX4K=(Y"RHNNGM"4PI\0/L00X;E*-5&L=KV1)P@_9OFB M3M%3K,W:":C9=$P*)O4'"'7349*MSG%T1U"BMNF('PFW&;GO4,9XR1:#S+T>#>@1G?,VS(I\YF%?Q55W#B04 M55**+EZBDU)S+JD(,Q8T:15SY-:%[24T]/#CPB,OJJG;SE[=8)/\)_:K_<"_ M_P`+OP/?03_]K?[Q_P!1_;W^\_ZSY^$?U7+_`)W?&NIU]<,?[8L_RMT^QTUB M2YR^*@@LX$R`)-D3+K*G7(1%,@$%4>HH<2D3(5$.RIDU&L7E/A%-_N$YGW#]Z?JX@DJ56L8E;7!-[7JR%98EDWC8\`*@IZ@==43& M/S&'F'O2=QTW2ZI_5F7=U4O*KS)[6AA+F%J2$NSM01&]2VV:9TG2LWT*3:5- M@"C=N"/!XK-=1[M(J\=E/+IL+]SW:3.`X!JWMU\'$LN]$XD:F99,C3P3E5V" MHD\LD"@@'*.@$'V\;=]4,?;Y+I:K=;5JLIN+0G%K0G<8S+Z>WM:AF6T6NVM< M\`]Q<5BYE^8='`E5[=^5KID[&E`M^4[*WJ^*\26&QUJ(D;5#VR6E5IMH,#/+ M(^M1*+=A#R*P^562#J:<^H&T'S9]*Z-W>=4?[1@;:TZSR\(2'`.8$/)5!U_= M[XVSK^K;V_3>VO5<;EP:0)2!:^?K"16#[`6`UJMWW M$P[%NM)8@QI8E?-6@<6RQTQ3C\[7IW&MHF.4,`E9PSF1=#J=$NNU?5^^LK1M M*CL8YYW>$F10M^+L&O>!KI&7_2FUK7+WU:[WL:"-.UKTUAJ7=[Q[MKQAORNV M#ML4([0I..(RDX_N$V2T3-HMUNRH0J#6\O):8L3F0=+V\LVN=LNJ4`16=F!3 MD`!$>+/]-[BDSHB_O\V&TJKK5YI[0FX[R@(.B-14G$-U=Y5?JFUM;*L]^RLU M53BT+,=NBRB=W?UM7H>!>U)%Y@W=Q5LE;[#T3&N$]I&W&9LCV.IN`'TA'HA' M6"TP\'(-&EASG/P5??2=EE5C.6K=X<&+=(K9-,1Q/HZ_O<:3UCLMND*0+ZCJGET@D@A+'+V\".'"(HNQI5:IBO*N9 M^XCF%!5/#VQ+$\_9`Z"Q6IK)EFZ0S^`J=-B_/(E;>LRD;(.E68$$Y?.`EX!K MIQJWU3M'9FFSI#'T?.O;MTF\A2^VCUZ\C*WJ7N-R1/6L.1-I/6:;C['L2)'TG#5E M650FX6O-5:^@5%W*G:+.%C&%14#&'7AW7L.E>C.D:E'(`TL@6/T`)+M02I!= M)/<(:4.,:3$GEC)S^.JL`JEZG(V%2$IU,3GV$+YU%JH`.%#.W*JBY'"JX"7$>E> MJ+JAE:AQ-(7M6Y>:9+MR(2%VM:3M8A)*%44+)8T_JCIUU]:T*]Q<5*+6-8XA MJ3`!L58P'M9Q&[EG:U?J=:D9 M<&$5?;RWC^1&P6F?1=J/9*2%/G9)FY4BIID.!MTIX&SPV`K9B_H4Z=S*I4(! M2==]5"C<.\NWWM0LU8"H`:'`B1F5F3J(U[/6]'I+`_/T7.J7&UQ1R M(2WQ31#Q27"(`OR\.,\-/=WMBS[GJ?IM>HF#:A$5JJEO,LP;#8TF M)B$'ASK663D((DNS<-BE,0!>`)P'VEU;ZOW67L\;9X6A5J.ITZ-%BIXDI!P+ MCM$D1I*<9)PC./IG2LKN_NLIJ@+PAG'=WMN$\K=PW, M\=MFQ92*/0J=)1N)86%QO5F=>@;E:ZX\<-YZ7+"5ADQ:N9&QR[CRR(/SEATTS(.JU*UNU4FH+M3^GJ%%0ADR"&M#Z>ZQM;_K&OENH&TZ+ZKJ;` M6@ANVF-OA+R%5-WI6+QG<'>6_3]/&8=SKD,#W%SSX_XDT(8)`+M'$@:JL-.[ M8W?"D]F6,5MIVX;$HNGZM5]PUK2`4+0@<\R"I(A9SXQ%]']; MT\*YV'S5)E*F00736>UBE2!,@I*7K,3T77M+[`Y[M`Y2JUM4MJ*`V8W`)Q4!#Z5 MBMO^7[7>MNZA@A=ET55C15Z;23DI#"(M7,6R!X0BHD4,'5*4!'0A`$WB8Y!' M4=]^K5@RKTZ;A2"&/*#_`$M$XR#Z=W%6RS>P/)9O9(H$\1,@/QB=CO&XJHN_ M_?)A#8)M[H])C[M6'IS>X7`(<1)$1T]"9%P]6L5J=Z^W3\BV7*D"L6=5)1)54XE3!,W.7<^E\KT?UO;.=E+A] MGZ2#13%@?;UOSVS=\"U[> MMM.]NG!AG<3C;)5=R?C:TTQ&%EZ'F)S53)^L8R4"THS,E7RVU1$IW48HD,QTJRXJ6C#4QNQ?$H62DR`:=JH?WB.,DB_=&]26V7KT;?(.\N M[-1&AI4:E!XBLP%Y"+2^?]RE3V^QM;KK6$?WK+5Z7/7\,X-J(MD[GD.90:I@ M'I^O[/4J7"HH"I*3+\$6$8Q3.;D$O-N3'$B7(G5KFB$IS8O'CW_;OCC;1]T-U23CRY<`.[G#WM M/G-_VN&&Q_YS[(E5=S]T5\-_M:[QF\G&E@PKM[Q9B/:5C>UMW&Q]'3K<.BNKUW3],#"F4$OI<7WI"_P"F[2HM:9.17(#:VJJQS=K(17I,(5E&"V=`'3!C\`#H)S,>K>H, M=E[XBUJG;MVM:FTM"D(BJ2O-#--(;]/87*XQQ;=MXJ>*_#R'(0Y7?ZS.QEB8P3+([E@[8R,1*)2#)9"6>0P1KM59PA MIS"8IPYAYODX]*U_J_TQD\$_&UP_$%KM1P MT_P]D2H=R;8SW=.ZU&[?*Y;,,86V]5O#47(O+4TE\Z,++'7?*LX1BRDK/$LZ MG'R#E&J146Q_\,3=?M95%U]?A.'&>]*=7=.])&Z^6W&O6J$@H2C!\([P5*HO M/2+;ENE\QGFT_F),IM#"%$R%4I+GWV-V/%5=0HU[W'3OVKN MD_+E<2,92[3D=RT<-:=7)"2,DW>EJD6'2244Z9!3*NJ8H:ZCQ5.K>J*G4.4^ M=<[^`%#00%"HI$E"H.Y."Q:>F^F6XG'_`"[`E62F?;K/@OMB*;:=^7%RA5]U MM-W7[M=R5'R?/164S9@MU#JM+?2;.[VY206E5$I^:L?D$QC?5E>HYZ+,Q3@0 M!+XZ<3M_]1FNP9P]%I:$>KMP$G#5-9>_E%;QWTW:`J`D/8A1 ML]-9B?`16+?Z9W[,'5IV*BY<6;=4DZ85>7[88ELT[8/>EV$[KJEF[%>TZMW" MTT]O/UX'5@R#3'&-IN#LS48N6UFF]A9RZ+1=M\;5P5)-=`FG,B8?#BQ9GKOH M?K*Q=;9FL:58@A6@J#)"`):`:@@Z3AEA^BB* M$>T(Y45*@HI]+'1G<;TME:=QT_O?;"NW^R+9$ M0(BJV"2KU-FH=O72JKMESE%*4.).4X@8.--ZK^LMAF\>^RM6JTA$(`";@4F$ MX'G%-P/TMN\5?BZN3X9\5*$$33T<.$2_]PSLW7'-NS2=P]MTR6I/9^O.2Z=E M#->7\_R9W]JSR[K'6+'QUJLL:T1;UN,@E%A-$0\9!88:9L_,16*L37>?J#Z#BK(U?/$$G,OP>YK8Q6W"`B[.I,6/)DO:XBSVU[)#+"\7>TB!JD MDNZ6?.55%%6;QP[:HH*F*=3F#4`O=#ZTXW&XH6K!N(```":&U7N[SY?,98S2WU;<\X&9-Y:4^^ M&OP>;EBQBACUFQ2Q+\LPC36N.8JBVD"'4.QING>JL;2*M MHY-CB2FG(`&0(3N(E*+K;X/.X+.U:Y:78QS&`<=`-W`G7\.,-8W&=E+=CW"M MY4[FH^WO'/;UPK8X^!86=DZN=1N-\L"\6HHK9+F6F8^?&*"_9!I&[&;W@.+1M/Q@TLMUB\>WFE&R):UW+''&$ ME[XV8Q262;7*E*1O./ZZFV.=G"M1,X?."@4P`4HZ^J?JODJ%'IRG1K.#=Q,M M=X`!V]QXGA'GWH?&U;C.[Z6NYLQ))F?88N177M>63%O;SW(;C1:_$%;LO:JC5DR[4%)H M?PAHM#@>X_%;#WNQW=)VSJUN,DJ?CHV,Z3D7[[\1JXMG8IK$JQD)9+@[FG+* MQ5Z1@D^0QG,>T%0J*>O-S`(\2HR.`NLT+_"7/E,WJX*9G@!.0<)$%=9(L-\C M:9>IC?)R-+<=NJ:354`&FO"(C.UAVL\\8\W$QF4*:I0,K9?Q%8'\=%ST)*N; M#MBP1:ET"@G;+CE"+%@GF2]5=FN/EJM52N6R;C5-X^1#4A="ZY^IMIU'B_TV MB@8&G<4"N#@`@"`C103I%0Z>Z.ZV,B:XN4JW"Q;))&(H&/8IT)S,Z_'%1:MS'`Z@ MNG`K+FP6\RE)=K?"P!$_;S[8VBTLBFY\RL.U%!(>4=!U*`@'Q&U$#"&H&'4. M;4/#Q]WA[.(]KQ1TCNX5A&(GY'*&[^7-;SQU8C4ZME395,4Q_`.70G$^S'6%!6-<6A MK-Q#="3RF)]B"(#]3OPCF,17(.!"<_7S@]QVZC)LUF:N4F/JM;,UD,V3>,[% MCIS`7)')E/I-9CI8JV8K+8CK)U!&$?.XQF[8))(*E=1TZT,(@L14"HOQ-@UI MKM`-39NWHU2==J*L^/+G!FY6^<0'!%29`YU&[=!LB5NT$%0`0U MU6?C;"HXLJ/W-!`0\]3J>'MX+"/ZG>@[Q3\1FH$_=!^O&[;/$?G6$PW4<0QJ M'4KN/)=1[87++HW)_:X]O(3D97IE[:X+RC.MD5.R4=EC9`X2"8E%+EX3HXZQ M%,O;4VL!/9IH0!SA1^7R.X-+"9#MU"_X]L.)W3W>^U+$SHF)6#YYDVVVJE4N MC$:`X1(1_.3[5U).I!\E$SGH<:A6(Z1/YU9HL1$QB:!\0!PC3L;=[@:CDD23 MKIP7G/WP#D[P`I3U/OXPU:[[D-Q&/4=PF0Y#'JLPPQB.),2TRAPT\XM%2=V& MZ30,;QD>?L M93<67R^12MH-]-L@(D@F6978-P[9B(TJQN$R M3C_'6X'*4=(9&W'6>ANJDVA9MO*`^P#:$;U-X>^Y5RU/TVKS[YO*35*BL>UZH2=N/>[)'5"V3WDIB7&%R.MN:VXH40*2J?8\((9T';:S6)HO2,:U]A&!#(Q=RBZQ,,C2+:5=M_34E"(-TUM%!05. M.L6+Y9W$%$""7YB>6H[Q!OG[UP1S3MX'7T>F!%[L\WSVY.VJ.G$.\=JB,6Q)!.C.$VJZ9G`&$JQ.G&V52 MB'N=XR`419G037TGAV047EW3>0Q@UU`U[85[:_G6YYO?Y0^T!:N2/HUO3@(E M:KPTRG!2K%RW]583L';)&0=IW%H[A7"1'908Q*[5Z51-1!,Q>4$*EG1MD=0& MVF1P0%>1Y3T,Q#NG4-TPFY=S.+O\`9:4W&C^4*`5)'`)H!K+G M#T[<6TDD=H+)&.#F?L,HYYG:RV=K[[I]6JZ8&XN M<@_*U>'8->,2]EC;#%-6A1I,4"KE:ER[Y:W+A4U.TD2'!1ZX+3;:9N%W.N&\KOFR4RB*&" M@+L=I6W*4GJOB]9H8P+)M,QY)763N.8NB<"@X8H!%0BRI/B:J)&,0Q:3[:P8 MF.:*1UW-&TKIH$24E]ZPHUM6L?\`=DO!YE1Z558D4I]+J./JS"4BC5B!J%.K M+%I#5RLUJ%:0%<@8IBB5!I%0\6P10:M6J29``"$(!.&%1VXSU.O;$G2I4:32 M*3&MEP`'N@UBF)M=/%4O24,(B(`B01Y""`CI[_=QS;4'_`'"H[XYO8LV2]$;$33*4 M`*D!-!U`/D,74`-X#[=/8/MX*:=0G^9[3`WM_+[H\U6R"H$*=%-0I#"8H"4` M,B8?:9(WM`QO?P7RZJ_S/?`WL_+/T)&P(D#7P-XARB(G$QC%\/IB/B(CI[/F MX[Y=3^H?;'?,;^4>H0#)$$H$$!$IOJQ*8`.4$S:\W@(^`?HXX:=7^H?;'?,9 MQ8/9&@-4!*"8I%Y4C%%+0.0I>4=2F+RB(ZZ\&:RJ)FH?;";WL*)37U1Z@!>< MYS`<3*"4PZ#J0!(``'@(AXCX>/M\.#;*G]2";V_TPOHC/(F'-HF!1,<%#=," MDYCAH(',;P$3A[A]O!AYC#N+U3AWP&['>$LV@\8PJ!.B8/$?;IIPWJ M56T/YE8CU_<(6%M;5!+:1'BJDU7(FFNF19$#`8J:P\Q`5+K\8`.HFYWAK*O8[\(-NK-6FRDH;Q\,QPXQDR2:OUQD@/JB9NERE3.L=$1\/V@A3* M)D$=?`/#ATVC6>%;4\,$\ZH)FB57L_&/E2DQ!UIBJ\EY*+@(UJF=5=S*O6<0 MQ;D+JJJLLX>+-T"$U$3&.(@'M$>'/RMW6HBC0#GU2OPS)]4,Q6Q[+IU:[J"G M4EX3P]A$^^&#Y3[JNQ+&#\:Z3/4+E*\`H5)#'F`(J2MSOIM(4%Q#>Q)J0=4EPAI>Y*Q#PZV:VH`0J M#OGP7AQXPG)-S^_//1U4-L.RI;#]1>`D5GF;>G;T**4[=T4QBR$7@RCFL61' M0-B!SBB\=1"@J"4H'`.80/:XO%8IU1UU=FN]Y!VMW.0@EMS+R2.^C(*KE,C>5#3K4GAHF'.(/8@\2S$]$A2E8VU%Y>TB8,O2O*%##]8<$W7!U! M2'!:P"21CA0!RA=(Y&>%($#@0(Z.!`CGX$"!P($#@0('`@0.!`@<"!`X$"!P M($#@0(P//H/)]+W>S]?M\/9P($<8]'X^7GZ?(?H='J>>YO'J\FG^RU_Z7P_J MX,SXQIJ-=/3V05_P'70Z:^B*Z6\[^%W]Y]L^[W[_`'\6G6=_:_\`AB_>!]Y/ MK7/]1]YGW1_\N?/^H\GG/7_K.KR>?^#I\6NS\]0OE^6H^->W3T^G1(I5YY7_ M`&?,7L3[:0QZ1_CI\B/X6/XB/HW,3TG\7WX2.GY?0.3S_IW_`!#Y;E_[_P"M MY?GXO6._L/8/UGR/F?WMBHJ\./KG%/O?[QG^G>=Y'!=-)]D?>#_]4/(R]:^[ MST?E_;_L1]Q7VN\ORAKZ?ZG^P];Y.;PUXG;C_P`3>3_"V[TX[M4B'H?^0O,G MO5>":>B/%&R/]O>?_\`C?*(O[RJLM.'/2+A8_W)L'S_`)Z)Z..JP;*C_`_\_`?B MX_%KZ]YY/T;^)I^)OT_U3J?^7?;#_@?DZOT]?V/E]GP\1S_U]'?*IL66Q%3_ M`(O\8GJ'R/A^:7S^.[V?#V18-VQ?@S^S"_X0OP[?97F+ZG^'O[`^3ZW1:\GJ M/V"^M\SY?H\_7^N^CS<0&0_5]_\`NMZ<-ZHL_P#A7[").C\C^Y[/NXPZ!IT. MN\YNCU^9'K=/V\O3-T>IS?6\_)K]+]7$"WSU/G)K)-(E+;R_%Y?.<=P\G]#3 ;Y]/YN#PZC'`@0.!`@<"!`X$"!P($='`@1__9 ` end XML 13 R11.xml IDEA: COMMITMENTS AND CONTINGENCIES 2.0.0.10 false COMMITMENTS AND CONTINGENCIES 112 - Disclosure - COMMITMENTS AND CONTINGENCIES true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_CommitmentsAndContingenciesDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> </p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>6. COMMITMENTS AND CONTINGENCIES</b></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Legal Proceedings</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Insurance</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported, up to specified deductible limits. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our health insurance has a retention limit of $0.5 million, our workers&#x2019; compensation insurance has a retention limit of $0.4 million and our professional liability insurance has a retention limit of $0.3 million.</font></p> </div> 6. COMMITMENTS AND CONTINGENCIES Legal Proceedings We are involved in legal actions in the normal course of business, some of which seek monetary damages, false false false Includes disclosure of commitments and contingencies. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 14 -Paragraph 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9, 10, 11, 12 false false 1 1 false UnKnown UnKnown UnKnown false true XML 14 R10.xml IDEA: LONG-TERM OBLIGATIONS 2.0.0.10 false LONG-TERM OBLIGATIONS 111 - Disclosure - LONG-TERM OBLIGATIONS true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_DebtDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>5. LONG-TERM OBLIGATIONS</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt, including capital lease obligations, consisted of the following for the periods indicated (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>March&#xA0;31,&#xA0;2010</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2009</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Senior Notes:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">$35.0 million Series A Notes; semi-annual interest only payments; interest rate at 6.07%&#xA0;per annum; due March&#xA0;25, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">$30.0 million Series B Notes; semi-annual interest only payments; interest rate at 6.28%&#xA0;per annum; due March&#xA0;25, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">30.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">30.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">$35.0 million Series C Notes; semi-annual interest only payments; interest rate at 6.49%&#xA0;per annum; due March&#xA0;25, 2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">$150.0 million Term Loan; $7.5 million principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (1.01% at March&#xA0;31, 2010); due March&#xA0;26, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">90.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">97.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Capital leases</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">215.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Current portion of long-term obligations</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(44.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 5em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">162.8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">170.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our weighted-average interest rate for our five year Term Loan for the quarters ended March&#xA0;31, 2010 and 2009 was 1.0% and 2.6%, respectively.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">As of March&#xA0;31, 2010, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.7 and our fixed charge coverage ratio was 2.6.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">As of March&#xA0;31, 2010, our availability under our $250.0 million Revolving Credit Facility was $234.6 million as we had $15.4 million outstanding in letters of credit.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.</font></p> </div> 5. LONG-TERM OBLIGATIONS Long-term debt, including capital lease obligations, consisted of the following for the periods indicated (amounts in false false false Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 4 false false 1 1 false UnKnown UnKnown UnKnown false true XML 15 R8.xml IDEA: ACQUISITIONS 2.0.0.10 false ACQUISITIONS 109 - Disclosure - ACQUISITIONS true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>3. ACQUISITIONS</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health and hospice services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows for each transaction. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>2010 Acquisitions</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">On February&#xA0;1, 2010, we acquired certain assets and liabilities of a home health agency in DeQueen, Arkansas for a total purchase price of $2.5 million ($2.0 million in cash and a $0.5 million promissory note). In connection with the acquisition, we recorded substantially the entire purchase price as goodwill ($2.1 million) and other intangibles ($0.4 million).</font></p> </div> 3. ACQUISITIONS We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base false false false Schedule of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This schedule does not include leveraged buyouts. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 68 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 52 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph a Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph F4 -Subparagraph e -Appendix F false false 1 1 false UnKnown UnKnown UnKnown false true XML 16 R12.xml IDEA: SEGMENT INFORMATION 2.0.0.10 false SEGMENT INFORMATION 113 - Disclosure - SEGMENT INFORMATION true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_SegmentReportingDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>7. SEGMENT INFORMATION</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the home of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. The &#x201C;other&#x201D; column in the following tables consists of costs relating to corporate support functions that are not directly attributable to a specific segment.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which exclude corporate expenses, but includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below. The following table summarizes our segment information for the periods indicated (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="12" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For&#xA0;the&#xA0;Three-Month&#xA0;Period&#xA0;Ended&#xA0;March&#xA0;31,&#xA0;2010</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Home&#xA0;Health</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Hospice</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net service revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">380.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">32.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">413.0</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of service, excluding depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">187.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">204.1</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and administrative expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">86.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">134.7</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Provision for doubtful accounts</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.3</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.6</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.2</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">280.7</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">45.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">351.3</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">99.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(45.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">61.7</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> <tr> <td height="16"></td> <td height="16" colspan="13"></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="12" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For&#xA0;the&#xA0;Three-Month&#xA0;Period&#xA0;Ended&#xA0;March&#xA0;31,&#xA0; 2009</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Home Health</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Hospice</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net service revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">321.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">341.8</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of service, excluding depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">153.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">165.0</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and administrative expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71.5</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40.7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">117.4</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Provision for doubtful accounts</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.9</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.2</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.3</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">234.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">294.9</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">87.4</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(43.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">46.9</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> </table> </div> 7. SEGMENT INFORMATION Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health false false false This element may be used to capture the complete disclosure of reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10% or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 false false 1 1 false UnKnown UnKnown UnKnown false true XML 17 R3.xml IDEA: CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) 2.0.0.10 false CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) true false In Thousands, except Share data false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 false 2 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 true true false false 25806000 25806 false false false 2 true true false false 26371000 26371 false false false A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false 6 3 us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 65658000 65658 false false false 2 false true false false 59780000 59780 false false false The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -Subparagraph c Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 14 -Article 5 false 7 3 us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 true true false false 13337000 13337 false false false 2 true true false false 11824000 11824 false false false The accumulated amount of amortization of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(1) false 8 3 us-gaap_PreferredStockParOrStatedValuePerShare us-gaap true na instant decimal No definition available. false false false false false false false false false false false true 1 true true false false 0.001 0.001 false false false 2 true true false false 0.001 0.001 false false false Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 false 9 3 us-gaap_PreferredStockSharesAuthorized us-gaap true na instant shares No definition available. false false false false false false false false false false false false 1 false true false false 5000000 5000000.00 false false false 2 false true false false 5000000 5000000.00 false false false The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 false 10 3 us-gaap_PreferredStockSharesIssued us-gaap true na instant shares No definition available. false false false false false false false false false false false false 1 false true false false 0 0 false false false 2 false true false false 0 0 false false false Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 11 3 us-gaap_PreferredStockSharesOutstanding us-gaap true na instant shares No definition available. false false false false false false false false false false false false 1 false true false false 0 0 false false false 2 false true false false 0 0 false false false Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 12 3 us-gaap_CommonStockParOrStatedValuePerShare us-gaap true na instant decimal No definition available. false false false false false false false false false false false true 1 true true false false 0.001 0.001 false false false 2 true true false false 0.001 0.001 false false false Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 13 3 us-gaap_CommonStockSharesAuthorized us-gaap true na instant shares No definition available. false false false false false false false false false false false false 1 false true false false 60000000 60000000.00 false false false 2 false true false false 60000000 60000000.00 false false false The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 14 3 us-gaap_CommonStockSharesIssued us-gaap true na instant shares No definition available. false false false false false false false false false false false false 1 false true false false 28548967 28548967.00 false false false 2 false true false false 28303216 28303216.00 false false false Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 15 3 us-gaap_CommonStockSharesOutstanding us-gaap true na instant shares No definition available. false false false false false false false false false false false false 1 false true false false 28435994 28435994.00 false false false 2 false true false false 28191174 28191174.00 false false false Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Excludes common shares repurchased by the entity and held as Treasury shares. Shares outstanding equals shares issued minus shares held in treasury. Does not include common shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 16 3 us-gaap_TreasuryStockShares us-gaap true na instant shares No definition available. false false false false false false false false false false false false 1 false true false false 112973 112973.00 false false false 2 false true false false 112042 112042.00 false false false Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false false 2 12 false Thousands NoRounding Thousands false true XML 18 R4.xml IDEA: CONDENSED CONSOLIDATED INCOME STATEMENTS 2.0.0.10 false CONDENSED CONSOLIDATED INCOME STATEMENTS (USD $) 105 - Statement - CONDENSED CONSOLIDATED INCOME STATEMENTS true false In Thousands, except Per Share data false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 false 2 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_HealthCareOrganizationPatientServiceRevenue us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 true true false false 412967000 412967 false false false 2 true true false false 341838000 341838 false false false Amount of revenue recognized during the period for providing services to patients, primarily on an inpatient or outpatient basis and from office visits. For financial reporting purposes, patient service revenue is reflected net of provisions for contractual allowances (the amount needed to reduce the entity's gross billing rates to agreed-upon rates in contracts with third-party payers) and other adjustments. Significant revenue earned under capitation arrangements is reported separately. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Audit and Accounting Guide (AAG) -Number AAG-HCO -Chapter 8 -Paragraph 10 -IssueDate 2006-05-01 false 6 3 us-gaap_CostOfServices us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 204062000 204062 false false false 2 false true false false 165039000 165039 false false false Total costs related to services rendered by an entity during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 false 7 3 us-gaap_GeneralAndAdministrativeExpenseAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 8 4 us-gaap_LaborAndRelatedExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 87499000 87499 false false false 2 false true false false 73025000 73025 false false false The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including share-based compensation, and pension and other postretirement benefit expense. No authoritative reference available. false 9 4 us-gaap_ShareBasedCompensation us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 2513000 2513 false false false 2 false true false false 2141000 2141 false false false The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 10 4 us-gaap_OtherGeneralAndAdministrativeExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 44648000 44648 false false false 2 false true false false 42266000 42266 false false false The sum of expenses not otherwise specified in the taxonomy for managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No authoritative reference available. false 11 3 us-gaap_ProvisionForDoubtfulAccounts us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 4345000 4345 false false false 2 false true false false 6166000 6166 false false false Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 5 -Article 5 false 12 3 us-gaap_DepreciationAndAmortization us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 8186000 8186 false false false 2 false true false false 6282000 6282 false false false The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 false 13 3 us-gaap_CostsAndExpenses us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 351253000 351253 false false false 2 false true false false 294919000 294919 false false false Total costs of sales and operating expenses for the period. No authoritative reference available. true 14 3 us-gaap_OperatingIncomeLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 61714000 61714 false false false 2 false true false false 46919000 46919 false false false The net result for the period of deducting operating expenses from operating revenues. No authoritative reference available. true 15 3 us-gaap_NonoperatingIncomeExpenseAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 16 4 us-gaap_InvestmentIncomeInterestAndDividend us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 85000 85 false false false 2 false true false false 81000 81 false false false Income derived from investments in debt and equity securities and on cash and cash equivalents. Interest income represents earnings which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Dividend income represents a distribution of earnings to shareholders by investee companies. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 115 -Paragraph 14 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Subparagraph a, b -Article 5 false 17 4 us-gaap_InterestExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -2411000 -2411 false false false 2 false true false false -3455000 -3455 false false false The cost of borrowed funds accounted for as interest that was charged against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 21 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Chapter V -Section 563c.102 -Paragraph 9 -Subsection II Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 false 18 4 us-gaap_IncomeLossFromEquityMethodInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 788000 788 false false false 2 false true false false 424000 424 false false false This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 19 -Subparagraph c Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 6 -Subparagraph b false 19 4 us-gaap_OtherNonoperatingIncomeExpense us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 201000 201 false false false 2 false true false false 354000 354 false false false The net amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 false 20 4 us-gaap_NonoperatingIncomeExpense us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -1337000 -1337 false false false 2 false true false false -2596000 -2596 false false false The aggregate amount of income (expense) from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 true 21 3 us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 60377000 60377 false false false 2 false true false false 44323000 44323 false false false Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Subparagraph 1(i) -Article 4 true 22 3 us-gaap_IncomeTaxExpenseBenefit us-gaap true debit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -23547000 -23547 false false false 2 false true false false -17286000 -17286 false false false The sum of the current income tax expense (benefit) and the deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b false 23 3 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 36830000 36830 false false false 2 false true false false 27037000 27037 false false false The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) true 24 3 us-gaap_NetIncomeLossAttributableToNoncontrollingInterest us-gaap true debit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -184000 -184 false false false 2 false true false false -15000 -15 false false false The portion of net income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 false 25 3 us-gaap_NetIncomeLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 true true false false 36646000 36646 false false false 2 true true false false 27022000 27022 false false false The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 true 26 3 us-gaap_EarningsPerShareAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 27 4 us-gaap_EarningsPerShareBasic us-gaap true na duration decimal No definition available. false false false false false false false false false false false verboselabel true 1 true true false false 1.32 1.32 false false false 2 true true false false 1.01 1.01 false false false The amount of net income or loss for the period per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 false 28 4 us-gaap_EarningsPerShareDiluted us-gaap true na duration decimal No definition available. false false false false false false false false false false false verboselabel true 1 true true false false 1.29 1.29 false false false 2 true true false false 0.99 0.99 false false false The amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 false 29 3 us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 30 4 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic us-gaap true na duration shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 27821000 27821 false false false 2 false true false false 26854000 26854 false false false Number of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false 31 4 us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding us-gaap true na duration shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 28359000 28359 false false false 2 false true false false 27293000 27293 false false false The average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false false 2 27 false Thousands Thousands Hundreds false true XML 19 R9.xml IDEA: GOODWILL AND OTHER INTANGIBLE ASSETS, NET 2.0.0.10 false GOODWILL AND OTHER INTANGIBLE ASSETS, NET 110 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes the activity related to our goodwill and our other intangible assets, net, as of and for the three-month period ended March&#xA0;31, 2010 (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="8" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Goodwill</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Home&#xA0;Health</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Hospice</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at December 31, 2009</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">719.9</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">67.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">786.9</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.1</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at March 31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">722.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">67.0</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">789.0</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="69%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="12" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other Intangible Assets, Net</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Certificates<br /> Of&#xA0;Need&#xA0;and<br /> Licenses</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Acquired<br /> Name&#xA0;of<br /> Business<br /> (1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Non-Compete<br /> Agreements&#xA0;&amp;<br /> Reacquired<br /> Franchise<br /> Rights (2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at December 31, 2009</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43.4</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.7</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Additions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.1</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balances at March 31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43.6</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">59.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td> <td valign="top" align="left"> <p align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Acquired Names of Business includes $4.4 million of unamortized acquired names and $0.4 million of amortized acquired names which have a weighted-average amortization period of 3.1 years.</font></p> </td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(2)</font></td> <td valign="top" align="left"> <p align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The weighted-average amortization period of our non-compete agreements and reacquired franchise rights is 3.2 and 2.6 years, respectively.</font></p> </td> </tr> </table> </div> 4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET The following table summarizes the activity related to our goodwill and our other intangible assets, net, as of false false false Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subjec t to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each g oodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 43, 44, 45, 46, 47 false false 1 1 false UnKnown UnKnown UnKnown false true XML 20 R6.xml IDEA: NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS 2.0.0.10 false NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS 107 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="center"></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (&#x201C;Amedisys,&#x201D; &#x201C;we,&#x201D; &#x201C;us,&#x201D; or &#x201C;our&#x201D;) are a multi-state provider of home health and hospice services with approximately 87% of our net service revenue derived from Medicare for the three-month periods ended March&#xA0;31, 2010 and 2009. As of March&#xA0;31, 2010, we had 532 Medicare-certified home health and 68 Medicare-certified hospice agencies in 42 states within the United States, the District of Columbia and Puerto Rico.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of Presentation</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201C;U.S. GAAP&#x201D;). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#xA0;31, 2009 as filed with the Securities and Exchange Commission (&#x201C;SEC&#x201D;) on February&#xA0;23, 2010 (the &#x201C;Form 10-K&#x201D;), which includes information and disclosures not included herein.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reclassifications and Comparability</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior periods&#x2019; financial statements in order to conform them to the current period&#x2019;s presentation.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">As a result of our rapid growth through acquisition and start-up activities, our operating results may not be comparable for the periods that are presented.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Principles of Consolidation</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Equity Investments</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We consolidate subsidiaries and/or joint ventures when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For subsidiaries or joint ventures in which we do not have a controlling interest or for which we are not the primary beneficiary, we record such investments under the equity method of accounting.</font></p> </div> 1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS Amedisys, Inc., a Delaware corporation, and its consolidated false false false Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS140-4 and FIN46(R)-8 -Paragraph 8, C1, C7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4, 14, 15 false false 1 1 false UnKnown UnKnown UnKnown false true XML 21 R5.xml IDEA: CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 2.0.0.10 false CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS true false In Thousands false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 false 2 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities include all transactions and events that are not defined as investing or financing activities. Operating activities generally involve producing and delivering goods and providing services. Cash flows from operating activities are generally the cash effects of transactions and other events that enter into the determination of net income. false 6 4 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 true true false false 36830000 36830 false false false 2 true true false false 27037000 27037 false false false The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) false 7 4 us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 8 5 us-gaap_DepreciationAndAmortization us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 8186000 8186 false false false 2 false true false false 6282000 6282 false false false The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 false 9 5 us-gaap_ProvisionForDoubtfulAccounts us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 4345000 4345 false false false 2 false true false false 6166000 6166 false false false Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 5 -Article 5 false 10 5 us-gaap_ShareBasedCompensation us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 2513000 2513 false false false 2 false true false false 2141000 2141 false false false The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 11 5 amed_EmployeeMatchExpense amed false debit duration monetary The noncash expense that accounts for the value of stock issued to employees as the employers' matching contribution to the... false false false false false false false false false false false false 1 false true false false 5705000 5705 false false false 2 false true false false 4530000 4530 false false false The noncash expense that accounts for the value of stock issued to employees as the employers' matching contribution to the company's 401K plan. No authoritative reference available. false 12 5 us-gaap_GainLossOnSaleOfPropertyPlantEquipment us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false 171000 171 false false false 2 false true false false 98000 98 false false false The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 13 5 us-gaap_DeferredIncomeTaxExpenseBenefit us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 1623000 1623 false false false 2 false true false false 1141000 1141 false false false The component of income tax expense for the period representing the net change in the entity's deferred tax assets and liabilities pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 289 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 false 14 5 us-gaap_IncomeLossFromEquityMethodInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -788000 -788 false false false 2 false true false false -424000 -424 false false false This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 19 -Subparagraph c Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 6 -Subparagraph b false 15 5 us-gaap_AmortizationOfFinancingCostsAndDiscounts us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 394000 394 false false false 2 false true false false 394000 394 false false false The component of interest expense representing the noncash expenses charged against earnings in the period to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 16 5 us-gaap_EquityMethodInvestmentDividendsOrDistributions us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 90000 90 false false false 2 false false false false 0 0 false false false This item represents disclosure of the amount of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporation; these investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 13 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 19 false 17 5 us-gaap_IncreaseDecreaseInOperatingCapitalAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 18 6 us-gaap_IncreaseDecreaseInAccountsReceivable us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -4648000 -4648 false false false 2 false true false false 15112000 15112 false false false The net change during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 19 6 us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false 4885000 4885 false false false 2 false true false false -2981000 -2981 false false false The net change during the reporting period in the value of this group of assets within the working capital section. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 20 6 us-gaap_IncreaseDecreaseInOtherOperatingAssets us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false 295000 295 false false false 2 false true false false 507000 507 false false false The net change during the reporting period in other operating assets not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 21 6 us-gaap_IncreaseDecreaseInAccountsPayable us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 4636000 4636 false false false 2 false true false false -99000 -99 false false false The net change during the reporting period in the aggregate amount of obligations due within one year (or one business cycle). This may include trade payables, amounts due to related parties, royalties payable, and other obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 22 6 us-gaap_IncreaseDecreaseInAccruedLiabilities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 7425000 7425 false false false 2 false true false false -5252000 -5252 false false false The net change during the reporting period in the aggregate amount of expenses incurred but not yet paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 23 6 us-gaap_IncreaseDecreaseInOtherOperatingLiabilities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -625000 -625 false false false 2 false true false false -167000 -167 false false false The net change during the reporting period in other operating obligations not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 24 4 us-gaap_NetCashProvidedByUsedInOperatingActivities us-gaap true na duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 71037000 71037 false false false 2 false true false false 54485000 54485 false false false The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 25 3 us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 26 4 us-gaap_ProceedsFromSaleOfRestrictedInvestments us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 356000 356 false false false The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15, 16 false 27 4 us-gaap_PaymentsToAcquireRestrictedInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -54000 -54 false false false 2 false true false false -454000 -454 false false false The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15, 17 false 28 4 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -9966000 -9966 false false false 2 false true false false -7478000 -7478 false false false The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c false 29 4 us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -1969000 -1969 false false false 2 false true false false -7490000 -7490 false false false The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15, 17 false 30 4 us-gaap_PaymentsToAcquireIntangibleAssets us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -2377000 -2377 false false false 2 false false false false 0 0 false false false The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c false 31 4 us-gaap_NetCashProvidedByUsedInInvestingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -14366000 -14366 false false false 2 false true false false -15066000 -15066 false false false The net cash inflow (outflow) from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 32 3 us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 33 4 us-gaap_ProceedsFromRepaymentsOfBankOverdrafts us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 313000 313 false false false The net cash inflow (outflow) from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Technical Practice Aid (TPA) -Number 1300 -Paragraph 15 false 34 4 us-gaap_ProceedsFromStockOptionsExercised us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 939000 939 false false false 2 false true false false 425000 425 false false false The cash inflow associated with the amount received from holders exercising their stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph i Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a false 35 4 us-gaap_ProceedsFromStockPlans us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 1445000 1445 false false false 2 false true false false 1222000 1222 false false false The cash inflow associated with the amount received from the stock plan during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a false 36 4 us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 714000 714 false false false 2 false true false false 672000 672 false false false Reductions in the entity's income taxes that arise when compensation cost (from non-qualified share-based compensation) recognized on the entity's tax return exceeds compensation cost from share-based compensation recognized in financial statements. This element represents the cash inflow reported in the enterprise's financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph i Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 00-15 -Paragraph 3 false 37 4 us-gaap_ProceedsFromLongTermLinesOfCredit us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 24200000 24200 false false false The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph b false 38 4 us-gaap_RepaymentsOfLongTermLinesOfCredit us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false false false false 0 0 false false false 2 false true false false -31200000 -31200 false false false The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 39 4 us-gaap_RepaymentsOfLongTermDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -12274000 -12274 false false false 2 false true false false -12250000 -12250 false false false The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 40 4 us-gaap_NetCashProvidedByUsedInFinancingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -9176000 -9176 false false false 2 false true false false -16618000 -16618 false false false The net cash inflow (outflow) from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 41 3 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 47495000 47495 false false false 2 false true false false 22801000 22801 false false false The net change between the beginning and ending balance of cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 42 3 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false true false false periodstartlabel false 1 false true false false 34485000 34485 false false false 2 false true false false 2847000 2847 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 43 3 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false false true false periodendlabel false 1 false true false false 81980000 81980 false false false 2 false true false false 25648000 25648 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 44 3 us-gaap_SupplementalCashFlowInformationAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 45 4 us-gaap_InterestPaid us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 3735000 3735 false false false 2 false true false false 5034000 5034 false false false The amount of cash paid during the current period for interest owed on money borrowed; includes amount of interest capitalized Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 false 46 4 us-gaap_IncomeTaxesPaidNet us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 14620000 14620 false false false 2 false true false false 16565000 16565 false false false The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph f false 47 3 us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false Designated to encapsulate the entire footnote disclosure that gives information on the supplemental cash flow activities for noncash (or part noncash) transactions for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. false 48 4 us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 true true false false 500000 500 false false false 2 true true false false 1534000 1534 false false false The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 32 false false 2 44 false Thousands UnKnown UnKnown false true XML 22 defnref.xml IDEA: XBRL DOCUMENT No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The noncash expense that accounts for the value of stock issued to employees as the employers' matching contribution to the company's 401K plan. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Carrying amount as of the balance sheet date of obligations due Medicare upon demand. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. XML 23 R1.xml IDEA: Document and Entity Information 2.0.0.10 false Document and Entity Information 101 - Document - Document and Entity Information true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 false 2 usd $ false false shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 dei_DocumentType dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 10-Q 10-Q false false false 2 false false false false 0 0 false false false The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type should be limited to the same value as the supporting SEC submission type. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, NCSR, N-Q, and Other. No authoritative reference available. false 6 3 dei_AmendmentFlag dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false false false 2 false false false false 0 0 false false false If the value is true, then the document as an amendment to previously-filed/accepted document. No authoritative reference available. false 7 3 dei_DocumentPeriodEndDate dei false na duration date No definition available. false false false false false false false false false false false false 1 false false false false 0 0 2010-03-31 2010-03-31 false false false 2 false false false false 0 0 false false false The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements this will be the filing date. The format of the date is CCYY-MM-DD. No authoritative reference available. false 8 3 dei_DocumentFiscalYearFocus dei false na duration positiveinteger No definition available. false false false false false false false false false false false false 1 false true false false 2010 2010 false false false 2 false false false false 0 0 false false false This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No authoritative reference available. false 9 3 dei_DocumentFiscalPeriodFocus dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Q1 Q1 false false false 2 false false false false 0 0 false false false This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No authoritative reference available. false 10 3 dei_TradingSymbol dei false na duration normalizedstring No definition available. false false false false false false false false false false false false 1 false false false false 0 0 AMED AMED false false false 2 false false false false 0 0 false false false Trading symbol of an instrument as listed on an exchange. No authoritative reference available. false 11 3 dei_EntityRegistrantName dei false na duration normalizedstring No definition available. false false false false false false false false false false false false 1 false false false false 0 0 AMEDISYS INC AMEDISYS INC false false false 2 false false false false 0 0 false false false The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 12 3 dei_EntityCentralIndexKey dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 0000896262 0000896262 false false false 2 false false false false 0 0 false false false A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 13 3 dei_CurrentFiscalYearEndDate dei false na duration monthday No definition available. false false false false false false false false false false false false 1 false false false false 0 0 --12-31 --12-31 false false false 2 false false false false 0 0 false false false End date of current fiscal year in the format --MM-DD. No authoritative reference available. false 14 3 dei_EntityFilerCategory dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Large Accelerated Filer Large Accelerated Filer false false false 2 false false false false 0 0 false false false Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 15 3 dei_EntityCommonStockSharesOutstanding dei false na instant shares No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 28559614 28559614 false false false Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument No authoritative reference available. false false 2 11 false UnKnown NoRounding UnKnown false true XML 24 R2.xml IDEA: CONDENSED CONSOLIDATED BALANCE SHEETS 2.0.0.10 false CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS true false In Thousands false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 false 2 usd $ false false 6 4 us-gaap_AssetsCurrentAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 7 5 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 true true false false 81980000 81980 false false false 2 true true false false 34485000 34485 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 8 5 us-gaap_AccountsReceivableNetCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 150572000 150572 false false false 2 false true false false 150269000 150269 false false false Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false 9 5 us-gaap_PrepaidExpenseCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 12651000 12651 false false false 2 false true false false 10279000 10279 false false false Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 4 false 10 5 us-gaap_OtherAssetsCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 15905000 15905 false false false 2 false true false false 23003000 23003 false false false Aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 false 11 5 us-gaap_AssetsCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 261108000 261108 false false false 2 false true false false 218036000 218036 false false false Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true 12 4 us-gaap_PropertyPlantAndEquipmentNet us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 95440000 95440 false false false 2 false true false false 91919000 91919 false false false Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 12 -Paragraph 5 -Subparagraph b, c Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 false 13 4 us-gaap_Goodwill us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 789054000 789054 false false false 2 false true false false 786923000 786923 false false false Carrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 43 false 14 4 us-gaap_IntangibleAssetsNetExcludingGoodwill us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 59093000 59093 false false false 2 false true false false 57608000 57608 false false false Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 false 15 4 us-gaap_OtherAssetsNoncurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 17750000 17750 false false false 2 false true false false 17865000 17865 false false false Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 false 16 4 us-gaap_Assets us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 1222445000 1222445 false false false 2 false true false false 1172351000 1172351 false false false Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 true 18 4 us-gaap_LiabilitiesCurrentAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 19 5 us-gaap_AccountsPayableCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 21554000 21554 false false false 2 false true false false 16535000 16535 false false false Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 false 20 5 us-gaap_EmployeeRelatedLiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 124832000 124832 false false false 2 false true false false 119619000 119619 false false false Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 false 21 5 us-gaap_AccruedLiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 35592000 35592 false false false 2 false true false false 33035000 33035 false false false Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 false 22 5 amed_MedicareObligations amed false credit instant monetary Carrying amount as of the balance sheet date of obligations due Medicare upon demand. false false false false false false false false false false false false 1 false true false false 4618000 4618 false false false 2 false true false false 4618000 4618 false false false Carrying amount as of the balance sheet date of obligations due Medicare upon demand. No authoritative reference available. false 23 5 us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 40581000 40581 false false false 2 false true false false 44254000 44254 false false false Obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future. No authoritative reference available. false 24 5 us-gaap_DeferredTaxLiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 11446000 11446 false false false 2 false true false false 11245000 11245 false false false Represents the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42, 43 false 25 5 us-gaap_LiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 238623000 238623 false false false 2 false true false false 229306000 229306 false false false Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true 26 4 us-gaap_LongTermDebtAndCapitalLeaseObligations us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 162799000 162799 false false false 2 false true false false 170899000 170899 false false false Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section H false 27 4 us-gaap_DeferredTaxLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 30821000 30821 false false false 2 false true false false 29399000 29399 false false false Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42 false 28 4 us-gaap_OtherLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 5787000 5787 false false false 2 false true false false 6412000 6412 false false false Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet due to materiality considerations. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 24 -Article 5 false 29 4 us-gaap_Liabilities us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 438030000 438030 false false false 2 false true false false 436016000 436016 false false false Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. No authoritative reference available. true 30 4 us-gaap_CommitmentsAndContingencies2009 us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 &nbsp; &nbsp; false false false 2 false false false false 0 0 &nbsp; &nbsp; false false false Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. This caption alerts the reader that one or more notes to the financial statements disclose pertinent information about the entity's commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 false 31 4 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 32 5 us-gaap_PreferredStockValueOutstanding us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false false false false 0 0 &nbsp; false false false 2 false false false false 0 0 &nbsp; false false false Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 33 5 us-gaap_CommonStockValueOutstanding us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 29000 29 false false false 2 false true false false 28000 28 false false false Value of all classes of common stock held by shareholders, which is net of related treasury stock. May be all or a portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 34 5 us-gaap_AdditionalPaidInCapitalCommonStock us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 374981000 374981 false false false 2 false true false false 363670000 363670 false false false Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 35 5 us-gaap_TreasuryStockValue us-gaap true debit instant monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -791000 -791 false false false 2 false true false false -735000 -735 false false false Value of common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. Treasury stock is issued but is not outstanding. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Note: number of treasury shares concept is in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Technical Bulletin (FTB) -Number 85-6 -Paragraph 3 false 36 5 us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 108000 108 false false false 2 false true false false 114000 114 false false false Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at fiscal year-end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, and unrealized gains and losses on certain investments in debt and equity securities as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14, 17, 26 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 37 5 us-gaap_RetainedEarningsAccumulatedDeficit us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 408735000 408735 false false false 2 false true false false 372089000 372089 false false false The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false 38 5 us-gaap_StockholdersEquity us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 783062000 783062 false false false 2 false true false false 735166000 735166 false false false Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true 39 5 us-gaap_MinorityInterest us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 1353000 1353 false false false 2 false true false false 1169000 1169 false false false Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 27 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A false 40 5 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 784415000 784415 false false false 2 false true false false 736335000 736335 false false false Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A true 41 4 us-gaap_LiabilitiesAndStockholdersEquity us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 true true false false 1222445000 1222445 false false false 2 true true false false 1172351000 1172351 false false false Total of all Liabilities and Stockholders' Equity items. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 true false 2 35 false Thousands UnKnown UnKnown false true XML 25 FilingSummary.xml IDEA: XBRL DOCUMENT 2.0.0.10 true Sheet 101 - Document - Document and Entity Information Document and Entity Information http://www.amedisys.com/taxonomy/role/DocumentDocumentandEntityInformation false R1.xml false Sheet 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS CONDENSED CONSOLIDATED BALANCE SHEETS http://www.amedisys.com/taxonomy/role/StatementOfFinancialPositionClassified false R2.xml false Sheet 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) http://www.amedisys.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical false R3.xml false Sheet 105 - Statement - CONDENSED CONSOLIDATED INCOME STATEMENTS CONDENSED CONSOLIDATED INCOME STATEMENTS http://www.amedisys.com/taxonomy/role/StatementOfIncomeAlternative false R4.xml false Sheet 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS http://www.amedisys.com/taxonomy/role/StatementOfCashFlowsIndirect false R5.xml false Sheet 107 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS http://www.amedisys.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock false R6.xml false Sheet 108 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES http://www.amedisys.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock false R7.xml false Sheet 109 - Disclosure - ACQUISITIONS ACQUISITIONS http://www.amedisys.com/taxonomy/role/NotesToFinancialStatementsScheduleOfBusinessAcquisitionsByAcquisitionTextBlock false R8.xml false Sheet 110 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET GOODWILL AND OTHER INTANGIBLE ASSETS, NET http://www.amedisys.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock false R9.xml false Sheet 111 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS http://www.amedisys.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock false R10.xml false Sheet 112 - Disclosure - COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES http://www.amedisys.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock false R11.xml false Sheet 113 - Disclosure - SEGMENT INFORMATION SEGMENT INFORMATION http://www.amedisys.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock false R12.xml false Book All Reports All Reports false 1 8 0 0 3 115 false false eol_PE2476----1010-Q0002_STD_0_20081231_0 1 eol_PE2476----1010-Q0002_STD_365_20091231_0 1 eol_PE2476----1010-Q0002_STD_90_20090331_0 50 eol_PE2476----1010-Q0002_STD_0_20090331_0 2 eol_PE2476----1010-Q0002_STD_90_20100331_0 66 eol_PE2476----1010-Q0002_STD_0_20100331_0 44 eol_PE2476----1010-Q0002_STD_0_20100422_0 1 eol_PE2476----1010-Q0002_STD_0_20091231_0 43 true true EXCEL 26 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls MT,\1X*&Q&N$`````````````````````/@`#`/[_"0`&```````````````! M`````0``````````$```;@````$```#^____``````````#_____________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_______________________]_____O___P,````$````!0````8````'```` M"`````D````*````"P````P````-````#@````\````0````$0```!(````3 M````%````!4````6````%P```!@````9````&@```!L````<````'0```!X` M```?````(````"$````B````(P```"0````E````)@```"<````H````*0`` M`"H````K````+````"T````N````+P```#`````Q````,@```#,````T```` M-0```#8````W````.````#D````Z````.P```#P````]````/@```#\```!` M````00```$(```!#````1````$4```!&````1P```$@```!)````2@```$L` M``!,````30```$X```!/````4````%$```!2````4P```%0```!5````5@`` M`%<```!8````60```%H```!;````7````%T```!>````7P```&````!A```` M8@```&,```!D````90```&8```!G````:````&D```!J````:P```&P```!M M````_O____[____^____________________________________________ M_____________________________________________U(`;P!O`'0`(`!% M`&X`=`!R`'D````````````````````````````````````````````````` M```````````6``4`__________\"```````````````````````````````` M``````````U!-YLH!;P```$`!````````5P!O`'(`:P!B`&\`;P!K```` M```````````````````````````````````````````````````````````` M`!(``@#_______________\````````````````````````````````````` M```````````"````]]<````````%`%,`=0!M`&T`80!R`'D`20!N`&8`;P!R M`&T`80!T`&D`;P!N````````````````````````````````````*``"`0$` M```#````_____P`````````````````````````````````````````````` M``````"```````````4`1`!O`&,`=0!M`&4`;@!T`%,`=0!M`&T`80!R`'D` M20!N`&8`;P!R`&T`80!T`&D`;P!N```````````````X``(`____________ M____`````````````````````````````````````````````````@```*`` M````````"0@0```&!0!&&,T'P8````8"``#A``(`L`3!``(```#B````7`!P M``<``'-S:'AB!#<`!0`9 M``$B`"0`(@`C`"P`(P`C`#``7P`I`#L`7``H`"``(@`D`"(`(P`L`",`(P`P M`%P`(``I`!X$00`&`!X``2(`)``B`",`+``C`",`,`!?`"D`.P!;`%(`90!D M`%T`7``H`"``(@`D`"(`(P`L`",`(P`P`%P`(``I`!X$0P`'`!\``2(`)``B M`",`+``C`",`,``N`#``,`!?`"D`.P!<`"@`(``B`"0`(@`C`"P`(P`C`#`` M+@`P`#``7``@`"D`'@1-``@`)``!(@`D`"(`(P`L`",`(P`P`"X`,``P`%\` M*0`[`%L`4@!E`&0`70!<`"@`(``B`"0`(@`C`"P`(P`C`#``+@`P`#``7``@ M`"D`'@1Q`"H`-@`!7P`H`"(`)``B`"H`(``C`"P`(P`C`#``7P`I`#L`7P`H M`"(`)``B`"H`(`!<`"@`(``C`"P`(P`C`#``7``@`"D`.P!?`"@`(@`D`"(` M*@`@`"(`+0`B`%\`*0`[`%\`*``@`$``7P`@`"D`'@1?`"D`+0`!7P`H`"H` M(``C`"P`(P`C`#``7P`I`#L`7P`H`"H`(`!<`"@`(``C`"P`(P`C`#``7``@ M`"D`.P!?`"@`*@`@`"(`+0`B`%\`*0`[`%\`*``@`$``7P`@`"D`'@2!`"P` M/@`!7P`H`"(`)``B`"H`(``C`"P`(P`C`#``+@`P`#``7P`I`#L`7P`H`"(` M)``B`"H`(`!<`"@`(``C`"P`(P`C`#``+@`P`#``7``@`"D`.P!?`"@`(@`D M`"(`*@`@`"(`+0`B`#\`/P!?`"D`.P!?`"@`(`!``%\`(``I`!X$;P`K`#4` M`5\`*``J`"``(P`L`",`(P`P`"X`,``P`%\`*0`[`%\`*``J`"``7``H`"`` M(P`L`",`(P`P`"X`,``P`%P`(``I`#L`7P`H`"H`(``B`"T`(@`_`#\`7P`I M`#L`7P`H`"``0`!?`"``*0`>!!\`I``-``$C`"P`(P`C`#``.P`H`",`+``C M`",`,``I`!X$(P"E``\``20`(P`L`",`(P`P`#L`*``D`",`+``C`",`,``I M`!X$+P"F`!4``20`(P`L`",`(P`P`"X`(P`C`#L`*``D`",`+``C`",`,``N M`",`(P`I`.``%```````]?\@``````````````#`(.``%``!````]?\@``#T M``````````!!(.``%``!````]?\@``#T``````````!!(.``%``"````]?\@ M``#T``````````!!(.``%``"````]?\@``#T``````````!!(.``%``````` M]?\@``#T``````````!!(.``%```````]?\@``#T``````````!!(.``%``` M````]?\@``#T``````````!!(.``%```````]?\@``#T``````````!!(.`` M%```````]?\@``#T``````````!!(.``%```````]?\@``#T``````````!! M(.``%```````]?\@``#T``````````!!(.``%```````]?\@``#T```````` M``!!(.``%```````]?\@``#T``````````!!(.``%```````]?\@``#T```` M``````!!(.``%````````0`@``````````````#`(.``%``!`"L`]?\@``#X M``````````!!(.``%``!`"D`]?\@``#X``````````!!(.``%``!`"P`]?\@ M``#X``````````!!(.``%``!`"H`]?\@``#X``````````!!(.``%``!``D` M]?\@``#X``````````!!(.``%``%`````0`@```(``````````#`(.``%``% M`````0`H```8``````````#`(.``%``%`````0`J```8``````````#`(.`` M%````````0`H```0``````````#`(.``%```````"0`@``````````````#` M(.``%```````"0`H```0``````````#`(.``%```````"0`(```0```````` M``#`(.``%````*0``0`@```$``````````#`(.``%````*4``0`@```$```` M``````#`(.``%``&`*0``0`@```,``````````#`(.``%``&`*4``0`@```, M``````````#`(.``%````*8``0`@```$``````````#`(),"!```@`#_DP($ M`!"``_^3`@0`$8`&_Y,"!``2@`3_DP($`!.`!_^3`@0`%(`%_V`!`@```(4` M1@`IIP`````?`40`;P!C`'4`;0!E`&X`=``@`&$`;@!D`"``10!N`'0`:0!T M`'D`(`!)`&X`9@!O`'(`;0!A`'0`:0!O`&X`A0!&`/JJ`````!\!0P!/`$X` M1`!%`$X`4P!%`$0`(`!#`$\`3@!3`$\`3`!)`$0`00!4`$4`1``@`$(`00!, M`$$`3@!#`$4`(`"%`$8`;;0`````'P$Q`%\`0P!/`$X`1`!%`$X`4P!%`$0` M(`!#`$\`3@!3`$\`3`!)`$0`00!4`$4`1``@`$(`00!,`$$`3@!#`(4`1@#P MN``````?`4,`3P!.`$0`10!.`%,`10!$`"``0P!/`$X`4P!/`$P`20!$`$$` M5`!%`$0`(`!)`$X`0P!/`$T`10`@`%,`A0!&`&7``````!\!0P!/`$X`1`!% M`$X`4P!%`$0`(`!#`$\`3@!3`$\`3`!)`$0`00!4`$4`1``@`%,`5`!!`%0` M10!-`$4`3@"%`$8`3LL`````'P%.`$$`5`!5`%(`10`@`$\`1@`@`$\`4`!% M`%(`00!4`$D`3P!.`%,`+``@`$,`3P!.`%,`3P!,`$D`1`!!`(4`1@`=S0`` M```?`5,`50!-`$T`00!2`%D`(`!/`$8`(`!3`$D`1P!.`$D`1@!)`$,`00!. M`%0`(`!!`$,`0P!/`%4`3@!4`$D`A0`@`.S.``````P!00!#`%$`50!)`%,` M20!4`$D`3P!.`%,`A0!&`+O0`````!\!1P!/`$\`1`!7`$D`3`!,`"``00!. M`$0`(`!/`%0`2`!%`%(`(`!)`$X`5`!!`$X`1P!)`$(`3`!%`"``00"%`#(` MBM(`````%0%,`$\`3@!'`"T`5`!%`%(`30`@`$\`0@!,`$D`1P!!`%0`20!/ M`$X`4P"%`$(`6=0`````'0%#`$\`30!-`$D`5`!-`$4`3@!4`%,`(`!!`$X` M1``@`$,`3P!.`%0`20!.`$<`10!.`$,`20!%`%,`A0`N`"C6`````!,!4P!% M`$<`30!%`$X`5``@`$D`3@!&`$\`4@!-`$$`5`!)`$\`3@",``0``0`!`,$! M"`#!`0``5(T!`/P`'R"<````G````!\``40`;P!C`'4`;0!E`&X`=``@`&$` M;@!D`"``10!N`'0`:0!T`'D`(`!)`&X`9@!O`'(`;0!A`'0`:0!O`&X`'P`! M,P`@`$T`;P!N`'0`:`!S`"``10!N`&0`90!D``T`"@!-`&$`<@`N`"``,P`Q M`"P`(``R`#``,0`P``T`"@`/``%!`'``<@`N`"``,@`R`"P`(``R`#``,0`P M``T`"@`-``%$`&\`8P!U`&T`90!N`'0`(`!4`'D`<`!E``0``3$`,``M`%$` M#@`!00!M`&4`;@!D`&T`90!N`'0`(`!&`&P`80!G``4``68`80!L`',`90`8 M``%$`&\`8P!U`&T`90!N`'0`(`!0`&4`<@!I`&\`9``@`$4`;@!D`"``1`!A M`'0`90`*``$R`#``,0`P`"T`,``S`"T`,P`Q`!H``40`;P!C`'4`;0!E`&X` M=``@`$8`:0!S`&,`80!L`"``60!E`&$`<@`@`$8`;P!C`'4`0`@`%(`90!G`&D```@`$L`90!Y M``H``3``,``P`#``.``Y`#8`,@`V`#(`'``!0P!U`'(`<@!E`&X`=``@`$8` M:0!S`&,`80!L`"``60!E`&$`<@`@`$4`;@!D`"``1`!A`'0`90`'``$M`"T` M,0`R`"T`,P`Q`!4``44`;@!T`&D`=`!Y`"``1@!I`&P`90!R`"``0P!A`'0` M90!G`&\`<@!Y`!<``4P`80!R`&<`90`@`$$`8P!C`&4`;`!E`'(`80!T`&4` M9``@`$8`:0!L`&4`<@`G``%%`&X`=`!I`'0`>0`@`$,`;P!M`&T`;P!N`"`` M4P!T`&\`8P!K`"P`(`!3`&@`80!R`&4`0!A`&(`;`!E`!T``5``80!Y`'(`;P!L`&P`(`!A`&X`9``@`&4` M;0!P`&P`;P!Y`&4`90`@`&(`90!N`&4`9@!I`'0``!E`',`&P`!3P!T`&@`90!R`"``;`!O`&X`9P`M M`'0`90!R`&T`(`!O`&(`;`!I`&<`80!T`&D`;P!N`',`$0`!5`!O`'0`80!L M`"``;`!I`&$`8@!I`&P`:0!T`&D`90!S`"8``4,`;P!M`&T`:0!T`&T`90!N M`'0`0`Z`%H``5``<@!E`&8` M90!R`'(`90!D`"``0`@`',`=`!O`&,`:P`@`&$`=``@`&,`;P!S`'0`+``@`#$` M,0`R`"P`.0`W`#,`(`!A`&X`9``@`#$`,0`R`"P`,``T`#(`(`!S`&@`80!R M`&4`0!S`"P`(`!)`&X`8P`N`"``0`@`&$`;@!D`"``90!Q`'4`:0!P`&T`90!N`'0`+``@`&$`8P!C M`'4`;0!U`&P`80!T`&4`9``@`&0`90!P`'(`90!C`&D`80!T`&D`;P!N`"L` M`4D`;@!T`&$`;@!G`&D`8@!L`&4`(`!A`',`@!A`'0`:0!O`&X`&@`! M4`!R`&4`9@!E`'(`<@!E`&0`(`!S`'0`;P!C`&L`+``@`'``80!R`"``=@!A M`&P`=0!E`"(``5``<@!E`&8`90!R`'(`90!D`"``@!E`&0`%P`!4`!R`&4`9@!E M`'(`<@!E`&0`(`!S`'0`;P!C`&L`+``@`&D`@!E`&0`&P`!0P!O`&T`;0!O`&X` M(`!S`'0`;P!C`&L`+``@`',`:`!A`'(`90!S`"``:0!S`',`=0!E`&0`(``! M0P!O`&T`;0!O`&X`(`!S`'0`;P!C`&L`+``@`',`:`!A`'(`90!S`"``;P!U M`'0`0`@`',`=`!O M`&,`:P`@`&$`=``@`&,`;P!S`'0`+``@`',`:`!A`'(`90!S`#```4,`3P!. M`$0`10!.`%,`10!$`"``0P!/`$X`4P!/`$P`20!$`$$`5`!%`$0`(`!)`$X` M0P!/`$T`10`@`%,`5`!!`%0`10!-`$4`3@!4`%,`(``H`%4`4P!$`"``)``I M`",``4D`;@`@`%0`:`!O`'4``!C`&P` M=0!D`&D`;@!G`"``9`!E`'``<@!E`&,`:0!A`'0`:0!O`&X`(`!A`&X`9``@ M`&$`;0!O`'(`=`!I`'H`80!T`&D`;P!N`"0``4<`90!N`&4`<@!A`&P`(`!A M`&X`9``@`&$`9`!M`&D`;@!I`',`=`!R`&$`=`!I`'8`90`@`&4`>`!P`&4` M;@!S`&4``!P`&4` M;@!S`&4`0!E`'(`(`!M`&$`=`!C M`&@`*@`!3`!O`',`0`@`&$`;@!D`"``90!Q`'4`:0!P`&T`90!N`'0` M,P`!10!Q`'4`:0!T`'D`(`!I`&X`(`!E`&$`<@!N`&D`;@!G`',`(`!O`&8` M(`!U`&X`8P!O`&X`@!A`'0`:0!O`&X`(`!O M`&8`(`!D`&4`9@!E`'(`<@!E`&0`(`!D`&4`8@!T`"``:0!S`',`=0!A`&X` M8P!E`"``8P!O`',`=`!S`!L``5(`90!T`'4`<@!N`"``;P!N`"``90!Q`'4` M:0!T`'D`(`!I`&X`=@!E`',`=`!M`&4`;@!T`$L``4,`:`!A`&X`9P!E`',` M(`!I`&X`(`!O`'``90!R`&$`=`!I`&X`9P`@`&$`0`@`&\`<`!E M`'(`80!T`&D`;@!G`"``80!C`'0`:0!V`&D`=`!I`&4`0`@`&$`;@!D`"``90!Q`'4`:0!P`&T`90!N`'0`,``!00!C`'$`=0!I M`',`:0!T`&D`;P!N`',`(`!O`&8`(`!B`'4`0!E`&4`(`!S M`'0`;P!C`&L`(`!P`'4`<@!C`&@`80!S`&4`(`!P`&P`80!N`"<``50`80!X M`"``8@!E`&X`90!F`&D`=``@`&8`<@!O`&T`(`!S`'0`;P!C`&L`(`!O`'`` M=`!I`&\`;@`@`&4`>`!E`'(`8P!I`',`90!S`"8``5``<@!O`&,`90!E`&0` M0!M`&4`;@!T`',` M(`!O`&8`(`!L`&\`;@!G`"T`=`!E`'(`;0`@`&\`8@!L`&D`9P!A`'0`:0!O M`&X`0!S`"P`(`!)`&X`8P`N`"P`(`!A`"``1`!E`&P`80!W`&$`<@!E M`"``8P!O`'(`<`!O`'(`80!T`&D`;P!N`"P`(`!A`&X`9``@`&D`=`!S`"`` M8P!O`&X`0!S`"P`(`!W`&4`+``@`'4``!I`&T`80!T`&4`;`!Y`"`` M.``W`"4`(`!O`&8`(`!O`'4`<@`@`&X`90!T`"``0`@`&\`9@`@`&X`;P!R`&T`80!L`"``<@!E`&,`=0!R`'(`:0!N M`&<`(`!A`&0`:@!U`',`=`!M`&4`;@!T`',`*0`@`&X`90!C`&4`0`@ M`&D`;@!D`&D`8P!A`'0`:0!V`&4`(`!O`&8`(`!R`&4`0!E`&$`<@`@`&$`;@!D`"``:`!A`'8` M90`@`&X`;P!T`"``8@!E`&4`;@`@`&$`=0!D`&D`=`!E`&0`(`!B`'D`(`!O M`'4`<@`@`&D`;@!D`&4`<`!E`&X`9`!E`&X`=``@`&$`=0!D`&D`=`!O`'(` M0!E`&$`<@`@`&4`;@!D`&4`9``@`$0`90!C`&4`;0!B M`&4`<@`S`#$`+``@`#(`,``P`#D`(`!A`',`(`!F`&D`;`!E`&0`(`!W`&D` M=`!H`"``=`!H`&4`(`!3`&4`8P!U`'(`:0!T`&D`90!S`"``80!N`&0`(`!% M`'@`8P!H`&$`;@!G`&4`(`!#`&\`;0!M`&D`0`@`&X`;P!T`"``8@!E`"``8P!O`&T`<`!A`'(`80!B`&P`90`@`&8`;P!R M`"``=`!H`&4`(`!P`&4`<@!I`&\`9`!S`"``=`!H`&$`=``@`&$`<@!E`"`` M<`!R`&4`0`@ M`&\`=P!N`&4`9``@`',`=0!B`',`:0!D`&D`80!R`&D`90!S`"X`(`!!`&P` M;``@`',`:0!G`&X`:0!F`&D`8P!A`&X`=``@`&D`;@!T`&4`<@!C`&\`;0!P M`&$`;@!Y`"``80!C`&,`;P!U`&X`=`!S`"``80!N`&0`(`!T`'(`80!N`',` M80!C`'0`:0!O`&X`0`@`$D`;@!V`&4`0`@`&D`0`@`&$`;@!D`"``=P!E`"``80!R`&4` M(`!T`&@`90`@`'``<@!I`&T`80!R`'D`(`!B`&4`;@!E`&8`:0!C`&D`80!R M`'D`(`!O`'(`(`!I`&8`(`!W`&4`(`!H`&$`=@!E`"``8P!O`&X`=`!R`&\` M;`!L`&D`;@!G`"``:0`J``%3`%4`30!-`$$`4@!9`"``3P!&`"``4P!)`$<` M3@!)`$8`20!#`$$`3@!4`"``00!#`$,`3P!5`$X`5`!)`$X`1P`@`%``3P!, M`$D`0P!)`$4`4P"`#`$-``T`,@`N`"``4P!5`$T`30!!`%(`60`@`$\`1@`@ M`%,`20!'`$X`20!&`$D`0P!!`$X`5``@`$$`0P!#`$\`50!.`%0`20!.`$<` M(`!0`$\`3`!)`$,`20!%`%,`(``-``T`4@!E`'8`90!N`'4`/``;(`%E`"`` M4@!E`&,`;P!G`&X`:0!T`&D`;P!N`"``#0`-`"``5P!E`"``90!A`'(`;@`@ M`&X`90!T`"``0`@`&4`<`!I`',` M;P!D`&4`(`!O`&8`(`!C`&$`<@!E`"``8@!A`',`:0!S`"``9@!O`'(`(`!H M`&\`;0!E`"``:`!E`&$`;`!T`&@`(`!S`&4`<@!V`&D`8P!E`',`(`!A`&X` M9``@`&\`;@`@`&$`(``Y`#``+0!D`&$`>0`@`&4`<`!I`',`;P!D`&4`(`!O M`&8`(`!C`&$`<@!E`"``8@!A`',`:0!S`"``9@!O`'(`(`!T`&@`90`@`&8` M:0!R`',`=``@`'0`=P!O`"``:`!O`',`<`!I`&,`90`@`&4`<`!I`',`;P!D M`&4`0`@`&4`<`!I`',`;P!D`&4`(`!O`&8`(`!C`&$`<@!E`"``8@!A M`',`:0!S`"``9@!O`'(`(`!A`&X`>0`@`',`=0!B`',`90!Q`'4`90!N`'0` M(`!H`&\`0!M`&4`;@!T`"``<`!R`&\`9P!R`&$`;0`@`"@`4`!0`%,`*0`@`&(` M80!S`&4`9``@`&\`;@`@`&$`(``V`#``+0!D`&$`>0`@`&4`<`!I`',`;P!D M`&4`(`!P`&$`>0!M`&4`;@!T`"``<@!A`'0`90`@`'0`:`!A`'0`(`!I`',` M(`!S`'4`8@!J`&4`8P!T`"``=`!O`"``80!D`&H`=0!S`'0`;0!E`&X`=``@ M`&(`80!S`&4`9``@`&\`;@`@`&,`90!R`'0`80!I`&X`(`!V`&$`<@!I`&$` M8@!L`&4`0`@`'0`:`!E`"``30!E`&0`:0!C`&$`<@!E`"``4`!R`&\` M9P!R`&$`;0`[`"``*`!G`"D`80!D`&H`=0!S`'0`;0!E`&X`=`!S`"``=`!O M`"``=`!H`&4`(`!B`&$`@!A`'0`:0!O`&X`0`@`&D`;@!C`&P`=0!D`&4`0`@`&\`9@`@`&D`;@!C`'(`90!A M`',`:0!N`&<`(`!O`'4`<@`@`&T`80!R`&L`90!T`"``<`!R`&4``!P`&4`8P!T`&4`9``@ M`&,`80!S`&@`(`!F`&P`;P!W`',`(`!F`&\`<@`@`&4`80!C`&@`(`!T`'(` M80!N`',`80!C`'0`:0!O`&X`+@`@`$$`8P!Q`'4`:0!S`&D`=`!I`&\`;@!S M`"``80!R`&4`(`!A`&,`8P!O`'4`;@!T`&4`9``@`&8`;P!R`"``80!S`"`` M<`!U`'(`8P!H`&$`0`@`&D`;@`@`$0`90!1`'4`90!E`&X` M+``@`$$`<@!K`&$`;@!S`&$`@!E`',`(`!T`&@`90`@`&$`8P!T`&D`=@!I`'0`>0`@`'(` M90!L`&$`=`!E`&0`(`!T`&\`(`!O`'4`<@`@`&<`;P!O`&0`=P!I`&P`;``@ M`&$`;@!D`"``;P!U`'(`(`!O`'0`:`!E`'(`(`!I`&X`=`!A`&X`9P!I`&(` M;`!E`"``80!S`',`90!T`',`+``@`&X`90!T`"P`(`!A`',`(`!O`&8`(`!A M`&X`9``@`&8`;P!R`"``=`!H`&4`(`!T`&@`<@!E`&4`+0!M`&\`;@!T`&@` M(`!P`&4`<@!I`&\`9``@`&4`;@!D`&4`9``@`$T`80!R`&,`:``S`#$`+``@ M`#(`,``Q`#``(``H`&$`;0!O`'4`;@!T`',`(`!I`&X`(`!M`&D`;`!L`&D` M;P!N`',`*0`Z`"``#0`-``T`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`- M``T`"0`@``D`1P!O`&\`9`!W`&D`;`!L`"``(``-``T`"0`@``D`2`!O`&T` M90!(`&4`80!L`'0`:``@``D`"0!(`&\`@!A`'0`:0!O`&X` M(`!P`&4`<@!I`&\`9``@`&\`9@`@`#,`+@`Q`"``>0!E`&$`<@!S`"X`(``@ M`"``(``@``T`#0`)`"@`,@`I`"``"0`-``T`5`!H`&4`(`!W`&4`:0!G`&@` M=`!E`&0`+0!A`'8`90!R`&$`9P!E`"``80!M`&\`<@!T`&D`>@!A`'0`:0!O M`&X`(`!P`&4`<@!I`&\`9``@`&\`9@`@`&\`=0!R`"``;@!O`&X`+0!C`&\` M;0!P`&4`=`!E`"``80!G`'(`90!E`&T`90!N`'0`0`@`&0`80!M M`&$`9P!E`',`+``@`&D`;@!C`&P`=0!D`&D`;@!G`"``8P!L`&$`:0!M`',` M(`!F`&\`<@`@`'``=0!N`&D`=`!I`'8`90`@`&0`80!M`&$`9P!E`',`+@`@ M`%<`90`@`&0`;P`@`&X`;P!T`"``8@!E`&P`:0!E`'8`90`@`'0`:`!A`'0` M(`!T`&@`90!S`&4`(`!A`&,`=`!I`&\`;@!S`"P`(`!W`&@`90!N`"``9@!I M`&X`80!L`&P`>0`@`&,`;P!N`&,`;`!U`&0`90!D`"``80!N`&0`(`!D`&4` M=`!E`'(`;0!I`&X`90!D`"P`(`!W`&D`;`!L`"``:`!A`'8`90`@`&$`(`!M M`&$`=`!E`'(`:0!A`&P`(`!I`&T`<`!A`&,`=``@`&\`;@`@`&\`=0!R`"`` M8P!O`&X`0!E M`&4`(`!H`&4`80!L`'0`:``L`"``=P!O`'(`:P!E`'(`0`@`&$`=`!T`'(`:0!B`'4`=`!A`&(`;`!E`"``=`!O`"`` M80`@`',`<`!E`&,`:0!F`&D`8P`@`',`90!G`&T`90!N`'0`+@`@``T`#0`@ M`$T`80!N`&$`9P!E`&T`90!N`'0`(`!E`'8`80!L`'4`80!T`&4`0`@`'0`:`!E`"``8P!O`&T`<`!A`&X`>0!S`"``8P!H`&D`90!F`"`` M;P!P`&4`<@!A`'0`:0!N`&<`(`!D`&4`8P!I`',`:0!O`&X`(`!M`&$`:P!E M`'(`(`!A`&X`9``@`'0`:`!E`'(`90!F`&\`<@!E`"``80!R`&4`(`!N`&\` M=``@`&0`:0!S`&,`;`!O`',`90!D`"``8@!E`&P`;P!W`"X`(`!4`&@`90`@ M`&8`;P!L`&P`;P!W`&D`;@!G`"``=`!A`&(`;`!E`"```!C`&P`=0!D`&D`;@!G`"``9`!E`'``<@!E M`&,`:0!A`'0`:0!O`&X`(`!A`&X`9``@`&$`;0!O`'(`=`!I`'H`80!T`&D` M;P!N`"``(``)``D`(``)`#$`.``W`"X`,``@``D`"0`@``D`,0`W`"X`,0`@ M``D`"0`@``D`+0`@``D`"0`@``D`"0`R`#``-``N`#$`(``@``T`#0`-`$<` M90!N`&4`<@!A`&P`(`!A`&X`9``@`&$`9`!M`&D`;@!I`',`=`!R`&$`=`!I M`'8`90`@`&4`>`!P`&4`;@!S`&4`@!A`'0`:0!O`&X`(``@``D`"0`@``D` M,P`N`#8`(``)``D`(``)`#``+@`Q`"``"0`)`"``"0`T`"X`-0`@``D`"0`@ M``D`"0`X`"X`,@`@`"``#0`-``D`(``)``D`(``@``D`"0`@`"``"0`)`"`` M"0`)`"``(``)``D`(``)``D`#0`-``T`3P!P`&4`<@!A`'0`:0!N`&<`(`!E M`'@`<`!E`&X`@!A`'0`:0!O`&X` M(``@``D`"0`@``D`,0`U`#,`+@`U`"``"0`)`"``"0`Q`#$`+@`U`"``"0`) M`"``"0`M`"``"0`)`"``"0`)`#$`-@`U`"X`,``@`"``#0`-``T`1P!E`&X` M90!R`&$`;``@`&$`;@!D`"``80!D`&T`:0!N`&D``!P M`&4`;@!S`&4`Q``@#]``H`"P`` M`!@`(P```+T`$@`+``$`'`"`5=%`'`!``/@@#4$>`-#]"T$"`/T`"@`5````&``M````O0`2`!4``0`<`'C?`T$< M`)C`#B\&D$>`,"<&D$"`/T`"@`9````&``Q````_0`*`!D` M`0`;`#(```#]``H`&0`"`!L`,@```/T`"@`:````%@`S````_0`*`!L````8 M`#0```#]``H`&P`!`!L`,@```/T`"@`;``(`&P`R````_0`*`!P````8`#4` M``"]`!(`'``!`!P````]0!P````\0`(`_0`*`!T````8`#8```"]`!(`'0`! M`!P`%.,601P`6#(600(`_0`*`!X````8`#<```"]`!(`'@`!`!P``+B(P!P` M`/B&P`(`_0`*`!\````8`#@```"]`!(`'P`!`!P```!;0!P``(!<0`(`UP!$ M`+H&``!L`@X`*@`.`"0`)``D`"0`)``D`"0`)``D`"0`#@`D`"0`)``D`"0` M)``D`"0`)``D`"0`*@`.`"H`)``D`"0`"`(0`"`````"`/\````````!#P`( M`A``(0````(`_P````````$/``@"$``B`````@#_`````````0\`"`(0`",` M```"`/\````````!#P`(`A``)`````(`_P````````$/`/T`"@`@````&``Y M````O0`2`"```0`<`'SR&$$<`.2U%D$"`/T`"@`A````&``Z````O0`2`"$` M`0`>`*SE)T$>`'QO)D$"`/T`"@`B````&``[````O0`2`"(``0`<```DE4`< M``!$DD`"`/T`"@`C````&``\````O0`2`",``0`>`'[@+P`>`#[Q+``"`/T` M"@`D````&``]````O0`2`"0``0`?`+:<2@`?`/Z-1P`"`-<`#@`8`0``4``D M`"0`)``D`#X"$@"V``````!```````````````"@``0`9`!D`!T`#P`#```` M`````0````````#O``8````W````"@````D($```!A``1AC-!\&````&`@`` M"P(4````````````#@````````"-N```#0`"``$`#``"`&0`#P`"``$`$0`" M````$``(`/RI\=)-8E`_7P`"``$`*@`"````*P`"````@@`"``$`@``(```` M````````)0($````_P"!``(`P004````%0```(,``@```(0``@```*$`(@`) M`&0``0`!``$`1@!8`E@"````````X#\```````#@/P$`50`"``@`?0`,```` M``"V/`\````$`'T`#``!``(`MA@/````!`!]``P``P#_`"0)#P````0```(. M```````.```````#````"`(0`````````/\````````!#P`(`A```0````(` M_P````````$/``@"$``"`````@#_`````````0\`"`(0``,````"`/\````` M```!#P`(`A``!`````(`_P````````$/``@"$``%`````@#_`````````0\` M"`(0``8````"`/\````````!#P`(`A``!P````(`_P````````$/``@"$``( M`````@#_`````````0\`"`(0``D````"`/\````````!#P`(`A``"@````(` M_P````````$/``@"$``+`````@#_`````````0\`"`(0``P````"`/\````` M```!#P`(`A``#0````(`_P````````$/`/T`"@``````%P`^````_0`*``$` M```7`#\```#]``H``0`!`!<`0````/T`"@`!``(`%P!!````_0`*``(````8 M`$(```"]`!(``@`!`!T`@#/90!T`P,#90`(`_0`*``,````8`$,```"]`!(` M`P`!`!P`H`?P0!P`@##M0`(`_0`*``0````8`$0```"]`!(`!``!`!T`@`S* M0!T``!C'0`(`_0`*``4````8`$4````#`@X`!0`!`"``_*GQTDUB4#\#`@X` M!0`"`"``_*GQTDUB4#_]``H`!@```!@`1@```+T`$@`&``$`'`#0$E-!'`#0 M$E-!`@#]``H`!P```!@`1P```+T`$@`'``$`'```````'````````@#]``H` M"````!@`2````+T`$@`(``$`'```````'````````@#]``H`"0```!@`20`` M``,"#@`)``$`(`#\J?'236)0/P,"#@`)``(`(`#\J?'236)0/_T`"@`*```` M&`!*````O0`2``H``0`<`#B"4$00(`_0`*``0````6`%,` M``#]``H`!0```!@`5````+T`$@`%``$`'`"P7/5`'``0U/%``@#]``H`!@`` M`!@`50```+T`$@`&``$`'```HJ-`'```NJ!``@#]``H`!P```!@`5@```+T` M$@`'``$`'```S>5`'`!`H^1``@#]``H`"````!@`5P```+T`$@`(``$`'``` M^;!`'```%KA``@#]``H`"0```!@`6````+T`$@`)``$`'```^K]`'```BKA` M`@#]``H`"@```!@`60```+T`$@`*``$`'@!4````O0`2``\` M`0`<``"@B$`<``"`>D`"`/T`"@`0````&`!?````O0`2`!```0`<```@:4`< M```@=D`"`/T`"@`1````&`!@````O0`2`!$``0`>``#DE,`>``!(I,`"`/T` M"@`2````&`!A````O0`2`!(``0`>`"![[4`>`&"DY4`"`/T`"@`3````&`!B M````O0`2`!,``0`<`,#^UL`<`(#AT,`"`/T`"@`4````&`!C````O0`2`!0` M`0`>`,#[X4`>`$!GVD`"`/T`"@`5````&`!D````O0`2`!4``0`<````9\`< M````+L`"`/T`"@`6````&`!E````O0`2`!8``0`?`,#DX4`?`(!CVD`"`/T` M"@`7````%@!F````_0`*`!@````8`&<```"]`!(`&``!`"```8!@0"```4!9 M0`(`_0`*`!D````8`&@```"]`!(`&0`!`"```2!@0"```P!P``$*]P`(`_0`*`!L````8`'L```!^ M`@H`&P`!`!P``)*BP/T`"@`<````&`!\````O0`2`!P``0`>```/S,`>``!M MS<`"`/T`"@`=````%@!]````_0`*`!X````8`'X```!^`@H`'@`"`!P``)!S M0/T`"@`?````&`!_````O0`2`!\``0`<``!8C4`<``"0>D`"`-<`1`!B!@`` M;`(.`"H`#@`D``X`)``D`"0`)``D`"0`)``D`!P`#@`D`"0`)``D`"0`)``D M``X`'``D`"0`)``<`"0`#@`<``@"$``@`````@#_`````````0\`"`(0`"$` M```"`/\````````!#P`(`A``(@````(`_P````````$/``@"$``C`````@#_ M`````````0\`"`(0`"0````"`/\````````!#P`(`A``)0````(`_P`````` M``$/``@"$``F`````@#_`````````0\`"`(0`"<````"`/\````````!#P`( M`A``*`````(`_P````````$/``@"$``I``````#_`````````0\`"`(0`"H` M```"`/\````````!#P`(`A``*P````(`_P````````$/``@"$``L``````#_ M`````````0\`"`(0`"T````"`/\````````!#P#]``H`(````!@`@````+T` M$@`@``$`'```E)9`'```&)-``@#]``H`(0```!@`@0```+T`$@`A``$`'``` M4(9`'````(5``@#]``H`(@```!@`@@```'X""@`B``(`'```HM=`_0`*`",` M```8`(,```!^`@H`(P`"`!P``'C>P/T`"@`D````&`"$````O0`2`"0``0`< M``#YQ\`<``#MQ\`"`/T`"@`E````&`"%````O0`2`"4``0`>``#LP<`>`(`Z MT,`"`/T`"@`F````&`"&````O0`2`"8``0`>`.`PYT`>`$!$UD`"`/T`"@`G M````&`"'````O0`2`"<``0`<`*#6X$`<```^ID`"`/T`"@`H````&`"(```` MO0`2`"@``0`<`,`#]$`<```,V4`"`/T`"@`I````%@")````_0`*`"H````8 M`(H```"]`!(`*@`!`!P``"ZM0!P``*JS0`(`_0`*`"L````8`(L```"]`!(` M*P`!`!P``([,0!P`0"W00`(`_0`*`"P````6`(P```#]``H`+0```!@`C0`` M`+T`$@`M``$`'0``0']`'0``^)=``@#7`"``U`(```0!)``D`!P`'``D`"0` M)``D`"0`#@`D`"0`#@`^`A(`M@``````0```````````````H``$`&0`9``= M``\``P````````$`````````[P`&````-P````H````)"!````80`$88S0?! M@```!@(```L"%`````````````,`````````T,P```T``@`!``P``@!D``\` M`@`!`!$``@```!``"`#\J?'236)0/U\``@`!`"H``@```"L``@```((``@`! M`(``"````````````"4"!````/\`@0`"`,$$%````!4```"#``(```"$``(` M``"A`"(`"0!D``$``0`!`$8`6`)8`@```````.`_````````X#\!`%4``@`( M`'T`#```````MCP/````!`!]``P``0`!`+88#P````0`?0`,``(`_P`D"0\` M```$```"#@```````P```````@````@"$`````````#_`````````0\`"`(0 M``$````!`/\````````!#P`(`A```@````$`_P````````$/`/T`"@`````` M%P".`````0(&``$````7`/T`"@`!``$`%P`!````_0`*``(````8`(X```#] M``H``@`!`!L`CP```-<`"@!^````*``.`!@`/@(2`+8``````$`````````` M`````*``!`!D`&0`'0`/``,````````!`````````.\`!@```#<````*```` M"0@0```&$`!&&,T'P8````8"```+`A0````````````#`````````)_.```- M``(``0`,``(`9``/``(``0`1``(````0``@`_*GQTDUB4#]?``(``0`J``(` M```K``(```""``(``0"```@````````````E`@0```#_`($``@#!!!0````5 M````@P`"````A``"````H0`B``D`9``!``$``0!&`%@"6`(```````#@/P`` M`````.`_`0!5``(`"`!]``P``````+8\#P````0`?0`,``$``0"V&`\````$ M`'T`#``"`/\`)`D/````!````@X```````,```````(````(`A`````````` M_P````````$/``@"$``!`````0#_`````````0\`"`(0``(````!`/\````` M```!#P#]``H``````!<`D`````$"!@`!````%P#]``H``0`!`!<``0```/T` M"@`"````&`"0````_0`*``(``0`;`)$```#7``H`?@```"@`#@`8`#X"$@"V M``````!```````````````"@``0`9`!D`!T`#P`#`````````0````````#O M``8````W````"@````D($```!A``1AC-!\&````&`@``"P(4```````````` M`P````````!NT```#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)- M8E`_7P`"``$`*@`"````*P`"````@@`"``$`@``(````````````)0($```` M_P"!``(`P004````%0```(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8 M`E@"````````X#\```````#@/P$`50`"``@`?0`,``````"V/`\````$`'T` M#``!``$`MA@/````!`!]``P``@#_`"0)#P````0```(.```````#```````" M````"`(0`````````/\````````!#P`(`A```0````$`_P````````$/``@" M$``"`````0#_`````````0\`_0`*```````7`)(````!`@8``0```!<`_0`* M``$``0`7``$```#]``H``@```!@`D@```/T`"@`"``$`&P"3````UP`*`'X` M```H``X`&``^`A(`M@``````0```````````````H``$`&0`9``=``\``P`` M``````$`````````[P`&````-P````H````)"!````80`$88S0?!@```!@(` M``L"%`````````````,`````````/=(```T``@`!``P``@!D``\``@`!`!$` M`@```!``"`#\J?'236)0/U\``@`!`"H``@```"L``@```((``@`!`(``"``` M`````````"4"!````/\`@0`"`,$$%````!4```"#``(```"$``(```"A`"(` M"0!D``$``0`!`$8`6`)8`@```````.`_````````X#\!`%4``@`(`'T`#``` M````MCP/````!`!]``P``0`!`+88#P````0`?0`,``(`_P`D"0\````$```" M#@```````P```````@````@"$`````````#_`````````0\`"`(0``$````! M`/\````````!#P`(`A```@````$`_P````````$/`/T`"@``````%P"4```` M`0(&``$````7`/T`"@`!``$`%P`!````_0`*``(````8`)0```#]``H``@`! M`!L`E0```-<`"@!^````*``.`!@`/@(2`+8``````$```````````````*`` M!`!D`&0`'0`/``,````````!`````````.\`!@```#<````*````"0@0```& M$`!&&,T'P8````8"```+`A0````````````#``````````S4```-``(``0`, M``(`9``/``(``0`1``(````0``@`_*GQTDUB4#]?``(``0`J``(````K``(` M``""``(``0"```@````````````E`@0```#_`($``@#!!!0````5````@P`" M````A``"````H0`B``D`9``!``$``0!&`%@"6`(```````#@/P```````.`_ M`0!5``(`"`!]``P``````+8\#P````0`?0`,``$``0"V&`\````$`'T`#``" M`/\`)`D/````!````@X```````,```````(````(`A``````````_P`````` M``$/``@"$``!`````0#_`````````0\`"`(0``(````!`/\````````!#P#] M``H``````!<`E@````$"!@`!````%P#]``H``0`!`!<``0```/T`"@`"```` M&`"6````_0`*``(``0`;`)<```#7``H`?@```"@`#@`8`#X"$@"V``````!` M``````````````"@``0`9`!D`!T`#P`#`````````0````````#O``8````W M````"@````D($```!A``1AC-!\&````&`@``"P(4`````````````P`````` M``#;U0``#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_7P`" M``$`*@`"````*P`"````@@`"``$`@``(````````````)0($````_P"!``(` MP004````%0```(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8`E@"```` M````X#\```````#@/P$`50`"``@`?0`,``````"V/`\````$`'T`#``!``$` MMA@/````!`!]``P``@#_`"0)#P````0```(.```````#```````"````"`(0 M`````````/\````````!#P`(`A```0````$`_P````````$/``@"$``"```` M`0#_`````````0\`_0`*```````7`)@````!`@8``0```!<`_0`*``$``0`7 M``$```#]``H``@```!@`F````/T`"@`"``$`&P"9````UP`*`'X````H``X` M&``^`A(`M@``````0```````````````H``$`&0`9``=``\``P````````$` M````````[P`&````-P````H````)"!````80`$88S0?!@```!@(```L"%``` M``````````,`````````JM<```T``@`!``P``@!D``\``@`!`!$``@```!`` M"`#\J?'236)0/U\``@`!`"H``@```"L``@```((``@`!`(``"``````````` M`"4"!````/\`@0`"`,$$%````!4```"#``(```"$``(```"A`"(`"0!D``$` M`0`!`$8`6`)8`@```````.`_````````X#\!`%4``@`(`'T`#```````MCP/ M````!`!]``P``0`!`+88#P````0`?0`,``(`_P`D"0\````$```"#@`````` M`P```````@````@"$`````````#_`````````0\`"`(0``$````!`/\````` M```!#P`(`A```@````$`_P````````$/`/T`"@``````%P":`````0(&``$` M```7`/T`"@`!``$`%P`!````_0`*``(````8`)H```#]``H``@`!`!L`FP`` M`-<`"@!^````*``.`!@`/@(2`+8``````$```````````````*``!`!D`&0` M'0`/``,````````!`````````.\`!@```#<````*`````````````````0`` M`/[___\#````!````/[_________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M___________________^_P``!0("```````````````````````!````X(6? M\OE/:!"KD0@`*R>SV3````!0`````P````$````H````````@#`````$```` M.````````````````@```+`$```3````"00``!\````(`````!B M`'(`;````/[_```%`@(```````````````````````(````"U ZIP 27 0001193125-10-094994-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-10-094994-xbrl.zip M4$L#!!0````(`&B(FSPEK"B=4$4``)9T`@`1`!P`86UE9"TR,#$P,#,S,2YX M;6Q55`D``Q-1UTL34==+=7@+``$$)0X```0Y`0``[%UM<^)&$OY.%?]ASME- M)54&ZQWDS>8*VWCC.MOX,'=)[LN60`/,K9`X2=@FO_YZ1A*@00()D+`37U5N MC30O3\_T=/=,MWI^^OO+Q$)/V/6(8W\^$>O""<+VP#&)/?I\,O-JAC<@Y`1Y MOF&;AN78^//)''LG?_^Y6OGI;[4:0NVK+ZTNZM@6L3&ZJ=UAWR4OZ+-I%CH]\NNK=(JHL(C7U_>GYV]OS\7,?FR'!K M#FNP/G`F9ZA66_3V[P#I.=+J2EU9?=-U9K9YCOKFT-3UIEXS%4VK*89@UII: M7ZLU=;$A:[HN:BI>K7;I8L.'%I$)8,^1)(A"35!JDM:3Y'-9/5>D_\2*.].Y M2T9C'_TP^!%*"VJ-5HF-PBG0/*BCEF6A+BWJH2[VL/N$S7K8U$O?M1`,O.U] M/EFAG#ZN.^[H#-J5ST@X<"=!R7/ZUMI0'KK^1D=V49X^B)5_EEEI4=?U,_8V M*DH\1Y'$QB8P08E%VQY):AF*BF>_W=T^#L9X8M1X"HP)-F/5Z`/BS3TVS70< M!5D6H](F7O;!P,R\,WA&.]%K@EB+E:P!8R65IL]3:GB^F5@#GB?4L/$(&&2] M!BR1D6%,S\+WM&:S)L@K-<,2J377^PK?)-*T\BZYINM8V$NJQEXDU_'GT^0Z M[$5"'5K$Y*8G9`#M+'@9*^HG%E6#HOX)K`F$V*JPSCW&.UT\1(Q%SRF$SR<> MF4PMRDCLF>$.*#79%@.K,7;Q\/,)Y;=:Q&?U%\_<8:UD7X9G`5G`4^=MVR?^ M_-*93!S[T7<&WQ['AHN]SLQG@A6$+1HXMH]?_"[%B1WKZT-;4AI:#?XG4IGT M3T$0I*^/O:NOPE=&@2))7T%8SVP2U/%8BR?(Q`,R,2R83N'D9ZFIJKHF*C^= M94,1(`YY[/S2\,8MVZ3_M/\W(T^&!5SGM?Q+PW7G4/K?AC7#^8`+.AWZ&/!0 MM'S]U^/5*OJ:#/!536E"_9_.?H.@CIU+#K^&+L@JZ'M,;8]\H3!JG0F^-;Q M/!C*SK!GO!0ZIT(JP5F@<729)I-JAO5@$//&OC2FQ#>L%554Z'IJ*'I3C%.S M%1!'@.=A,.2+'&])DA1%C:-DO28A*4-@:N(:#ZSVS<&R+.>9&OO7CGOES/K^ M<&:MRX`R8,-"U>*H\T#CE.V2'T!-=]Q'G_(_TVG M[XOCF,_$LHI$W6CJ`K=!BKJ-@^$I`(NO_3*P9G0=EP%4U05=CN',@BA.PPI# M%0E5D9N"'->"*SVG0H+]`9.28\O1O8(_+]OVW(8G%7T9-I[L@:])#3VN$;.!VH60$B9!$51N M4Y4+6IRJ.V*#*>C/82ECL&2*U3>R&N<=OO-RS@]S2CW.FM[U^)#MW4O;0XH@ MK.-B9;W_5'SEF$YBHZ$*:1#3["56I'0K3VTT&^M(,YAW#VYH#;Z^G6PV:)O( M*6<_J_+;V(\<+%;FE?/')N$^OSB>_. MEDZ]%213@YCMERFVO3*.MT1)4T6>$=Q M;Q`;FVW#M6%2O=B!^Y`,2,'&3;,AQS77=D!Q`LHUX1M-6=#BF^AM-OOZ^QL[ MW#4]T)VH8[=\WR7]F4_/1WL.U2Y`@.M8%A0IPU)K-!5%5+<0M0OH^$#T7#!1 M9^Y\1?04(^]$4=(;\I*8A(XW("OUNOKS$:CJ#2Z\Y0VZ^G/.J;@6&/-Z7/TY MUY,F:PUN^DIP]><=[X8D)6N_JPX)=@BR9*H'<<:5WFO$A'=?7G'75=$^/H7YFK/R\]32EN.QW'U9\/=:.IZ9S[M"Q7 M?TY;O*%Q$8@ENOKS057`?A+C)E1)KO[];<]R7?TYQ1W(.R%U7$MS]><%:PQW:.'PAG*<[Q;4NP<.=X3G$E M2`V=9\3RG./YP.JPR>?!'LLYGO.0M2&!?7-4YWC.#0]8O%K,Y[?.^`H'_V;'H.^05D!J"O$=\9+6.P"VZ#ZA?1'M?2X,CPP.BC5E91,1ADX8!`"NQ65G( ME-;`)T\Y3U=WX1@NO<1>2+D3=S!<:3A#QWX$L=\9QJSP'4).=J"NIL=/N;-! MBI/Q"S8L?WQ)];X[,NPH&`7^'XJ&8K6+G["=QTS:11.BQ?"#GO\`1](DW@K@5U\A_TQ5>U/4(090H6. MB:+($O_)8FF4;1K2HPP&YS';F0@V*C2F)]=&?3=KA3L%70>0`K!,4Z`A-;5D ME)ML`-Z\O;&Y8,F")9_.0]Z,)BOX9;1/L?A%5>3.G;-@RD`%%P1:+!6JI&8@ M@H.TC0AV`!\*-%"_.>6Z[)G'%"G7 M0$VLF!578">;V"X6ZAH#;(7#.<>-ON/"VS!NJ(Q);\B"Q"5)2`3!?3^.?7JN M!#8\)<.\F/_+H]OSLG=0($^B4\+\R#)1%$QAF12I`G>JGQU9)HJ6BJ()G"^431^%/5!`0)@21?8-/B&A8]%30GQ":>3RL]E3*XBB1Q M`B8+I`0BCL,;,A>TM1D*YQ4WYFSCW7-85A$77\P\8F,PNX+O?BZC?"/N@0\T MUY2NHG.Q)3F0;:'I`!^8[411H[F9HHR?D*W5ZX)0&/:WSA-V3=<8 M%NW_$^54"M(AI9,1G#J7STVRJJ72L0'3!D*H<[XS90>J[1?L#HA7L+A2N!W" M5C1;P%,14+`O5N+LMV0,:SB'Q"_#N.12*2X[7@/T1.C5,`E?_A7KF>(CBS8A MX:.XEDMS-:"ZZ.GF\EVEP=@.MCPI+8N\E-Z*AXOG2G0.%LN\O&\^&4,3/G8[P]!=NT?H:1H!Z[[C8.%)7)+-G,`R4;56ZT#N_!2: MM"9GK>2"M1+>%7VS=F?X@W$I&Q$U3".:VGV`CM[R$@:Y7A-O8%B_8\-MV^85 MO8DK'\!%>I:?X;U4D\7@#IFTUI?]]UR#CMGC?-)W72763`,09S8-3S+JVJ6 M"/X9CF]JRVF=TSG8KVOZ=U+GBY;7NPYP[)WT7 M[XTVQ[/5)3R''?Z-;>*7?^`2X MNW=]:[@CC,#P""_B,Q%K=Q5'K*,EBA:,BLG8P#+R*IAE_T,07CCH+=9@:3&A M.?-+-10]2ZJC(\:$YB/H4#&A!PH5YBC8$BFS,4]Z/?"RI5/AF/1 M[RW_DTF>OA_YGZH5^F.*/'].[Y6[:W6_W-S7>IV'GU.G?G M2)B^G"##(B/[\\E_9YY/AO.393MGTVUM-E/:I/5HK2&0%%6\[MSW:M>MNYO; MW\]1CTRPA^[Q,^HZ$\,^01[Y`]-XOZAFG_ZAU=%EY^[NIG?7ON\]HM;]5;5R M"M!\9RGY4YXQVM_BQ%7S:@!P(//V#T#]N\L%FM$!M9E"9D#()O`N"!/\;(=EQ8N,#' M,Q?$G#-$_?!(\Q1YSH0]>1Z3P;A:\3#^AB:.C7T#=(-I3,!LA5(D^LP##2R# M3#PT=%PTI6*"/.&H6!T!(-.I5FS'1WUL$0SO_+'A4PS0;PCJ%/K"-AJ"A+`L MIG]HVZ`_P!:N5DSLPT:+?NH#Y>CG_V,#6C'0!-2(2X`(,IE"0_1V5Z"&UO8< MB]#+5:'R,)`ZC%0[R,ITBL#4GED@#(%(9Q']A@`_36D-=2SGV:OOP*4%+[$% ME][8((UHSJ&WR)S5BA-\)0+S2WEF@%WZ(1?,#Z@%9'B>0Z.RX>4S\<=L1DE$ M+IJZSL@U)MXI9>R(_W"X-T%C%O0)3.*XW[#K?6],II^^>P'QJW^"UE>VX(RM MH*TA\#M+TX6L,))E#AP[!AL%/6/@+V(S9$\&*."9M\3!*C,@R'>@:=C+A0SM M$N\;9>=@&7K8&M98K9!6`Y;3K$_W>#YER6GPA13C0Z!SZO@X>!$L*;9Z7#QP M1C:,(BVR&#O&L/Q8!1""<0R7^939#O076\T4`&L;$5J$?9QLKJYEU@XLCRF& M!06T]1WVFP*EIY@,5K5BV-'?BT9`?OB(KO*H\"F:36D+M"DR)%`"%O0,UGO? M@O&S"&A;(+"W`IDMZU'@Z`(IT,<@$J@/?<(HC&YPKE;&L#]R7`+;!7J#LA&- M7@@(OU":07/C.GJ<`,2K42"`!*L!O# MGN<()I^R#?K?S`#:7&M>K0`>LI.0R*_;=UMM'1B38$70Q1*MH+$!?`-T,DX# MFMA$T"'\(-15-`'QRB0D'="$903N+:R]B>7*V$#6X> M_K/0T(KGB,INY!WP4Z5\=K0D*'QBY0(_5U3I;Y_!`NZ8%6L MUM%MY_Y+K=?NWE4KG8O;FR^MWDWG?B\KMRP]3,^N:]2F@KGM^S%=.@BRJH#- M2'>_*\KFE-E5('FI$!XRW3)T:.I#6@M46[6R5#=4*]#O06G9'XQ)L/$$%12N M6N_'\_QC(R2/S2?$R'Z\^4\[$*W1X`1"JR6LM<[":T"ON29VZ4?`8']8E@<& M)!"R^#TU3#/Z_4Q,?_SY!#CPXV(F!IC&XX1]A>VZ*WV84:V&]G'!.&>^&2OR M%#8&.M9W)HN.FJDU#O+X*-V>Q4;'W80GOD`9UXK!P_B4QKAG,XE9FLS>>,B< M%YWN5;N[X,7OF*](0.+T!;'MQ\G:0`\+K\047H)MFT_P@>H("I9R=U-@3]B+/!+4?4'\&`."`.O[N\;+>O MKT\2>_>=ZW?9#5NK#8LCS2S:2'6M4*8[]/ ML*>?D)IAVS-Z\!2%##LV;%BCX(!/R^?4"X(,OUK1ZD+CXW).P$Y"M`U`;\XP MX@2WI)XBD-?RJV?U'01B':IZWS/SNGDYN[?=IY=8_KY)/AWWSW$P2>@ M`'W\/J<%SVFI*O@00E%8%XH7>PM%J9E7*"I_4J&X>[\'74G"VUM);T`ZOD_N M@<3D:Q.*"9;BY=Y"4='S"D7U72B^FQ?O0O&O,KEO[/CF@ZBN&H\T:A[=.H8- M2#XTEDY'-'6)/2!3ZAG? M01O3J44&[.@?)"H]ZS-&&%&W17OF.J9C68:[4ISZ,I*K_$!3LGUDDGK]N)7* M8N''9$FM_:GW]*]C,>MOT,)YE]19)Q=DQ5N;W`+-U_WE\H/K3(CGT8AOFUJL M[Z*I0.X5Y7J"['_=W/LNFK).;J.NO;7)?6-&Y.5J8,J[J"J2FVMOC97?Y51& M%$)=?&MSRXNIU2[#J*]ET-?&B'9%M2Z]M=E]:R9Q>+O9\BNB:L5:A':OQ&Z_6\L% MP.*[KB3VA#J^EN;U+>FZ&20Q:8SZUOXT%)^OY;+575O=!06 MS!;]I($@"9KM6)_V5RO/82;!FA&D$N1"8&BZ"?JI_9"F8YECPUT&WK!W+`]" M&$#C(6S3="LI$2TL&P++O?1L>$BL"Q^#)W7MXRG+I4"S14`WUOPUYT-H>6R' MG$)CD/+`=P(?4SBB+#,,^F%&,T^P1!^3Z-B>.(;A(:!LJ_8D,:@L(^H%_EI/!^F+0A[(E'^&Q*DM+EV M8.9$H?:/']D,"/4&ZY@,T8"U^IJ7TR/&^_%RD!#'#'(R MT:1;P1KQHCQ.JX.3>*R5-_M'2B:*(F_6S9=;`TSM>&:-(]VLFP]U4^3N`"SU M9MW-6#?=K"NO7/Q>VLVZN\.567KA3+Z[XG=@$>XZ MC7S(CG=?<#XB&V(\^^5KOR\X'W4UL1'/++[+A<%?',>D&?S8/;(@VT$W5ZO[2[UX M[X[:X=0Z&(6L%!G"R*$W#=%41A%?T?1XP%BGR,;^*;7!P*RBABZCII`[EY%\H*1";[O]]^Q'JREWF@6EW(F4RR;)]SXK M:;-25"*D7V#CLB3D%Y:/,NL,_95'S9N2,+WO^T!M&*BEVR__BG_M\3T7AD5S MH7KT:\8HG]C_V7O6WC269+\C\1]:T5G)EFP.+V-SLGLDQW9R+26VC^WHZ'Z* MFID&^F288>=AA_OK;U5USQ,PX!@82*]V-QAF>JJJZ]55-54,G)%J)6D?9G*= M;YH6.VUT5T^+&6+.?GCG=/67,0TMYS#F66<18Y:Z4\:Y#O.:4L2U%MVN_GJ' MH>E;OPQE*/JS7+IK=1[E+.8SR.XGLCM\B*&X:GR":^4&7F!8SQ?_E+[P6?N6D?<=[D M4`:%E>_QR!.P@^::MV<+2Y9WGU=*YJ_?5NU2:.V7J0\H1PZCW:K-&$1BB/IS M1*V=&IJ^,4V[V^Y-LY?O[I=C;T]VO^OL6QI44Z6R&VQ;7[TQG*'IVS=V-31= M6*>RLCNR;>UJ3.>R4W]V;T[(C@V,S+[U;AMT]QO=S?K<.TJ%=;WMT%GZ98<\YA>WGS^? MWSW`"A9.C!\'@/0K7X?(XO7">2*^IYV^0.&(_L_';@Z7MBH$1?'1,?WU]\56 MB:],&>@"38:%M-2N+ZZ9C9L(!^RW=JV=]%6&*R*7JT0#]NV+*SR92PM@L[_? MZOGKDZM9X>+GH;2&U,TR,A[VH5QVQ['5I.NYQY:J1P:F2VJ0B>'\I,Z8]>/28N:K:F(9`,,TX][Y MU)0_6*F!_BIL--W_>K7NJ_G.K:IQVP7WQ:T_X*ZFRQW\/V#^(/PG:8E[\23< M2*RU#6V[T>QV3NO91K0K@);'2775QAZVV)KW`J"6;@0B+?)S8?BG4O]?N MN651$]T[/B%#MU9MT6EUBC"_#,ZRT-\+2\BG#2#0GF+GA1`M@8,?"?NS5&,N MUMX7O=T\68Q#`:)%.-#KCEJ=N0-EQ-;;_[S9783%+)A6PV-36W+<6;@EQ4^VSLT78+0-D$5%E%_6EZ]6U[4:C@$#NX;,A M0U.Q5K!:IZTB7=,G%V&*;:NR$AFO(A[SL-Z9)$5`%X*3A_\SA],5_'JOFLYO M8M//3MO=;@[JV4#D`07?X(('PSO?0S3L#Y.O`8Z+V?3LB^-NXS1O:9<';"F$ MU`YN$*%&N]59"J,9D"V%46HH-C6>!(X)RR`T`[`IA%*O>KT:I]-I3VU"^NP7 MP#H/U0`9](<>O1O/13!]SW$`KUCZU^O5G[7G`[X,=`7D/->+]T6MLPF==-QH M%7EF'AQY<&_SUZR=43J-XO2=&1`40,P$"^"$3(4C\<@J<`\",!;TYVW_8SS6 M["&9:K;Y:36+9N05WL1^_9RXGTP7.OI=[D:-W9P_?KV_8KW=U?WYX_7M MS<-1M7(!_]Q^OKZD+VB0S=W]U'US?G-Q??ZY6GF`;Z^^P(\/ MA%4OP6]>B&RK`VW.1\*6P20X8L!U-<"5LTLPWL_<1SGUQYZ*OAQ1"%`J/U@S MGK!9$/4":4ON@\:M5@YT:@)8Y2)=./WR\CW+7O$LYO\6%>[S_"3Q0;][D9_] M_9`AO)R-(B>4QS3*CXV5D?`Q!#H$>6)#BKHA(M7*4$TK8($*M@7L6>)/8[CI M!PAI*)P).SO]5Q(^%6%\*?-58`Z'__GRB8*FWHA]`6PM!&+^K)Y@T;">>&9I MC='8QWFS38_BT8PGK28LIA]\;*F&*@!0`5O6.6,SKR(28#A8@*X0-".HW61$ M/440^`)1^0KJ#&X@70*,@E^I<6=62(,4+SPG&O4DIX?=1?`$C]U+RWO-+,@U M#Z3"#Q(_X+@\-5LSJSD)1IE`6W+9O=93)\?211%5$RVYA7%^[DYP"&7D\LB6 M>N:?C4;/S@MP,O^R6LD,P$2[P'%2+`ZKLA%<]?T!WBO)=<2R11028%/7\T>X M@"^LR/?QM\P]AR`[.%2.^Q.<@S56Q&9]+GV\FZ;])B",O4`J;8,_P*4@SB0) M7A(%3H9G6>`'LK[C/2/?8B(-M)6--85*E+_6'FH,&!ON<^!!\+,8AY1#H]@3 M0CD&6"TY=J94%]W[Z?S\+J=B:NQV+E#)=&(::"Q'B<1K?/'!H!M<+TS((0$J MZ:)48AH%U]-+5RM:Z4RO#PHDE+Z>C8R$H-P?KMH3`K9+[W5O`FO``K"\&*/. M`8+3;]ZBI-]VY[-B2RB.FRG=/O(4Y;'4_#,O='%PJYTX,8%F.Z)B.JYU-C^/ M,7;BJRMF,@INMB(F$K):2:4%1U*/9!C&>AYW(=[D='AL!F#@XGC/:^QQ"$H& M'N[Y0(ZA%SFP.6A!.($"3_DG/AO7S,VP1"V(B-40[;L62LS6J)PM.H>M+1]@*0KSQ`>5F6V3[!P9:LTQ6(UBCND;8[I@E59:IJ03T3 MRR(SDN8%_K9T]`"WK"")-?!%M M5KY;+)U8)W\*M<1RP,[90ODY$M2L]@)2K=5]/\="H=[&VAB\-Q8*X+$1_DV\ M!IX5FG&U8G;!(#$X!$R9[3N<:KCF=-)MY.3QL;39P/>>R;KX7C08JD(GY0J2 M>`*A_/`X&L>C524>0\C.)9&=1()&?*(](F9I9G/24UGLEY&0DV9(K76)I>DN M<57U@2L3_-DM*7H<`KG3L]N M(58!>A>.-@%@1E+LAMISU_HY71Q7"GWN!MPJBKIPY`B`##->URO/7EF+I4QE M+ZXBA/5Z^!"E01540@T$!L=L'/G@>P4BR/JN!5_PM6?`V-N5=.;1U5[,)I.) M58FIB)*YYKH1$1@I[V7:*Z/L!)X"VE)JE0FJ%WH/\_'@@+>P*4R+5^'@HW M.9V&$ZP9Y.P)[D#-JP4+!('/H1][S@Z$<(Q!,T'![Y-V3^K_H:.;;#.P#@*1X M+[\VQ1@R8E*M%-!&!'S1=T`R\'B/1PQW+J3QR6Y9/5!F,_X1@[$YOICF"4!9 M;0ALHNV1059URK-W$U=`R4[NB:,E&0ZI5C(L0DH$'#%PFD"YT"$P51N12YX4 M,H?:V!%5SY&E2`\E"^I6IVI1WSK[4LCM8!7')\6ZL."Y#;8%8ZP4'=I$XJP] M5;BU#$@SD-A.WH^N+P*_9.KOCD]HDQX]7<\?%_&+X$:$MWU,.2>5_FO-P'8[ M^7J*52!;@%.Q?GK-I9>%\MZ%X"R`_L['C0PG=PXX:\",:%W'>,E:T>AV"P45 MR\.U`)][H?(G8F-5QB?MES&9"5$!"]^SA+"I+/DA!!5VJT(F5S_`DC?:[9.70288IN#LRW`#=2IGK7H1./W@*8">)$9UP>Y? M>E$O[$=.7,&[7HO4FB;?7$CR,-^+L>;OV_YGSQT\"G]T*7IKKI]I-D_S0C8/ MC#RP#]90V)$C;ONQ=C]/#U?!ATGFKTV5;JP[L-&JP9G]XJ^OUP_75&.Q"Y&+ MOU5`R5&O4&5V2!^5X5Z*UN&_V7`>'-*#2-!Y@IPG,9B0)RI5B2^ZP?@;N+C? MX5"KPE$6'.;A6/)C#(>E^(*X_J`'!WX53!7N4%4FTN]Q\I0R2_I0/1#>P.=C M\*K1HX8S"OZ7.8+;%)5_H42"%2LD\,0DDH@#.N58.X`ER>I,GB4(G,)<,?!" M2>>;)*KGCW*!2X##'83#:B4;8#E2N0!*--LZ_TDHVY@U0CRYRYV)2MX?87`> M$?%HE!`6+`Q@A4S<+P<6H@4T50>V3/ZXCP<:P>$4D8$$0_/9>V=%(=+XBXKO M^Z*8B5LE]E.MS(ZY9*.A%'^IL?B].'W8C;.3!;ZDW*/E#5QZ>S3)(2?GX'#& MAGI/2,AX(A,5_6#^6/;I-(\'MN0WY4;VA,4C2E:I1$U*8#SG8-F2'>;D5];]UJ M93KCFZUG2EY!C5679B_D0"=]E8.*(WA>66'Y$@9OV*7X*Q+"/6+G_G>48U4W MP8'/0A"TF--1[:%B@X5^:]9.DE>M#^"O>O(7*E'4$)0=Q'>RDPM);6*BV_,I MTR`.*0`*[.Z*3"Z_P.V9@`7&DC!\`I(4JB1?IK0C+X^H9`:QK".`C1B*0Q4H M5HHOEA.R&&NK(B"[9[S%!MY2LVKEY"#Q&JCA@Z?/9V]5^,T-6L`&ZO- M#OZ8YSZHHJGLC_H6\)T=,&Y^@!6GSV!CF$]%)""524VFCO#2W?`]5DN!NQ*! MPXW9!C)@`*O#02&"'5G!`LP<<$#LF6@$\\8;@S!%P5(H%VO?J"2(KK"P[NU,09RCJF(J*]+ ME3)I&8S0VJ"UK!!+[#)O"*!IY\`>X`I@@BVF19FCVE_`KQR0(P8^S!-W(LIT M@:Q031$R`YD"H"*-+$0'#40#V33Q3LG_23/2DB*.L>>3D9]8:N*D!7ADZ#-F MB2Y4G!(N`8JF%4ZZ]CB(8='ZG_:O6IF[%?C\J;U@6E,GEA:SX;BC\!`IGJF. M4->Y4$XS[[M;0RF2$DA`%H_">#2GZAI?&2>$C5[:SS`+&0-51\;0:#PS_>S+Z36-+_B:1OKE7;;*"OZ^ MPBK9],_I]S(R5:QQ!]LYGJ#9_'F;OZZ]_Q\O.^-6M=Y9=H=^9:J1%VL(M=04 M\_62:0M+EI?>*TW!&&+.(6;3 MT')KV&/O"DNG[=MP, MT-L,5S7.3E>?!FFHNHBJIV8DK;%H.V#1RK&SS7I[D;SLV/%+U[HK6Y:K=E=E M+9B0,79MC2QUUJFUC`9^8Z*>[M6\JG+0M%U??9Z:,6P[LKF-5GO16+)2G]F2 M,GG*DMNZ4#YY]PMAPT->>R?=W9]B(?>L=.99>%,",8 M,A-GW)0QVZ>IP>6@:=T$&=>@\E9V$(PYVY&]/:LU5S-G91_>.[]X1J^PG84- MLGN*[`Q17N/8WC+2H-31FF3J@\DQ;"9M=59?%-TS5%V=JB\M7'_R94-NGN,[F;] MUW)2X:78[%"@L@)5VYFK#C*79-I(M&9?;_HM%)MM%.SKKC??4"/KB%R]A'`_ M5<3YZ[##.MMO5"NF[89INV':;NPPO4W;#1.:^OE.$8V]RA)NE9C-^EZ]*V?: M;NQ9EG6[FJ;=6!0%+W51D&F[4<:4?>.DM5?VJR14W2^GH!Q$-19M7W>VT3E9 ML:-4V8]?INW&EEGJU&C@MR?JR:+W5@Q-7]-V8^72;6/8=F1S&XW36GN'SVRF M[<96M6W7:-LWINE^!1C+05-S+MO7G>VL^IYRR4]EINW&%MMNF*/#VQLS0],W M3T&N[G09<[8C>[NP$^NNE7B7\?4M@^S^(CM#E-=8W%U&&I0Z6F/:;FS85V@M M[!9OJ+IZS/34N+5OGV5X1=M#X]?NR.8VN^U%IQ;CV1IGSR!K/-NE/=NRAW)- MVXWUVY6SA#&(R$&]Z+,98`N(-+&5B.%T2^ M>!0_P@^.9WW_LUIA[-_)#4/NBP\\$/:%-\+PJJHCL$!SP0WWHO^?=\)SOMU= M-=NGG6/X3Z/>J!__!6@UOST\7G[KUK\UX9MZJ]7X5G_'(E>JFV3@M9N-TV]? M'R[?,5M8-%IP?P;HF3`4X`2JR;ZTN!N>JSH]P.X.3@66 M%$&"VVOA_A.IJ8E9\/JUBT\;VFB.?R1.?_S2=QTT=6P]_HF"4/8G&L76/]_V>W':N7A^M/-];Q M^N83N[O]?'UQ??5`(/<2XS+O[+$:==X($_P@\<.]>O.[6KD7E@=LD=2YR`36 M5Z+067E_7X?3WX()[KO,%6&UHM\=9/J%=A8.?2\:#)D7^6P(IT`VI)X<]-K% M4+6=8'P@7.1\UIM4*V,L:,5W#AD'_>)+$4XR[R0&`/P(7U.D5Q,#^22<"9PO MX3&"E@_@VFH%'S8&N0/E$=38XU`&"!PKP@9?(^#")FAZTG'@HY#8XP'6P/HC M)L8@^[9`""R0:];C`=QU@#^R3OW8YI,YE_0]6".+<(H`/(ON[RZX'Y&J5OK2 M!W3#9R\AE[XA2.Y(5IP-4;62+LG="0NB7B#^&P%QII8\/%(+P=&=85EQJ*'Q M-$&8S2407'UI"U!OM%/1V%-;,.83U-@L%/Y(80HZS":>#JH5$:#*E\$0R/P, M9`;J6T.\!P!#X!(2*1X0=HW]C;O5!VA"C_87:*K(&>_A]`:^M#<10S($?LBX`Y<00:*O1SN#P`?!7UM=>&L+Z5>ECQ\O/9A M;ZX)AL)%LOF@RGQ;$:H@=$?I[PS8"\42-@C6N$V0H7X0G$:[0B_M[#)P*J_X<.QVQ..P+68#;X%U$` M3`$2(QSOF=@//DF`Z8@I=@'NDBXL,=*N1>3[``;(!'\"T:`'P!,CX!)BR?@> MI,0_D4W^S!&P&0^9->0NL!!>[KG`HCX;>A$OTB7U/'`%T%PB/LVXM\% M:EM;H(!+%V&9H5AACX<2P-(8`BD`+T=^1UV-V%I`-=;WO1'J&>DAF/H3W`E" MS%PO9(B(+[GC3!(J((X^.8."^('BJ(1G7[H<3`@@D^B;([@TB)Q06P05C(1[ M`'<>#%D?]A?U&BW:C\((29^LHF]]A5ROT0,BAP`;6S'5UXHMX3J4Q>>)\$.L M1!'@M-U-5&[O9E:;'O0 MTC\OWQ^F6F+*;L4+^:3)4&N@_0$#_@_J.Q";5';352SAAQRD%+TG5$@HR+J/ M`VBQ*$3QJE8<.9)*1?S!#G@F7,916X6@]/SD\;+/,BY5"GSW?:`]C&=009$; M!1$*+`AA`"KQ/3OH9==E('(L"J6CJ[DSP!1``!4MB-1CV`"RP& M>2>@ZN&Y??%,&P"`]\$AA-T^L'+/'7,X/H)4ST:'@2)T`_`Q?*(&J$!/>8#: M-OBH)931$K"\C>Z1OI-TF+Z>)9?W!-@'H(D%YS]'D,)&V/6>`E7L`G0*JJFM M1*^J6L%;'6`[!['&!_'Q)+5?/CAR$@$_`$=;!$//L0/X%58+6>>(-=JJB+Y9 MUP0[A,>+S./S1)WR+&/S2'0!BBB\4;4.N&\#:]&EST-!%"#OB8]$SM&/R9+0 MTU9+:P>7P7J``&(DU8-C(`#2?@;2Q)AH;Q]I5)23@&5=S-XD+Y5W2AJ1/P;9 M'<@[$_/71H@M_&4D?RBR#@2N.`9C!XPX0)#1?AX,,ZNCFGB*<0,[!)_C!5]C M758_L[_Z3(?&/N^&`7428L::D,(KQ.<\/"`)\)G`3YB MZN_1Z_?*#TD$0;EQX)*YN-L<_'H9*L^A1XJ-CX&5QJ#<0"FBTX\29GM6A'\<\BK-" M'A$H36)?P(@*KYQD`I]`^/*@!](%0+5(U-^$!RVPA$=H8`+^Z81=F8HH*W*^ M+`8$5Q30'9`P#;``$/@BZQF\!$L:@T2O6`S^?ZDT'I),!C0E6=A'=6"+!Z:-]PH M1?YP%:B[:HOV$B8)FE2-\XP;!\&]$YXRHCQ1G/ITJBA5W!7TTV$@5)WD(PCN M1@485:!?G2^/8U>?3FN7QS.P[/*VX0.TL^#Z!X@D4:4;0I(7[RA;IL5N<&[) M5U(WV1%(V5!("63&YK';6[--8P,,T]%/F8\BC@=NU:"\\836X99TUS@7B`8;NGMM2,+;]GV";&5U#1(Q2 ME=LKR51AR!B%;F"IHU2.1\M,],'Z.8%VP%4BB8J7$S";VF4YZUJR&(;^;``X\R967J@5FX7D2#=%T/USIC M/S#2I"TMJ6+'CR6+2:XO*#FPKW@Q]A?%/S7Y+.P51`C7H'N.4GK&-G>Y&.(8 MUDP9*X5?H[.H]4B=>H`]0`R&H2".KY5)+QD3DXDUJ&#;CV`H7R0EH'E"1J.,%&AA'Q^O1A<;2](J/W8U2\(Z! M*0!A99`I8%5M$:+^UXCN M'00V_JOU[GIYX>2N_I%GS8WT9DTLI^FY_;6FWD[^(\B5]9>N#$+3FZ`#B@0>)/QT$#5Q/+[@C`UTHHL9@*% MAV8EU]I:NUS@WQ0.+`'%T.0L`FT"Q5@!NZ>P>03X?K-!R$J\MW!PD784:Q0T MQ9=1M46%X2BM-G6$$W4ELUH-T--)(F26!)]!H0*=I$%65/7Q8L:Z,,T^:5MY M'GB$'LEA2!TJC>>B5LI+`'[12'T5/;X0ZNX&#I9J.*$+Q`M)ALEKK95SCH34 M9NX\`H%OD--,.3T&"TD'39)2Y*:"T4(.;'#%\5@RA:X8YTTQA^NES26FREFP M38NGZGEOI"7RE!.`[<7:*5BJG*A3A*^=")=:;>3$4@4,S_QHE`A*-J4ZJ%%"2NX''HHA&&+OPKG10CZSP0<5`5 MB)#0"[Z2%H5)IL6=OT?5EF23?*(XTF:2P.@B)J7<3ZX#96R6Q7",M-I0"PKS MRK&6P`^U4/.IF\9:@DJH97MK?JR%#;N[JCDQ%CYEN33(4@G,5*(LE/FN"ZTX M:M0!&RMB)S7QBAXL&(E:^Z,1Q<$G2PR(\) MEKDQ;C[$\V-F)V$"0'K.>D:4EZ@4M=1X,T&],^,$M!=[,\%\9X;-T:IQ^#N: MI@>N*35NP`>9]IG1"A_-O#>K(O.]S6[;3J!!1<=-,@0Z6&4C'K%468$DD4KU M%+L7]]3E<$F_(=J=^*V)_#9EJ*<\18M0E&JJ2!WC'63=(U.J8!+<#@2LQNNW MMS)'B\DP@*]S`Z$'8N":%"2%R7S MK,L,5+"G*6X,HBXL6-*M2(&21;2L:$>9(_DQ!3/WG.&(D@FXYS2QD0_VL+ZBU4H:G:*/%R]>+L`P773&S=0Y;@)BF MA'VN@-]*#%Z@VKXN$I*Y@;V[)O6(>\)^!0P5?QM&L(ZXS[CB0>,4I0FQP<4'_#0O'(BA M?ONXRK&(F10_1=RN*.)&A').9NC!.1=,D+LWP>28*`Z)`((L.D%WNE_?B9X+ M'UU@K>X4"YIH@RT7J*23!Y1DY?N]O#*/BP2UR6LB7%0ZL_1F46+YON\"4'4T M#:'#]\$%1D+LL&3,T3KR)FH@(@I5-`FNN1V*@J$'>QOEDJ,1T/Y7+NWK*"`N M"'/>8T*?N&_PC7(S]'J1>F':94=C.1ES7:#-X',%)ZA)MC,E(PFJB2Z4HS:!HBK;%B`YWFO`]XS97:[P*T)'AH"AP` M6W#(+VYJ3:=WU,1]L2YS(*4O&-N1HA>`(5>)/BEBM,1,X8=W5D@_0#B#/'3_ M%-I[-)!RX(D1A2/;&>B2$3.O'I\B\80^F8'Q?V;\&@-LM.*L=V]B\*R0UH_S MW/!4X)QPX*#DYG'CC*NZC"5M4H+-,:`N-#.604W-N5]\[["*GZ>V5LH&JK1W M0YSH,,3-&%$[VY;U/>XR)_'J1[>9&DDDUZ;J,?PF%6/63DOLS2+7Y86U#&!M M@/^&#GN@_74=-[05;HZ_D7M!NFLG:R66!R"MB1;;LB?8!PY+`PCB8U?HV1GL ME'D16S,_6QB,P;@H2=GAPV<07K+NE@3,)*B!@_4 M4'"'?`2PIG2#?$L.(=A2<*[A5217O#;TRV#[R!+'*C$HK<$!R,(A; M81V`R@8)GM[3GL<58(`LF+=:0+TYRX7)98[B]Z;RIE%Y8I#,)9QGQ^")M2(^"P*T7LC_D>A\EIKKJJ$D,$ULE26&D*KKPN M(@3<@\5X/Y04P7\HN(2L]KLY"WF1J;*@?+_:K"@X5UX@.\D;C%%?*N/2\.H2NSH\QU3X MBE]'VQ#5`WVVM_@SIW""G[72!R&2I*GZY>6];?&KP&VA%-H>2CXW.4_GDHLN M!A"+7W=:.T$O3E,UCGJP%/-YC#I*/E\G_7((7-IJO3#D1W,0%S*6;NKDC-'7 M=^T?OEBU_DY*6 M[N7=0.TBC^LD\S9:L>UK?D?A@[W\"`!=G]HX1Z/^&9,!B]3\+;FMKLU?13/R#F:B2A!M%+:WK,U;T=!M&$^%#\139\I)X@WLW[-I M0_L!\X>K\MF/2]D_)WEI(KRPE`\%.M_VMYCL,,GZ?LNNDM47&(N MN\C&D[*>].$SZ6]$>H^&G[/\9M3NK$SM#>O*_2[/KII8Q17(:0V*!E`QJYRN MZD7C!'/W*5:C/M77TWS7EKIAJ_.D7G+[78EYXW?;/A-RSEM]3@YVCY^)^2A< M:8Q&?2O<[ULZY)Z,4E0'Q35TX"Y^E?@@!=%28TKZ<;=T4C(4ZHVHX@SC8Y3$ MD;)#'4^+TBE5#0UT[S7;E`V[:YAS0_$W3""@4SK)I%BT-`T_M:6BPE6.Z(X8 MYDKXG4NR"UZ'DX'HQM)*AI.CW;PHL#45-?(R&0P3*^<"T>TMVY%.!P!->8+M MO*<3$1-UNQS_8VZRW5),+<0%.FE3FX6@$'\1Q\ZAM8004X.;/F$>CC@#ZV"` MOM=\0E0G7?`)!G298O8T4B50VOXB)86C"),+3#?KAR#]3'R;^_?O3O[\`F>0"778Q7OW#9*ZZJ-^K#LP8N5M/*J MRA&1JGYT:*/$:3RXJXXTJ>PPO-UTV@^PTNKR-,?Z6.U1,B0I=94I._>ZY*!N#<]ZXEE//!T]T?'UA!OJFY$Y-1E+#T%\U0!( M0\G2E^5:NDALL;I''XET:Y/$*7%QLRX"^@YR]FB^@JZQE5-"M<43;G\F:B(6 M*7[)`_V!76J!8'3APAYD#?OE.)H:ST&?'M1-A>_4$%B#U2=<."F`"[A(KQ]+=^">^U:9<8KUA+3OW.'<8-]K:WZ.TU"E9M"@EIQAM3\X/=NOEUDWAL&WO5 MD6=8ED72G9B.)&>CN)^H*3#M1=;;Q6T=P8:J,N_]C1V4L=T8'M9,L>:QU)YP MC"5SZ)1.^4HI'6Q4'&8\!<54!:Z0OH6VA:)B^KJ%FC.]0^0X@2E="L00BA]0 M#ANF_EPW'$5DT\.I-O0($VJR9CKZC4`/>E6->I)-/23G0IXGUL@"FNDH;/^43!,#]2>=7QSE==`+)A!#&)!?%35U;GS_G\B7R@?4ZIT;7?[7@LEC@Z>KCHZ:'TW771W7L1SQ%]C:CS"+CIZ MIO07U@\DY8_!GYW#]2HNNU?9.WYB+Z.?#Z+E"=_A%>IWF--3Q]T2YOHA]$AX MW.@<+!&W35[>42,\6:(I-TV;=$!R\O<0 M-8+'-@_[C3`,Z;?]=N.@U9:@?+5](K;6,FVT`^MLZ1I'ZIZ7E4E3>V1+$I'] MY"M^.MV;J.95%(U?.NK4DDE M_4&*]/W@G!4FYY67KYX6VX?W38A/_:0*#FG\`YX>6G MO\XO3UJ72+)6I].^;.T$B./H)J;-3M"/>_A*"_7K3K.S\SH\!IT%]]K%W'!B M*ZUJYJXWE`AYJ#4='8?M5=94/RU>432*^R_?CL9I/HWC?T=E;_B6DZEWGW6B M\OVP?73Y^=-Y=>H'1ZT#FOG54/L%GTQH$5'9O M&(]`9(=E.7ZYMW=]?;T+$K-[E7_=^^WB7SNO444=GQR&A^'IGKU-/WC/>_(I M"[<=ASJ8X7'9USBI9JL-_T[W[+?F0M`&SF6=9J>-C^X[%YWN.0\_W1."W(8Z MK9,UI$[K9"7JX&4/1IW.X0&1IQUN,'G:X4.1I[5.Q,'2$C`_WIKU=_>]YN/U M6_/Q`Z]Y;32H7;-5C`^US^NB%SW>?M@UPS[OA^%:K1GW>;\9AC=9,T(-6K`` M)'V+G!)YS5^?[NG/_`B\JW*_"U6J#Y'?7L)O-WO2)4S\LC(SP-1`([M^O`]@ M&O8BRPOS]2JC,VWJ[Z?'GL?\KLTY#ZZCC7WF[,VG>\[]= M7S?^_./GGS[\I]FTK*O+3]V!U2<>)LBZ;MXBG^&Y]=5!'F*VCZP'>TX)G2ZL MGNTY@6?[T*]U@\GWH7C2/#I].#H^.WYW M=G+T=Z8YG2T8'D]\ZU?GO]#Z\%U3D&1$\IMU39P#J^MYUD`TY=8`<<0>D7L0 M=^7%LK!`\(2?-U+PYT/F'5`V;D'?QZUEP\;//UE1X[,YQQF"I^-E\W;KZ^W- MO3-!4[N)"?=MXF0(16=YI.U.I],*?XU: ML"W1LJ74:6M;UJ^C9?/MWH>))Q[3'WW$!,8,V]X=Y5@\I>?9G.,11FYE$(K= MOC*,.YNAZ@-2H6]_@GSLV-Y.@,&RIE/4]7S$",R"1[0-DLW.=L%RS^:3CQY] MXM?$Q0PY_C8L;W;V8BQ_IC[B#W0UO*NG\CX;VP3_&ZZZ'B6<>M@-/W2)>\=@ M8X4%*CZFYD9"?(FYXU$>,/2`YOZ%1YWOE07PBJR]@CCO\9C`ZH\N`@[G-.==YY\`1_L(OUBD/NU$$,]Y M_"N(Y1.E[A/V/)BTU^*P&^.AA[J\`K@>G4ZQ M'_X7)`[[E5B(H.?#,MPMYHH/?HV=`(W%WP&:42:8V2U^E:>]&&@A;$HNZ=3& MY!9-AV`O58:2UT?,H)-8=,*@RS`*8!!QA:X:?2OZ>E&=.V*AM<;#;AE3U*-# M)H`-&,S,HSUA0E&6';WXR?!E$)E/`6P%OCFU[)BRG3@MY_NH;83AUFH?M MV'#Z)?[Z6WRD\CM[8S\\`/(1EA/J`Q7J3C+& MHQ\U,U>R+C)MM+$J[%RAJ<"?*]#)'VTOU%W\GLW8`@[POVPO0!((:K3ZH"7S M-.2D'_C"42AHKSI%M/4#,IG2IQGH$F1:0-T!>HJ M72#08\-S0'E\RNFT05I:JA+.5S]K8W#=?H8#]FKN>(%8I27,*Y%J`Y::!1+^ MTRWJP"9L_N%F.:&>"X:3.`3\13GO^61U`%2\:NNT3&\H&3\@-A5.EO`,#E6S M&V1SU!]Z>!Q:A])YI$9<A5MK8!`&X@[%JN05:R! M$B*=8&9@CU_-9XCP$C=8?EN-K-,98O[BSA-79,051_],>!Q!$Y,B*"#1!F2` M?!L3Y%[9C,!DX"EG$%@KV,$R.`J$VD`IZW)UTMXV>;DFL4I_)^X@*.GZ/L/# MP!<>U`[H/8!-K/0'V^SX` M4W-1)*#?[P-HB8Z;H.R8AG)-M4J#572;)^#;>P2^^"XSP7RT1Y@E2G<"]GB/ MP.;9V`G2$W.0YKA4TSCS/'\KG&V#SM@RG(K.P@2[0<=P"?;R.Z<$M4'G<`GJ M(J]-@M>@$UGUUD&RO%.HX=%[C?JE#.)$8&9.$P4%9CV2+%D99LZ1`L@*-]4) M>H.45>4!EP6M):@-4E>+4Y$@S:(=3@UX8[);@-FB/4\.M$MR:P#=HUU.#G^?@3^!FMK;F/N"M M'+J="&/O=CN5.\@$OD'>C)>]TBNVC=(B,LCIL3L1;08$)0)ZCG^DECE,V?QY MS7QN9L?KBYCGP,\]8H_8D0:AKC72&-[/PR3+V"5?Q&ZFF<;H=SBJ8#[&6?/= MJ5BH_\9U.W)Y+Z+0!N-_R/;\24^8EJF:`'?P+\SF>%H,T",BTF"#*CUH##-? M*A,?8>>-,GD#V#O[,U'X)TQC1R/*8J4#=`W$U[?.,-D[W4NT4]\B?T+AET=H M$B;-2L3TFAS41,S;"*BFT&!'E`$GL=^V>#`DC;4Q#V98LD8E/&?;U(/5 M+2(&J_>C#S+T$!TE@AO!<_'LDK?7%YR>Y:=@FN6UU!M3_PDV>&:+BC!==XH) MYCX+M?_B05`BU0NLZKPJ(=(9K`X'<,&<2C70R>0C%F4B/U)V28.A/PJ\Y?6F MG&TYB;XX[@G8`Q>B7*;PZ<'(%QE&DL9:73(R>S3KI<\:V$;&RJD`E:DM1L;+ MJ0"635\CP^94`*N=84:&YZO`+]YWC0S45X%=Z,,R,HI?@Y\GLXSR-%@C8^8U M"[)`ZS0RUB/7=E[;@5;JJ9&!NZ4(GV&32V)Y:W[W76HQ99.+%!Q=1D8R5A3# MFGM2$KZX7T.OM#D:&=)821!E?@8CXQP+G%EI[)7NWXQ,0%,4Q*:^*LFHK/D6 ML.EGDJ_Y':M51L:&JL@OYQ9.DNBE.EGTQ8MLOII`6YW+E/FWBKU5W4='V`4E&S M,WCR'FH$,ZZ`LM3Y8M4$=*54M1!EQ$J=Z0P&$_IZ>,<']MK%X@L72J[ZJ5^A M@[J!C(ZQ+4#F=5`WD,EN\DR0>1WHBP&R%Z':\4##]ZJ!;AF_=`U%B7"A"1K] M(HN!K=1%?8"N%UI31;=!5Q](T@J`JMCD'=0'Y``)@\_QD8+&K4BL,P+/0<@- M[8%E$8(;L79@UH#26QM2@.4-/X115S"Y'Y$$:_% MR)K<6\I&T4DJ*=^]W_.F@I=<4NC[;I?4_3Q0%TZ>J/`*AN;IVLP].`DIAYVE^X$V'0YM,DJ.&EBH>)XE`<, M/0!W%YYX6TV]X-WC,<$C[`@O:[3TPS=,>-B!0:PMT\X$N8&PSI9NT-#G%[T$ M@E\L4I_J"F'YEO"P=$/645G_22/NM^K/I7A%%([L+Q&:$Q;6&",B)G;]F;]' M8_%W@&;"AB+CNG``L``00E#@``!#D!``#M7=USX[81?^],_@=6>6EG(LL? M=T[LB9.1OU)-?2>/[*1I7VX@$I+1HT@%)&TK?WT7)"6*$D$"DB@`*O.0LR0L MN+\%L!_`8OGCS^\3UWK%-""^=]4Z.3IN6=BS?8=XXZO6KT_M[M--K]?Z^:=O M_O+C7]MMR[J[_:4[L/J>2SQL]=J?<$C)N_6[C5U,48BM9_3N>_YD9MWB$?%( M"-U:#\3[.D0!_LYB_WWMZ.L#-&M.W'?1_9 M_J1C6>WVXLF_)4Q>6N=''XX^+/\R\"//N;2&SLBYN/CAHNU\.#]O?T#'3ON' M\^%Y^X>+D^_/SB\N3LX_XF6R&XI1S)\#C%]:I\5A05R]X*KUA+\]R%UCWPZ[D#?9YUYP]8W?[&2QI?O`63''E^%LBJ]: M`9E,7=Q*OWNA>'350A/LQ(-S?);0?WOKV]$$>^'\7^0Y=UY(PEG/&_ET$G/? MLEC_OPYZ.1BL+Q+,@GA"ANGL[K"6':%..]NRWDO6V)>G$*8I>TQ_=$\\&&&" MW$<_B)?8C8N"@(P(=J1!"':[9QB/B&+Y`9'H.WS!(;&16PLP4`+^!'?=$%,/ M9L$KW@;)>F=UL'R#@I=[UW\+>IY#*+;#;5A>[VQG+'_V0QP\^XOA73PUZ-,Q M\LB?\:J[\;W`=XD3?^AZSB,%-0P+E'U`3.;0(4-0A)\('[@`Y&S8E`^BN,7#L%[,O"?L`=R-/YF0,/X3)`[ZBBU$"`I@&=:+6?+!^]`$>,S^'>"I M3QDS]>(7>=K.0#-A^]ZM/T'$^X0G0XBNI*$4]9$RB*@MRB,G(IC'&BP4^!BS MCERW9:4=+W.YH")>V''(I).VZ3""&OF!1V&/Q:1M!X]0Y(9RW*V3[X?7>+@V M9C6AKI/3^`GM23R?)-G,D=;(XPMT0>UHB-L+RMJI\%JS`'P`*HF]V"7!?@^+916^AA0THG0HJ`3!>TQ0E,FNXN. M![,F_N1@PB1XT3X^2)-1%G( M>`_Z&+G_QHC>>_?\MAJPSB0IQGC6 M4BG;B?SX\Z2XG5*6G^%))9S&/RMA,-%3-\`#16X/%.#[/_&L@-/B=BI9COVC MIQ`?S7T:D$,P]<3&]@5DZ]BE?^OE6"MD=X#$)8")X MX6>PBEQ^5YHI8?@!CY&;L--])T4J;K5%+6QB-UQ\L\IF^G6V8PB^">[!GZO< MEC14S_0S&KJK4X'32,E$>*:(K?*GV63HNP73(/_[@L7,8^S2/+/@;LZ[23U/ ML:`II1E1?U(ZI/.'^5PY6CYU,+UJ001Z=`S_`4GL2U^RR!8[5ZV01CC[$F)^ M<'+OW+@'<-*3B+AE3<%*4IC]5ZW3EA4%`,.?,L"H-C&LA"'R`EDWK7-1'!V? M,D$8BFG%7\]`G1D,BN.V9>`^'`"X-5X-! M%7MI&;8?C,>V%K!DX"X,!L??#%G@.SDV&%]AM)-!.S$>6GE4FB%5Y*04[JV6 MXLVY]7.L:T%5MOJJ9N?<&PT1'>-P(+')6G(@TLGOZ]:ZURN8TZ,J'DN/]X-' M-&,CERH43ES&::PLF)SS,\`V)J^,I<\X%(-02*(2"(1>S@-!0^+"U,!!)0I. M>Y40HDGDPF1W^N$+Z&M_,J7XA2F-5YSD33WX00#2[H^>T3L?F%0OZN`Z#DE4 MU",B3L^[05,2(G=)G_,05A.J`Q7GJ`HJI7!2]18+EG_X(D*A#,8M'F&8^PZ8'F%;74ZC&93/OF=O@&:)3!F@ MN\G4]6<8#W#L/@B/3S6=,DCS9$L.YXN?E3&XF@(*?MG=N^U&;)56,"]$VAP! MELM_:;)RQ+S<0@>Q?QJ'AP\8!;@_=,DX3@[DKG8Q8LW!5PLICC@27.MF3*&X_T>D;BYH*$. M3%>ZSL5MU;(NX_J7$"@#\4C3>$0FM*P@4@EFBHAS]S[%7E"Q%5_<5B'K_A33 MH!Y,A6-J09E44;,*#(T"H M/NEN[32RR13<%;.",8U.4]D/HN M\#.N<"QVU+GAPJD(0';\$&7">J;@?D=TEAE4#N""ANJ2-(I/E)83:#EG(R8D MCU:#*[?9)N225F/,-B%-2!^MQB.VX6I"+FDU5DYL94(>J:AF,2.!M/2$>!F4 MX'FL"8FEPIC+KK M;FT#MC)M+!.`OK[7-@+8];9-)B]]';@=K0Y.:L9"`J?ZNG?5)_]%+OOJG8<, MJ;Y^GAQ2@9RX#+01#J#8\/(N4V1@C?#X2L#R\Q(RC$9X-,A'IZ^+7+R*1RZN9I/2-"^J75%%B M0R89?8.(/F=CTC4OJ%YM(?F$F*7T#F/HE5;H7=:9OI%._9-93^S.Y MZ+NMK6+&;);/F$E3+!#1L)Y,_KU*&M0$N<5@'8!7QB;\[>)X.#RG.V$CD[R. MAYN0QDDFW%GWZFHON*[_QEX0=^_36S\:AJ/(74\HJ2@C(=6'#A4`8'+V:3R/ MG=BE>L0T+G[%`2A"J0.LI(!7-PI?0%W\F:UN/IPU"GU@]((@$H>0MM:'?:GZ M$GLJ[2T"Y)Z9#/P`+O3:ZY66M-VR5N/`VZ"CYK)]^=CDMU\DE9@@L2;@!%59 M!9%68$H56@F!5B!D[S9JI-F:.VA[O823C#R'XZ*6S:&9\OA8Z-!,+F(PX::2 M(/"=Q9(FW&P2D\DFWJ()]Z#$T(OZ8R;\'_0\ZG"'.!7['$+\G(+GT<8U'/DW3 MS9[1.PY632$K@EK\0!'Y8+H9I27=5B-/0I M<)+>HBP?#$[CYG"]7,:?<9BI$HYH\VWT8'6+"HGR_:B###TD%H]QPW@N7P3\ M]OI!J/`%J^G457#.\U6R%B\W"(D*H%)KM4*HA45G0&UZ=D3BTU M4,GD*V&;@@6GX7RV^23J$DW2D!\[[!X-C'S99@VGL?HLF;4-YB:U9S?,_@N3 M\0L[RG\%)3'&GR.VF]P?I=LLHKEALKWH!G>-PPK3+=V-]H#+-A#E^E!W'%6U MJYNK7U.\@6I"5M,V,!>;K2:D*DENM>;J)'`":Q-RE+:`S3/V)B0J;0%;S.\W M(8=).);,E^X6V!PS(;=I0_0K.YDFI#9MB%1H-]V$7*>-\%=%P29D/VT$7`BS MHG2H)@U_M]E24@>PAY,DMIJVHSP_;&?(A/T:$XIEBV8?EVV>F5`26PQG:3:4 M"=6OQ==F/DO-A&+78M@*3SI,*&4M!D_`W3"A#K48V+TF]9A0O%I&;`69+"94 MK18V2(LC)Q/*4@LN;OET`1/*5&\`WHS:U&+`^-N[)I2?%L,H?PRCO!+U8=X7 M43%%-CV#VV0"K1[KJ*KPK58L_--S7@-VB7T0:71O"_Z2$=_DI1;BDZ7E08],;SX/*6!*79-<+DZBYSB;VCLA"=&*UFT,!#(2PJLMD%3WR+ MDW^E$'*Z4`J4Z1GF/\.?2<3'%I+G+*97V26#OB"6/HLY2I^U<[\34J?4&B_%&=T\MNIN\57N"\R/VX.^O26 M;72S@)3$[PXJE*UD)^K`OML8;"UZ3^[Z([BQS/'H M>T^@P?NC7#6DJK*Z@L3-=;4:KZOA@+V9`9S(4ARYABJ9SOD%/6_E!7M\#!5T M&D+*:JQ)HUHBU0O8RMOR9("MDFH$;!%>I6\WJ7#^)#K0"21+MLD"R;CTFSC` M(F)MP6TR0_D]:`3SD>(IZ/"Y-SX_^O.C``)!55SGE.](-=+8GL>'(%G5@`,C-1K:L(]U`%^P&RX$M MZL``D)N-K)9[Y^F^89\^(AJF'[HVQ)C)VWGBUQ<'033AEE&2Z$#=E5LT2\\Z M8LXHOHX"XF%P+))WO=W,>:;\:OLR7>@#=+7$LBBZ-3I](,F^<4FB`WU`#C#; MGK1#++`_)$BL\L*[C;$3[U[-7XO.1M&.984S5ZK,1^.`X#;7"H"(-:FF:PJI-(54="RD\A1- MI\D]1.3.TSUZWLBGDR1UH#P8%:56EYY89]Z;_)TJC:M6[$M0@I?L-"YTL2]) MF5P5HVX9E:0@F5`O8U]32#3MQ80J&_O3Y!6I@R84ZMB7L`ZHML>^1":>4&Y" M89!]24TV<5-Y@1&-9">3"F1":8Y=9;NOW#@7/JHRH=J>?/I7^8PI2O\2@I# MYFI.)A7C/%7Y1(?UXHUGQKFDLJ=;M9QI9/(SSHN5E)_,9:A,*HK\VJ:(_LZ+ M@VZQ-/1UX[="7VJ,,O3Z>NQ;H2\-`#/T^GKG@K7:I2JU9;CU];^WP;U6?&\! M^(.^CK6@SA?--\X@Z^LHBH_Q=ND*F2P4N8]-%>&=31FY?/NB-X8EM4*R.:&O M2[P5V/7"7QED,7]WKU5_/_LAAM`F7='(7:R$8/F%2#>^%_@N<>;W!!YA0)EX M8-39HF,9LBBI4,2ER%*T8L7IK MT9BXQL1I8.)$%UMCN`[:<-DOV(E80LK\6'WIRDEP/5OZU)@Q4:6YB4PYJG63 MKM1;B\;$-29.!Q.WT4)L#-XA&[Q??-]Y(ZX;OZ\VGS"UKXU.H;>%R+%9K+4D M.VDJ>S?FK3%OYI@W61W1&+9#-FSLHHE.%HS'3[$&XK5N;%)CDQJ;9(Y-XJ[Z MQO@,I*)GKC)AE27E<*B)"C0`4HU9N`QFXU=DL#NR6TS!IC9;ZQ M*F)#A0E*Q)_P46!_LM MU5N\QDSOVC[QUEB^2DG!K,F4M:JZ)'/;TX9^4>2&Z\`X*W-N@/*XQ:U/_8!R M0[$1'E"&ZA$U[J$F_A+7P_FQPQXQ1`&&#_\#4$L#!!0````(`&B(FSQ"`%2I MVQT``#Z``0`5`!P`86UE9"TR,#$P,#,S,5]L86(N>&UL550)``,34==+$U'7 M2W5X"P`!!"4.```$.0$``-6=6W/CN+&`WU.5_X#X3-7N5DF^C#W>\60W*5F6 M)ZK8DF-I!'V(T[-[CA/@OZ)\N#C!Q$HRFSDL41LL-NG-F.(C1G1_^-G-B MW$'L_QZ*0O3/Z\<[]/[X#*%%DJP^G9Q\_?KU&'M/#NE&/-]C-UJ>(-3M;DO] MNU#P$[H\OCB^*/[R&*U#[Q.:>7/OZNKC5=>[N+SL7CBG7O?CY>RR^_'J[,?S MRZNKL\L/N"C6)]A):([(HTI_0N]/STZ[IQ?=]Y?3]^>?SC]\NGC_OZ7DT6I# M_*=%@KYW?Z"I3S]TF4C)&QTT#-UCU`L"],B2QN@1QY@\8^\XS2I(?8&HS\/X MYZ."^2\S$AQ'Y.F$YGU^DB4\^OWOD$C\Z27V2P)?S[/D9R?_O+^;N`N\=+I^ M&"=.Z)8$669UHF=75U1.O8_Q3R7N\CEOM%0$$E3L$_=+%F7?=4]>]\] M/SM^B;VC/[$"?R)1@!_Q''$=/B6;%?[Y*/:7JP`?I=\M")[7:Q$0>"J>WJ6>2#]^M>>Z](02>('9^/,`MQ?$X+#)"N.&_GS44/BDZWR M+'E)?8+C:$U`,TC@KQH/4OFZR`7H4G>O?_0^7AZB9S0HW]?=LY_/+.!0%4=UG$H M=1PDC62-O3O?F?F!3^LJ;D11DMXLA_5*R!LOEAX5!&QH??>R`;^LT5?+Y0IN>-.,X2=U@[GQ6+O$*YP(0?E(Y* M0!S.S3;$SSA98-*/EM26!6V;_&=,!Y?1$M]%<4S[N?&"="SG>UT_1*Z0!:50NU9*X.DY`9"U?Z_CA#76 M\32B#__4#SY_]L^#8AKUG7A!&_EGW\/>]>9+C*DAXQ6;H?3#IYZ;^,_\J:DW MBQ/BN-('CK9N M&B9M0$-BGXHML=[:>6\"<1B%XI.'_2K$]*M?>S0:/1:1MX'S5.%@]W<#\.T4 M*FN`LS2()8)`1>H^AD&]&7#M5&$P.)[?^B$EDS:G_2A.8CH>O/%C0::L)=`5 M-]DZ:>HDY2<79[/#'IYC&HML^F!&>_`X7O.&R679@39$+6NNU`:U<1$2)'TURQ4N44#.-Z-``.3S)F\SZ)JP`Y9SO:]0S!FVI2DM(YNH#`] MUW>,L@-5K5:JFA8*W88VJU_"`7;&0^5C*1=V-&5L@H0^O;%_V'N<9R=@$RJ] MI.\0LJ&/=W]W@C665)>>K$%^M!22\<0FUMB+0#[#AG/Q-VD75YCXD3<(/57; M^";F("=!="3)1BE"B3>T;Y(X)`&Q<(:?_#!DLZ)*.TVU$*VBK-ABZ#O(LA;D M@?M\&+H$.S&^P>+?5AA(L@!O3^KUDE`Z$C/X/`GB;[9,-C.-CU_0%L(&H!K2 MYCA4^`DT'&^#Z.N(.H7^.0R?<=LXF?_'!9FV"*%X3W/!L^.IL#8?M M:W25@#Y9KU8!9E.P=#222_'EH+2H+N^0M@7P$-@6C7IVO)P[%!W5V'BUN^'B M)5HN??$:D05X%#+5,54:QTQ"AEB#E$G:U:K(GIYR*4YJ20YU*=`)1I>@J.I5 M3(E$#5?8"%H>$U/\DEP'\B4_+3.Q`\,:S614CN_OA]/[P6@Z0;W1#>J/1]/A MZ/-@U!\.0.C@]LH(UK$_?6R2(B_G_S?8+R:MV1 M@*&KJH8653$70LY6RA*Z9+4@H:K6=GMH&L;Q6I^D-#4D14*%-@3Y7,(J>LI> M5Y)3L-<>:L;KA&T&9SOY=>NM*`+)3T&/-A!%N9A5)-74A!*GJODV,,5[VU9( M[4C`$%550PNH=Z?'IZ=G^4-3!UV>=DY/^7^[G=X?T?N/G0\7'SM7ES_RH2C] M>'YZWGE_=EENW_Z8_7IQ_J%S=761?3R[.NN<_7AA+\>RVI=@7.MS0(KC9#R? M8/+LNUBVL*J2R"BKQ9*E>,9\7WWN`.7&9@-O9@ZIKDEHZS"H8KMC&,AR M]70AQJT?NT[P+^R00>C=T,%QI4:420TM8I>5W[`X1J1'3`!1"<1$H%:W-WD[ M6^BN-!6L@;O!LT1_FE:6VF!S)U%!`LS=>/2Y.QT\WJ/Q]=WP^["UKDY11?I2J2#C*I)`08P?:H500 M?9^*_@!UPLDK3,EGQ.IG/TCK4NYA-$HD:HAIT9U M3M%@W_QZ$[EKMH`A^Y?Z:Q`F?K(9AO.(+$7A]6M#6!#OH%#V&[).%L1VK`;2)K< MX&!/IH-ZFQJ;,EAA(A:+("=)B#];)^ST+';"7H\^]?GQ)DYO(W$+RUH64>!A M`KM[IZF6BB-"I7NLX>S:B7U7LX)%6D#"N`(2O+*TK)=!/'4'\?10TVMME)8+D*H@W&]T[B+M+7@'4S1;7I3$_*U2DA.R1H@5$H=J!F2Z%0LG`*AX6R M8T$3FHJO2>7+`5F_GBXN9;T_3DN+D1/SE.D7)/X.+9D&;)D5K6[QS,`FN*@0 M2\=.4'?"S736@?7 MZ*<:/6)^R+SV>^MF.9,=09,RTF-X-S3O0%R;D>:!9F(I`>BK..U:*;6X6EX` M&7:+R>8^U8$XP3#T\,M?\:9F+%R?SM!`O+9PV<.$>$>0)D8\-:+)H0;G2@=G MHW2Y@9!0Z&]8TA0RBTO[34L9.V),/A%;380P&L/N^6A7+16N0/8OZ4%V$RT= MO_I@MO.S47!$F6I$?A&)0%XZRIQ7KO2"%8#5>^L'F/1II_<4$7FW4DYEM+)+ M1:OKG"=%65K8FJ_U:QF`7M^68:@Q#FY@\Y\UU>@>)PMVL!D[R8DO@/#9#2JA%X_)#5,U'?_*MGFU MS,3DD*>59A+.'G&R)B&[C!WS[)"_S0ET]+-7U96&0NV]`P?JBXOC>.J\I&O8 M;ZDOLBEA[+$+WW`8\XFEFD/(9'2\*D^3&+]&4=D$FO.2#>(1`RN='HM6?*8+ MOV#B^L#;"P]2YR7@7^U',/ZI0GZ"[_QGMJN#CA>>_%F`TT/R\]L/-=;N[I&1 M0=+;:R?!.Y=.CPPOW_-JR[K?_:NUR/6>7@.#^3,=#;$+V\;AQ`GP>%ZZ8K;I M9F--88/0ZFDDVXI)!=FSA>?'JRAV`GZ"=>U-Q:][Q5"MK-RJDQ`_.?)7F(#6 MF8K"=CP6(Z^%<^"BC79VQ`G8/@%O25L*-O:@G1I.WZPTK/W1E389;WHJ29!, MI<7VCY+\]DP%T%4_+:NK1&,+Q\#A&$7>5S^05F[VLTF@TC)EQ*0_@U)1\5JI MVHOJ@]Z//P M^FZ`Q+U<'30:3&U`K5U%U@'9PE=@V/X%.T&RZ--!X)@\.6'Z?)Q>/9N>MO2( MGW$HO1>G30X&@6VAEF(-;7J&%B(B)227>]14$I>TTA9U[RT"X-!]F8) MX6P!-I^47],\PS@*?(]/6_X[\L,$T3XJ83?1`$T('=C.:-[>2IAV8.\(MCCV M^/4`3)N&:2!9:N/QM:."NF/9)@<^G4#3Z[L,U=L+3`WOS5RSP^-2Y?Y><'>OAH=$Z M%=&"TQ#;'1DXW%*3S2"#]LR'5=LXV3D^DCW5_$IR'SG(ME*P/4CAHR!CYY=TO0"J.()NV*(K$L[ MV]I4,R*VRX\J$-;HV!5&>^18&TO6RC[ZS\ MQ`F:ITAT,P`-*IE6LA'R@GYBMS*%*-K>/B+65/(U-$'QG.%TR.PO5S1#]I?C M_F?MQSZ?M`9=5M.^>M7X*KUH$\3)`I.MLN(EO#XJ=<*P\-9H)+LKAR5-2;7F M0>J`^@-&CH*IAJB1F6]MQ.SS&"7/P:+8V?NA2G"9WT1EY<-56UN%44$4/G43 M3)8HF@7^DWC7:G/LM7[J4OO%HBA\()A-RV='YV=+6$./6]"R']/*##0V=31L M%Z9ICAVTO4(ANYF'/;4)WGMV=8ZO<(*P)[U/P,U(9ZFRVZM^ M80G!#HZ3>#([+:K.'KC&H7$:%&B:LWEJ;\IVP11?4\'LM3F0HL8:*/7,HC4S MAP5%:",Y*=S=(5;=-]=&O1@,PK6ZZ.*R/5`CJ3T1T2CB;VD(0`@HT9+$A=P% MU@9+PPH';7&+@J=A=[#I0>.`>@/@KSC%W[8[YW?UT6]*JP*@B#K/*S#4]UU]LLDLO>VUJT=VJL2 MVY.Z?_\KN;+L'GN^RX[ID39]TF2F+RRKT4'Z^HN0#5\YO63;1]B58Y09=IO8 MS*$)78SB!<8)8B<@L%\*#"%OC5%6$EJOV'&:>$F'R(8O'=,W=BQ1'NS:,052 MVUO'9.:!-<+5(UTDS=E.,H--:;5LV4%B4;?8`-:: M!\;#""?L)?H#B=C;0N]Z\R5FYSWKGW??(@.##.EKI3BFCM\#^?V:2E*Z?D#S M3!@Y6VF8P3BD=:9"J3V8Q2!KZ:%O(/P:AOY[9&1E.#9-%3!H;X/H:WJ4U38' ME&P?X7NAZ\=Q&-"MT/7ZM[D7QGYYZ]2%T&\-C6:-74 MSJ[2+-!L4]PV;V<_8L@^X)!4P*D1BC(??0,AN%]/HLK(RI!LV9/D&YCM[DDT M*G0_?*WI2?+#&.HFX+I.="H62"/66V//C3=RACRWN MV\S6ZS3Y;VN"P?#8!:5"?L52.Z#N%5PZC7:TQ>V>'&@ M;^O>>QPMLQ@D\MK0+(U.;=_!13#5B7:C8_+@D"3]T,O/LN*OQ.-XO92SHI^! MR9C5UDKZ*B_!V_-0D4_38K&CLWC0%RBLK2NN1&D[_T#BN1UUB;!2;]>3IS<+ M7[T2RO6I$3_9XR`':^_]#/4VBAL,"34LE0A0V&H?\$V#VT8Y&P*@8>@J#K?Y M/D7IA_39`7:PJEL?6FR]8B@J643&^ZEIE+Z&#53%#4Y?28,-:4[RL M*=W.^LD/DGC[!XK#ZFNJS5?@4&SE9<;!85RX[[._O6B,?NB%W@.MWZSY'<]K M(E'_[N*#%V,R@`ZLNZP1[TV_/`[0^!:-'P:/O>EP/)IT4)_^?WPWO.&?^2[, MA\?!9#":BB]HZMOAJ#?J#WMW:$*_'-S3WR:@D?!&1)7"Z"VJ!"X&\Z,)U=M& M:A*:C(.=TK^1\R;E_BTQ56^>#52PR19=,`II8=C(%=`XNYN?^F@)&[M>EN!1 ML1"6D,\XI(\4[#KYGK?T0Y\]&R?^<\.NU0O8!IF&JU4+9(!8D.RF6@SFW?TPKKMEHV0[03%'*K84.A[9N%!B'3 M(=%VJOZ>/BCC@'Z%H[4E/76KZ7H-H\%X>G`8T_UHN7+"S3U>SC"15%U=2H/D MU!0OO=Z./^^G2=$O(C'HC=(*+Q=!D=D(2,>&#U6G$7_!2O#U.O9#3)\^V5GA MXWD_>_5*I._86V5AE"=]O:1WON6OT]E^\-DVA^TA\GP=KI-F`[0BQA)+S<5: M>V;+0=C27?9$9_4\?UT@=N0@X["JC":2!&?PH3EQ0G?AQQ@1_VD!MA(-R#*P M.)/1IPRN6I_8$U$/A#VT)9L'6D/L?!5V1-]J*1]XML@`,L:D6LD>J:@V"X>V M@(S'52J\/0&42]H29(9,`XNR1B*5X:;VCCUQ]XCCA/ANPK9%9$?R:W=G]<*0 M\5:KD0Z07G8O&!TPLM&BN(%H105@+\T$MA`L^I1<*B-/[B"XJ".I[_DAM'3P M.2;\[:3W=R=8XP=,)@LZ()41H"=L,NJT-)(QF0FCF$EWT,HAZ)D)@O+7JH9* M_.D[PQ+^N$)Q;YTL(N+_5][RJ(7`>*MJHLM9S.60LQ6TAS=9C<@YJW6"57P- M^6Z(%C6:"@!S);3094IL^;`-I++KFR`J6&P50.-U$M,A*[LBL47]%:6`42JH MHLM3E(O8!E5-=321576`)7CQCKDM73M"8'!5-=%EZ]WI\>GI6?ZXU4$?.J>G MI^R_W;[QCVSOY79+6T3L)%-6DW(P:YT'R26[!#)]/ZE>"EB?UBR%NPK(X>.W M6Z:;=&"'EBHG5TB1&`@(2.1B[,6WU*+L`.H[]HYD/.]3I'TY+$UR1L%I4$8* MD9`3)Y0\XN&9K_YDLF]`0PK!H:59/&3,==UB!W",-"#&[,IY?.^%OXV=, M/.+,Y3.$>L)`\,DUDBVPRCL*Y"ZP^UN,_)`V:BZ[?X&]G:699$>6V\)AM)JTUI8&85*BDU2S&5-[^V=UV-2@#M,E7=A#*'C/'*_Y2 M>?""B>O'BFF0)CDH*NN4T>*1C1CX#0Z423[P$'\K:N9K7,=D6HX[KKY3I@+QWI<^"*8-=WLHNXWEU^Z%Q^^,@E MWWVXZOSX\128KL9ZJ_"F=A8D@<]^3+U\&Y&;:#U+YNN@Y[KL/BM%PR@7,4N@ M5`\Y@4*$'V_FI4*,/"X%C%1C15204EL/AE1Q`%Z\;DY2C=+D!E&2Z2#%B'9P M_LH)4";6ZK)`?5/V7F]EUB!3,=)$5C$^E!ZP*C9T9L*;Y8"C16*F+)0[7Q!@X)J;?C7O[L>(/GOJL(I$9!HY'4I(V4 M.B&(<"H)"YAN990)T[(=#+&)N\#>FDW59ANZBAMMKC>%3TVG2.V5E4$,]]%/ MMAFI_[1K:J](Z=ZN@>,6/[%VFS;@[![K\$G_L#,=29-4-JLC M@7`R^,R.$T/#T>WX\9Z?.`;*HGZ-E-#3M!^.-+;;:QZ_?[XRV@Z''U&#^.[87\X M@.U`6]58B3]]Y\#QF)VJR,8T0_JG;+*S)J%)SG9*ES&5)42_\($G3PMZA(G< MPR56Z@V$YT*'2(P:].F2B\)0)M5'A[;\Q/=,VC[J&NM*0I_:,?`43MD]/TWU*Q)!D,5+ M;N[G>#([4"DYM!:*W";`ZJ=/78LH\#")V?OG9".MB)V$1C&HEJZ\D*=\EZ%8 M(I5*?\?7&"0;F'4R9NPPA[H,GC+NM39;A#QU;K#V^'B$\)9Y_WL<#Y0Y:&CM MH[$28[LBSJ!Y<('X&J35P;NW^[[Q@&]\)#]H(=]<`]#PF"\R!KW([&TP.'RP M6#(N6*]6`7]*=8)LX#P,YQ%9.CH#5$UIDYCKJ20;8A2D4?[.)2[-D:!"?K"H MMZN\$L,MW/0F<(91*#YYV*_"2;_Z=4H<%E"3S7(65>MZ]W<#@.T4*GM8$&F0 M2`2!A]1]#(!Z,\#:GRG!#HVP3>'(#4E@UZ4TV*[4%"\%0*1,M^PX"7*C.,D. M;X)L+Q3.+K8-,E/M@(0??Z%322(A%"*\]):$G)V][US]>,XW.K"_3R_>9\>: ML$.SH^4R"H4,T#I)8`M!XJ3$FS1,`1/+VR+QATM&T98K;.!CT>I;DT!Z:0!F74(>0Z@HZQ]:U(#7;6KK&?W MVHE]]Y5PB#PLI)8K=I@^A&=E60_2REZI`;;%8(G(?0(P]X)`,C7ZCN9'/]-/ M](^9$V/ZX?\!4$L#!!0````(`&B(FSQEI64X>A0``'^``0`5`!P`86UE9"TR M,#$P,#,S,5]P&UL550)``,34==+$U'72W5X"P`!!"4.```$.0$``.U= MVW+CN!%]3]7^@^)]2:HBRY<99^R:V90LVQM7/".7[$TV>9FB2$A"EB*T`&5; M^?H`)"6*(D$"U`4`C7D8VQ(`]CG$I1OH;GS^V]O4;[T`3"`*OAR='I\@0\)<6^]]KT8]^O1X\M,Z. M3UNM21C.KCJ=U]?78^"-'=Q&4>O'+IIV6JUV>_7L?\9B7K4NCC\?`3KU7H8Q/)Y M5/2KUMG)Z4G[Y$/[[.+Y[/SJ_./5A[/_9(JCV0+#\21L__?"'5ESXZHW`3(77\V7QT\ZO7Q^>W`F8.FT8D-`)W$Q%UEA1U=/+R\M. M]&U_H)_;`SQCY8`!& MK4B&JW`Q`U^.")S.?'"4?#;!8/3ER)D"+Z+[Y#RN_^,-T%+V`;)/G&]B%RSR&3.Q^]DOO`@QBXX38BYQO;F.L+S%K?2"O?0.+ZB,PQ>`9OX;6/ MW-^D"3B@:`>@\PF.`SI<7"<(NZY+U\R0+O./5'(7TAI[($GP@8>`3A?P!:?D;(>X6^3SOM/5OLQG#H@RXA M8-_#1_+!!Z#B!@S#_6+F/>$`X'IH.H5A]"MEG,Y7;"!219\.P_UBEGSP(68" M,&8_!V"&,!-FO_A%GK8ST(QL%-R@J0.#KV`ZI/:2-)2B-A(!9VO+&K/H,I)2 M-"#PF+(:?\H:VZG2']2:3PFT9WOC)=/\)TA\+\+[_L4^^B[S$[I"$V&&*:$8X^?I* MJ%Y*%A/X"#!$WAW]C!1PS2^K@>CLW8L)GI94*G;,'[]G%Y=3*O(S?5*)I-'7 M2@2,!U6/RH`=GQISX.T?8%$@:7$YE2)'*]-32)?,IPFU]TE_'K*-+K97R9>_ MK))",/$"RQ4[^5JA@'?0![A'A]$887[WR)92*.X`C"%;&X+P&UU-N/)N%%,B M\`,8.WXL3O<-%LW!FR7V(B;PP]4GFV(F'W^/M]7H&)HYP2+6!C?$+2NI3.R5 M^DVU5'!/?]TDN:2@>J&?G:&_V8,YA93TWV?LL-GS:3$=(K^@]V:_7XFX;CUT M<59ZB0E.C,HB[7=B?07UD=(XRF=?3)I32(2W4+80_@Z(B, M_CMJS:BF@6EK7X[.CEIS0@5&,]:DHP8R;V591U0XFE-8IYK"XLR7#%D>M=YO MJ7J"6J+*JI$IJC.C46W8TRFL*$IG8+34>.2[IVE MNS(I5B,4EXSIM<29TS\34!]/#%$R`7`!?&$B?0.A&(3"*BJ!X#GP'J`SA#[M M&H!4HN"45PEA/IW[M+-[_7!"EQ!JN6,P`0&!+R!V(7M`A%"V^Z-GYXT/3*H5 M=7`]#\83RZ,#O?N@Y\Q@Z/AK"PP/875%=:`BEQ:>X/&7BH7C',IR"BD6MF(0 M9\KH(:H0O9MEE8G.W#R9HP[](6/YIJ$@-93!NP`C0ON_1I4=XK2ZOHQF4;RAP:Z!9 MJZ8,T.UTYJ,%``,0J0_"[Z>ZWOL\>1?A?.D8RZ%V];4R`3?==:GB>/OF^G,V MC50(+U35GLF7\[\VFC@TKY?004RZ;D:+S@3Y'L"$Z0;AIDN)<#5M`57H><+5 M=0!8/KWKM.;F91%_#]HHW0\H&#\#/&4!`I$"'=FO#\`AH#_TX3C:0N..=K'* MFH.KZ'%2;>S$G?DK\*#KX)(7P"VFC.JO,(BV:NDZ"S`@/#9SQ90)'&U(B1CV M!05U$+I2MR\NJU9T&=NDI()U2I04&R=VGHS)7E%))9B9`[W;MQD(2,411W%9 MA:*C&<#AXM%G4:F!Q]2O&=O?H=8(%T%)%65`!B"DEBKP;ATB_8W+&S":Z[!0>2%>JH4%7UP%3[)(L)*VACZF15YF6Y#Y(=D4<6 M,4I[01AB.)R'C-QGQ!9@%(08^52><86BMZ/>G<@3N]"'*R'K&U!R:XT6J M*7``%Q14Z:92?`BY[J;".4XSPRFZ&EZY0F*&CW0URG1KV`RWZ&I$8AOA9OA( M5Z/E6+UF^$>+SC$%CM&)_?40SZ%<62)!0L1VI5A)S9G@;)6N$R+H"&"&J[4P MZG+W-S,38AQESTO7WV+9 MJ5[:NW56B+="+W@(`#UGNUWP5W;>DS)W M89DKFX'6J6JF4;`-495>M2EY.EL(VU"PZVW*E#&=S8P=C2Z.<]B*@[.3I@\Y M";-T,Z0L9>FT^7.X`$\"#LLI93KO&DMW#UZL6PKW_%WW$+Y/5\J0(5JT0(>0 M]+E+*=!YCUJ.@HJXDA2RSOO6DF^]%&Z/;AEK)Q,E/J*[KJV^?OFZ?2&-B4)!UW_0]'DDA> MA90KG:VB_7-5Y$25*5;/OEG-QY2EG.J=._+P_:V>ZW;*YZ<]]U%- M,[5E+V_4(-O6#:",4%F9F/1W'T0O,_"Z4_9>XSO_N%Z[2P'Y:;BV:UY=5B/? M1Z_L7MD[A&_0?!B.YG[>7ZXB09-4&SKDUJ&=LX^C?NQ%^N`CP%&>2PY`D9HZ MP(IS=7;GX81.&?]+1SXN-.--TS8$A>*`V M1NZ2R;7I>'W:Y?!?HR&;QJ;\W30BBEMR<1"LK`DXP26BHI)68$H7BI(*6H&0 MS1IPH!7#1G>7P+#1W3L-;XV[-$?BHI(V7&&GL!H8KB#H2"!G`YL1HBP(?6?[ M(V:$-(NQ4L?$,",`6@R_J#YL1AAT'MK0S>WX'CAY,>BS_$8R=8[I/1 M_^E"E,SH`_`"`F[F1ID6%-X/LW3GO:/*1)P08$X'0G\&`U&""=NO\_. M&R";/H;T'69;B=WKO@)JM-%O7FB1*.$`AZ9#2J`)S=L0I"FTE8Y6,>YYI16+ M3[M5,O-WBV,?@V9W-#?Y3LOHEZT,JVHAOQ<1G@MB%IM8>?6J0 M29W%V60QPT%S"^`\'-P4#SGK1- MOVY&C)?"D\;<93+ODAH!+<&,.V3$X![4H[#I%\_(4%[@PR9VXXS!YI?P.KPZ M\LW=*/,N>TP-#R6QNVD:WY31=YW(BK<]<#T`JWZ,E=[O1'FE5&;K;<\CDSD>OY)X"QX"R MIRPULO??>6)!/*,!H-J."WV06=B?$1,WVK^AR*\7OQ"6,6AEY';=$+[$ESB5 M>^KLY5'JNL$@4$X^6>R`TDI1Z*PM75Q4G3-Q'=P$X`?%/*8R<)I0"99,H,]+H MK_%>")LE`F\UGM(9@XTH'Y%Y9>#YULTJ3!00KY9R87Q5M=YEW@.VC%.YJ.I[ MGD@57<.ZO*7WJQ.ZD^)(!7XY&S[/34]0N*6Y]!(A?7S#SLC8M@R,+KXM?/F2 MC:@#^^8"JNDX;\D`8WNZQ5YM!=,-#_M6;:I+FT!['5/[^L$376+ZHTSFS:IK M200KVS#W/<:)`\(NYJ,J?"F.3$&50F<4E_M@XVYZ/H:*>AI"2C/Z2J-:JZH7 ML(V+XF6`;5;5"-C*N$TNMZS.&2':@$X@F8M;:L9'28;%`195UA92(1MF9Q(:T5L>DJROFDZW[1OIZX?BO1 M@`$@JW(HR#>D&^ATTZ3FFRUJP`"0]=YL64.Z@2[8BY<#6]2``2#KO5DM3RZ2 MC,G\80D<-'2W<(Y3J>EI`&E";*WX!_=&U$_S6?P'8 MP\ZH+(V.2&4MP,6;P%*]4;"V'O#8/0K]R(.%W+X![$)2@% MI85MMJP*(9N1+6M]PEE.JDRUY(#@%M<*@,AJ4EW/9C![?QG,UIP&Q:]NS5=1 M#\2$5&Q/\]G,CP1Q_"6']\$(X:E3=`O0)@K!VBK=>_?I]RD?#*OU=9J'HDHP M0EKKS$Z'XLKL-%#[9JG$5\V,!%&'ZD:B#DBY-$5-B_<[W')0X:(JEB3)Y,": M0U%=-[&2[=KU^!8/"#$CH=.A>)-U_C7C/M@#CG)AAS(S\D/M*JQC(^V(\)%G M+NNP5BPU/"6NO']D^6`H\H?-I1)KVHJW:Q+%//]RR)8LE?N!;)7_3FLRF9KRN[USA)8N,4D$>.42X77L$2)]0-FN$MCF7=G+AE;DTD1]+\6 MRZ36O%&[+9TE/OLII0T]*=L3I:4A+"M2S\N25EM2J\-E4B8;FM]Z-TS*1*RF ME)Z]IW5:WF\MGU'\W$#C0_;`?R]'O"F#.OOY[89!F1CCE)MQBV%,6FW@=<$RH1#9E+*=-ZN%^\GV_FJI6SHK#"+ M1*&9>VMS>8B:O?M#:W1RD7I%%S3'6=[2@:BSW;45W'S2UA2T6+C4P>_,^(9" M0*WH9#)U_%57)>OWX?900)`/O664X>.:."M7_/7*Z4S\3*6[]I'[VUYNX-`^ M.[?J)(..?=-8M_;X^Q";QJAKGG]$83D@S4B(..8"!N-'VHU= MNOA8/=KJT58MY&M88F.'HWF)55:O/EJ=U^J\5N>U.J_LS&4U62U1-5>3=2?` MFS./\J5OZEHR"'*]6/O+ZK56K[5Z+5^+JC.2.+I6G:;4JX]6Y[4ZK]5YK\5^GXW\#8CB:QOA,P-UG(\%J^XDHU81=\J^E;?M?JN MU7>MOJN!OBN[!%I-5T=4C=5T61*;0ZFT(FL23Y[BQ8E76HD.J%PCMTJJ55*M MDFJ55*ND6B553DGEKKI6&]4156.U43HU3F&<,X;%EZ/((08$;B8Z6+V2*BEF M\9HEV8A5::U*:U5:J]):E=:JM%:E%<@](KE&6TU71U2-U72?P)C]'(`9NQ8Q M&%NW`JOQ68U/1'D2&#@/>$8D1WQ)/G?8`X8.`?2/_P-02P,$%`````@`:(B;/*9AVV%Z!@``NR8` M`!$`'`!A;65D+3(P,3`P,S,Q+GAS9%54"0`#$U'72Q-1UTMU>`L``00E#@`` M!#D!``#M6E%SVC@0?N],_X..I]Y,C"$06IBD'0<,]0S8.7"NO7OI"%L0385$ M+;F!^_6WL@T8`A1(YNXZQTMC2?NM=O6M5E*7ZP^S"4/?222IX#>%D1%=(8^!X21""N" M?#P37$SF:!`\D`F^0$,L28@$1Y]O^UUT62PC]*#4M&&:CX^/11*.<62(1%TQ M$!,3(<-83O9[:E<#U8K58C4_TAOU=W0BKM9I1Q:70>%<;UHQW M]?+;2JU>+]>N2![6C`A6H!&%8&L#79;*):-4-2YK_F6E4;EJ5"__7!,7TWE$ MQP\*O0E^!>G2E:$A:XMP@1P>%)'%&.IK48GZ1)+H.PF+F2J9K`2"A>;RII!S M_K%2%-'8!+UE\W.OFZY8X?4KE,HV9L.(T36$[EE@*B;E4F$>D!P$+/JZ!Z&' M-2'Y29Y`,K/*]7K=3$9STGA"PC5AW4'E7";DZ<4I52KE#1]"M83DS;DRT\&< M="P--9\2N2X?2W,QH'%UHU0VLDD4CL9$N6"%G.*`'&@:!.N$<-46T:1%1CAF M8."W&#,ZHB0L(*P@J(>Q(FL",5^)O-=:KC'G0B7QE+1USW1*^4AD3>C0R]>( M!",^6(_TQWW?V6VERG:/J27-E@AB;>?B+^:AS155P*R8ARFMA?+I61@1;P_">H0JDNE%-V;6YJV%0>P[;W^/OD.\`LB%D"[$([ M`V<2^X#3"/825R<@5Y;MQF6]"WI>B+4!F)N$ES=J4P[[DV)V)V1B2Y-A*;,H MT[PY:?[\B**P.*>PFBCX`;754ZA%;]9L^_5,]2%4PVDN)L1BBD0'D>BX3:\''/K0ZMGN>8L>QEL3RX#K>C#\@_/N#ZVW^J:U1$'#M?S[OJT# MR+NS^Y;O0(1=Y.(,VLAR6^BN;P\@U-(.D&X[+F1^Q^J>\\;S`F]`QQR.Y0!S M904!O#(5O(3O(`P""HACP^E`;?N#Y-UFD`SN>SVK_X?F?>!T7*?M-"W71U:S MZ=V[ON-VT!U$2].QSR%P4@C`.SR,&?%&M[&$%[Z45O`MINF]3=[.=;072)ND=SVM]VS%\N]]#WFW7Z5CG'7XJGTTQF5"5?,)VA(N>/I<)UZ?R M,V@^4NM^]B\WV8=78<_QTP>&WN1P*=1GO>V>#_I3#WHRUG_[9"HB3=4SJ#]$ MU7Z^*T]N>79'DPUIO.WU>\EF/[.\DV6]]P1OB0FFO$ZV">QGI/ID M!R8J4*H#94K^!YSH?W35J$]&*"D(-70MYJ8@Z63*2"'KPU&@\?M+2>8T$E," M6X3(53$J4_`$O5Z[2FC>6+_,JH6&AXB,;@HZ2HQ%O><+((JS"5N(**KT+,V5 M'J05R0N$&2N8_UW/UVD\P'$`;'&\M53SD_C-\)"P`UT&V2TN=[6&G\3;S6U^ M@-,`V>)T_C^KMOE^;>9KE=!:KV5>@^MPDB&^M;*ZHPR-TDIW5P2)HCT0W3(6 M.$-W&>5+HU(NSF28F7B,!:N5/LZ"!>Y8"[96L0^=>P'0DUX=/MV.(OBN6;/3 M$>*PF(./,9XF:),PM5)HK!0>:]!2XPO9HWM.-25"7T#OYR'"Q-2^K0N()Q)W114%.M\DTA! M'J(B]!-<&$?9SP4X99`F=8I(964,8*IB/=J)1#Q=3$)!_79_;4B+8DY(#ZO@ MP9Y-"9[%X;::;&C[_!E!+ M`0(>`Q0````(`&B(FSPEK"B=4$4``)9T`@`1`!@```````$```"D@0````!A M;65D+3(P,3`P,S,Q+GAM;%54!0`#$U'72W5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`&B(FSQ?4U\KK`P``)JI```5`!@```````$```"D@9M%``!A;65D M+3(P,3`P,S,Q7V-A;"YX;6Q55`4``Q-1UTMU>`L``00E#@``!#D!``!02P$" M'@,4````"`!HB)L\S#DVA[$3```I30$`%0`8```````!````I(&64@``86UE M9"TR,#$P,#,S,5]D968N>&UL550%``,34==+=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`:(B;/$(`5*G;'0``/H`!`!4`&````````0```*2!EF8``&%M M960M,C`Q,#`S,S%?;&%B+GAM;%54!0`#$U'72W5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`&B(FSQEI64X>A0``'^``0`5`!@```````$```"D@<"$``!A M;65D+3(P,3`P,S,Q7W!R92YX;6Q55`4``Q-1UTMU>`L``00E#@``!#D!``!0 M2P$"'@,4````"`!HB)L\IF';87H&``"[)@``$0`8```````!````I(&)F0`` M86UE9"TR,#$P,#,S,2YX`L``00E#@``!#D!``!02P4& 2``````8`!@`:`@``3J`````` ` end XML 28 R7.xml IDEA: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2.0.0.10 false SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 108 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES true false false false 1 usd $ false false iso4217_USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 iso4217_USD_per_shares Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares 0 shares Standard http://www.xbrl.org/2003/instance shares 0 5 3 us-gaap_SignificantAccountingPoliciesTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> </p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue Recognition</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We earn net service revenue through our home health and hospice agencies by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis (on a 60-day episode of care basis for home health services and on a 90-day episode of care basis for the first two hospice episodes of care and on a 60-day episode of care basis for any subsequent hospice episodes), on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day episode of care as episodic-based revenue. For the services we provide, Medicare is our largest payor.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Home Health Revenue Recognition</i></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Net service revenue is recorded under the Medicare payment program (&#x201C;PPS&#x201D;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&#xA0;an outlier payment if our patient&#x2019;s care was unusually costly; (b)&#xA0;a low utilization adjustment (&#x201C;LUPA&#x201D;) if the number of visits was fewer than five; (c)&#xA0;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&#xA0;a payment adjustment based upon the level of therapy services required (thresholds set at 6, 14 and 20 visits); (e)&#xA0;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f)&#xA0;changes in the base episode payments established by the Medicare Program; (g)&#xA0;adjustments to the base episode payments for case mix and geographic wages; and (h)&#xA0;recoveries of overpayments.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We make adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of such payment adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. During the three-month periods ended March&#xA0;31, 2010 and 2009, we recorded $0.2 million and $2.1 million, respectively, in estimated revenue adjustments to Medicare revenue.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of March&#xA0;31, 2010 and 2009, the difference between the cash received from Medicare for a request for anticipated payment (&#x201C;RAP&#x201D;) on episodes in progress and the associated estimated revenue was included as a reduction to our outstanding patient accounts receivable in our condensed consolidated balance sheets for such periods, since only a nominal amount represents cash collected in advance of providing services.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Non-Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Episodic-based Revenue.</i> We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Non-episodic Based Revenue.</i> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Hospice Revenue Recognition</i></font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Hospice Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four main levels of care we provide are routine care, general inpatient care, continuous home care and respite care. We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider numbers and estimate amounts due back to Medicare if a cap has been exceeded.&#xA0;We record these adjustments as a reduction to revenue and increase other accrued liabilities.&#xA0;As of March&#xA0;31, 2010 and December&#xA0;31, 2009, we had $0.3 million and $0.1 million, respectively, recorded for estimated amounts due back to Medicare in other accrued liabilities in our accompanying condensed consolidated balance sheets. As a result of our adjustments, we believe our revenue and patients accounts receivable are recorded at amounts that will be ultimately realized.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Hospice Non-Medicare Revenue</u></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per visit rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receivable.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Patient Accounts Receivable</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. We believe the credit risk associated with our Medicare accounts, which represent 74% and 77% of our net patient accounts receivable at March&#xA0;31, 2010 and December&#xA0;31, 2009, respectively, is limited due to (i)&#xA0;our historical collection rate of over 99% from Medicare and (ii)&#xA0;the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. There is no other single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables, and thus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">We fully reserve for accounts which are aged at 360 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Medicare Home Health</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#x201C;final billed&#x201D;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Medicare Hospice</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Non-Medicare Home Health and Hospice</i></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor based on either the contracted rates or expected payment rates, which are based on our historical experience. We estimate an allowance for doubtful accounts to reduce the carrying amount of the receivables to the amounts we estimate will be ultimately collected. Our review and evaluation of non-Medicare accounts includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. Where such groups have been identified, we have given special consideration to both the billing methodology and evaluation of the ultimate collectibility of the accounts. In addition, the amount of the allowance for doubtful accounts is based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectibility based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk.</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font size="1">&#xA0;</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Fair Value of Financial Instruments</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The following details our financial instruments where the carrying value and fair value differ (amounts in millions):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="46%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="8" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair Value at Re porting Date Using</b></font></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 72pt"> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Financial Instrument</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>As&#xA0;of&#xA0;March&#xA0;31,&#xA0;2010</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quoted&#xA0;Prices&#xA0;in<br /> Active&#xA0;Markets&#xA0;for<br /> Identical Items<br /> (Level 1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Significant&#xA0;Other<br /> Observable&#xA0;Inputs<br /> (Level 2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Significant<br /> Unobservable&#xA0;Inputs<br /> (Level 3)</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term obligations, excluding capital leases</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203.3</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">195.8</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">-</font></td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The estimates of the fair value of our long-term debt are based upon a discounted present value analysis of future cash flows. Due to the existing uncertainty in the capital and credit markets, the actual rates that would be obtained to borrow under similar conditions could materially differ from the estimates we have used.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 2 &#x2014; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable and accrued expenses, we estimate the carrying amounts&#x2019; approximate fair value due to their short term maturity. Our deferred compensation plan assets are recorded at fair value.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Weighted-Average Shares Outstanding</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income per share attributable to Amedisys, Inc. common stockholders (amounts in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="86%"></td> <td valign="bottom" width="2%"></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="3" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For&#xA0;the&#xA0;three-month&#xA0;periods<br /> ended Marc h 31,</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2010</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average number of shares outstanding - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,821</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,854</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Effect of dilutive securities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">175</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">250</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Non-vested stock and stock units</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">363</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">189</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 1px solid" valign="bottom"> &#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average number of shares outstanding - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28,359</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,293</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-TOP: #000000 3px double" valign="bottom"> &#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px" align="justify"> <font style="FONT-FAMILY: Times New Roman" size="2">For the three-month periods ended March&#xA0;31, 2010 and 2009, there were 4,222 and 41,501 shares, respectively, of additional securities that were anti-dilutive.</font></p> </div> 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition We earn net service revenue through our home health and hospice agencies by providing a false false false This element may be used to describe all significant accounting policies of the reporting entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8 false false 1 1 false UnKnown UnKnown UnKnown false true
-----END PRIVACY-ENHANCED MESSAGE-----